PTO/SB/05 (08-08) Approved for use through 06/30/2010. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to r	nation unless it displays a valid OMB contro	I number.
	10-1188-US-CON1	

UTILITY	Attorney Docket No. 10-1188-US-CON1			
PATENT APPLICATION	First Inventor Robert Frederick Veasey			
TRANSMITTAL	Pen'Type Injector			
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Pen-Type Injector Title			
	Express Mail Label No.			
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: P.O. Box 1450 Alexandria VA 22313-1450			
1. Fee Transmittal Form (e.g., PTO/SB/17)	ACCOMPANYING APPLICATION PARTS			
2. Applicant claims small entity status. See 37 CFR 1.27.	9. Assignment Papers (cover sheet & document(s))			
See 37 CFR 1.27. 3. Specification [Total Pages 14] Both the claims and abstract must start on a new page (For information on the preferred arrangement, see MPEP 608.01(a)) 4. Drawing(s) (35 U.S. C. 113) [Total Sheets 7] 5. Oath or Declaration [Total Sheets] a. Newly executed (original or copy) b. A copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(s) Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) Landscape Table on CD 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, items a c. are required) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. i. CD-ROM or CD-R (2 copies); or ii. B. Specification Sequence Listing on: i. i. Denerod or CD-R (2 copies); or ii. Paper	Name of Assignee 10. 37 CFR 3.73(b) Statement (when there is an assignee) Power of Attorney 11. English Translation Document (if applicable) 12. Information Disclosure Statement (PTO/SB/08 or PTO-1449) Copies of citations attached 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or equivalent. 17. Other: Submission of Substitute Specification, Substitute Specification, Submission of Replacement Drawings; 7 Pages of			
	Replacement Drawings and General Authorization			
18. If a CONTINUING APPLICATION, check appropriate box, and su specification following the title, or in an Application Data Sheet under	pply the requisite information below and in the first sentence of the 37 CFR 1.76: nation-in-part (CIP) of prior application No.: <u>11/483,546</u>			
Continuation Divisional Continu Prior application information: Examiner Mendez, Manuel A.	Art Unit: 3763			
	IDENCE ADDRESS			
The address associated with Customer Number 203	306 OR Correspondence address below			
Name				
Address				
City State	Zip Code			
Country Telephone	Email			
Signature /Thomas E. Wettermann/	Date November 11, 2010			
Name (Print/Type)Thomas E. WettermannRegistration No. (Attorney/Agent)41,523				

American LegalNet, Inc. www.Forms*Workflow.*com Mylan Exhibit - 1006 Mylan v. Sanofi

PTO/SB/17 (10-08) Approved for use through 06/30/2010. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it displays a valid OMB control number.

Mylan v. Sanofi

U.S. Patent and Trademark Office; U.S. DEPARIMENT OF COMM Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control nu	
onder the raperwork reduction Act or 1996, no persons are required to respond to a concentry information and so it displays a valid own control in	unibe

	Effective on 12/08			(Complete If	Known	
	Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).			pplication Number	Unassi	Unassigned	
FEE I	RANS		\L [⊧	iling Date	Unassi	gned	
	For FY 2	009	F	irst Named Inventor	Robert	Robert Frederick Veasey	
				xaminer Name	Unassię	gned	
Applicant claims s	small entity status.	See 37 CFR 1.27	A	art Unit	Unassię	gned	
TOTAL AMOUNT C	OF PAYMENT	(\$)3,222.00	A	ttorney Docket No.	10-118	8-US-CON1	
METHOD OF PAYMENT (check all that apply)							
Check C	Check Credit Card Money Order None Other (please identify):						
·	unt Deposit Accou				nt Name: <u>MBHB</u>		
For the above	e-identified deposit	account, the Dire	ctor is hereby	authorized to: (che	ck all that apply	y)	
	fee(s) indicated be			Charge fee(s) indicated belo	ow, except for the	e filing fee
Charge a under 37	any additional fee(7 CFR 1.16 and 1.1	s) or underpaymer I7	nts of fee(s)	Credit any o	verpayments		
WARNING: Information	n on this form may l	pecome public. Cre	dit card inforn	nation should not be	included on this	form. Provide crec	lit card
FEE CALCULAT							
1. BASIC FILING,		EXAMINATION	N FEES				
	FILING	FEES	SEARCI	H FEES	EXAMINA	ATION FEES	
		Small Entity	- (4)	Small Entity	- (4)	Small Entity	
Application Typ Utility	<u>e Fee (\$)</u> 330	<u>Fee (\$)</u> 165	<u>Fee (\$)</u> 540	<u>Fee (\$)</u> 270	<u>Fee (\$)</u> 220	<u>Fee (\$)</u> 110	<u>Fees Paid (\$)</u> 1,090.00
Design	220	105	100	50	140	70	1,090.00
Plant	220	110	330	165	140	85	
Reissue	330	165	540	270	650	325	
Provisional	220	110	0	0	0	0 -	
2. EXCESS CLAI		110	0	Ū	0	-	mall Entity
Fee Description							<u>Fee (\$)</u>
Each claim over 2						52	26
Each independent		cluding Reissues	s)			220	110
Multiple dependen Total Claims	Extra Cla	aims Fee (\$) Fees	Paid (\$)		390 <u>Multiple Depe</u>	195 Indent Claims
	or HP = $\frac{41}{41}$	× 52	= 2,13			Fee (\$)	Fee Paid (\$)
HP = highest number of			· -				
Indep. Claims 3 - 3 o	extra Cla or HP = 0	<u>aims Fee (</u> x ()	<u>\$)</u> <u>⊢ees</u> =0	<u>Paid (\$)</u>			
$\frac{3}{\text{HP}} = \text{highest number of}$	-		<u> </u>				
3. APPLICATION		·-·, ·· g···· ···					
		igs exceed 100 s	sheets of pap	ber (excluding ele	ctronically fi	led sequence or	computer
				e is \$270 (\$135 f	or small entit	y) for each addi	tional 50
sheets or fract Total Sheets	tion thereof. See Extra Sheets			37 CFR 1.16(s). Iditional 50 or frac	tion thereof	<u>Fee (\$)</u>	Fee Paid (\$)
	00 = 0	/50= 0		nd up to a whole nu			=
4. OTHER FEE(S)							<u>Fee Paid (\$)</u>
-	Specification, S	· ·	all entity dis	scount)			
Other (e.g., la	te filing surcharg	ge):					
SUBMITTED BY							
Signature /	/Thomas E. We	ettermann/		gistration No. 41,5 corney/Agent)	23	Telephor	ne 312 913 2138
This collection of informat USPTO to process) an ap							
USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent							
and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS							
ADDRESS. SEND IU:	If you need	d assistance in cor	mpleting the f	orm, call 1-800-PTC	D-9199 and sele	₩ ₩ ₩ ₽ ^t an ² Evh	American egalNet, Inc.
			C	002		iviyian EAll	TO MANA LALIAR AND COM

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	10-1188-US-CON1		
		Application Number			
Title of Invention	Title of Invention Pen-Type Injector				
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.					

Secrecy Order 37 CFR 5.2

Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Applicant Information:

Applic	cant 1							Remove	
Applic	cant Authority	Inventor	CLega	al Representativ	e under 35 l	J.S.C. 11	7	OParty of Interest under 35 U.S	.C. 118
	Prefix Given Name			Middle Name		Fam	ily Name	Suffix	
	Robert			Frederick			Veas	ey	
Resid	dence Informatio	One) (US Residenc	y 💽 Na	n US Res	sidency	/ O Active US Military Service	;	
City	Warwickshire	C	Country Of Re	sidencei	UK				
Citize	nship under 37	CFR 1.41(b) i l	JK		<u> </u>			
Mailin	g Address of A	oplicant:							
Addre	Address 1 35 Hitchman Road								
Addre	ess 2	Leamingto	on Spa						
City Warwickshire State/Province									
Posta	l Code	CV31 3			Country	UK			
								Remove	
	Applicant 2 Clegal Representative under 35 U.S.C. 117 Party of Interest under 35 U.S.C. 118								
Applic			Orege	Middle Na		5.0.0. TI)	Suffix
FIEIIX	Robert					Family Name Perkins		Sum	
Posid	dence Informatio	n (Salact (()) US Residenc	y 💿 No	n US Res			<u> </u>
City	Warwickshire		`	Country Of Re	· · ·	UK	sidency		
-	nship under 37	CED 1 41/h		JK	Sidence				
	g Address of A	•	יין						
Addre		67 Erica E	Drivo						
Addre									
		Leamingto	оп эра		01	(D			
City	Warwickshir					e/Provin	ice		
Posta	I Code	CV31 2R\	N		Country ⁱ	UK			
Applic								Remove	
Applic	cant Authority	Inventor		al Representativ	e under 35 l	J.S.C. 11	7	⊖Party of Interest under 35 U.S	.C. 118
Prefix				Middle Na	me		Fam	ily Name	Suffix
	David			Aubrey			Plum	ptre	
Resid	ence Informatio	on (Select (One)(US Residenc	y 💽 Na	n US Res	sidency	/ O Active US Military Service	<u>}</u>
City	Worcestershire		C	Country Of Re		UK		Mylan Exhibit - 1006	
EFS Web 2					0003			Mylan v. Sanofi	
								IVI YIAII V. SAIIOII	

Mylan v. Sanofi

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76			Attorney	y Docket Ni	ımber	10-1188-US-CON1
			Applicat	tion Numbe	r	
Title of Inv	ention	Pen-Type Injector	·			
Citizenshi	Citizenship under 37 CFR 1.41(b) i UK					
Mailing Ad	dress of	Applicant:				
Address 1		36 Shire Way				
Address 2		Droitwich				
City Worcestershire				State	e/Provinc	ce
Postal Code WR9 7				Countryi	UK	
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.						

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).						
An Address is being provided for the correspondence Information of this application.						
Customer Number 20306						
Email Address docketing@mbhb.com Add Email Remove Email						

Application Information:

Title of the Invention	Pen-Type Injector				
Attorney Docket Number	10-1188-US-CON1	l	Small Entity Status Claimed		
Application Type	Nonprovisional				
Subject Matter	Utility				
Suggested Class (if any)			Sub Class (if any)		
Suggested Technology C	pgy Center (if any)				
Total Number of Drawing	g Sheets (if any) 7 Suggested Figure for Publication (if any)				

Publication Information:

eighteen months after filing.

	Request Early Publication (Fee required at time of Request 37 CFR 1.219)
_	Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.
	C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.

Please Select One:	Customer Number	O US Patent Practitioner	 Limited Recognition (37 CFR 11.9) Myden Exhibit 1006
		0004	Wiyian Exhibit - 1000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	10-1188-US-CON1		
		Application Number			
Title of Invention	Pen-Type Injector				
Customer Number 20306					

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.

Prior Application Status	Pending		Remove	
Application Number	Continuity Type	Prior Application Number Filing Date (YYYY-MM		
	Continuation of	11483546	2006-07-11	
Prior Application Status	Abandoned	Remove		
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	
	Continuation of	10790225	2004-03-02	
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.			Add	

Foreign Priority Information:

	applicant to claim benefit of foreign p information in the application data sl			
			Re	move
Application Number	Country ⁱ	Parent Filing Date (Y	YYY-MM-DD)	Priority Claimed
0304822.0	GB	2003-03-03		● Yes 🔿 No
Additional Foreign Priority Data may be generated within this form by selecting the Add Add				
Assignee Informa	tion:			
	n the application data sheet does no gnment recorded in the Office.	t substitute for compliance w	ith any requirement	of part 3 of Title 37
Assignee 1 Remove				move
If the Assignee is an Org	anization check here. X			
Organization Name	DCA Design International LTD			
Mailing Address Inform	nation:			
Address 1	19 Church Street			
Address 2				
City	Warwick	State/Province		
Country ⁱ UK		Postal Code	CV34 4AB	
Phone Number		Fax Number		
Email Address			-+	
Additional Assignee Dat button.	a may be generated within this	form by selecting the Ad	d Mylan Exhi	Add ibit - 1006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	10-1188-US-CON1
		Application Number	
Title of Invention	Pen-Type Injector		

Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.					
Signature	/Thomas E. Wettermann/		Date (YYYY-MM-DD)	2010-11-11	
First Name	Thomas E.	Last Name	Wettermann	Registration Number	41523

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Mylan Exhibit - 1006

Mylan v. Sanofi



Improvements in and relating to a pen-type injector

- 5 The present invention relates to pen-type injectors, that is to injectors of the kind that provide for administration by injection of medicinal products from a multidose cartridge. In particular, the present invention relates to such injectors where a user may set the dose.
- 10 Such injectors have application where regular injection by persons without formal medical training occurs. This is increasingly common amongst those having diabetes where self-treatment enables such persons to conduct effective management of their diabetes.
- 15 These circumstances set a number of requirements for pen-type injectors of this kind. The injector must be robust in construction, yet easy to use both in terms of the manipulation of the parts and understanding by a user of its operation. In the case of those with diabetes, many users will be physically infirm and may also have impaired vision. Where the injector is to be disposable rather than
 20 reusable, the injector should be cheap to manufacture and easy to dispose of
 - (preferably being suitable for recycling).

It is an advantage of the present invention that an improved pen-type injector is provided.

25

According to a first aspect of the present invention, a pen-type injector comprises a housing;

a piston rod adapted to operate through the housing;

30 a dose dial sleeve located between the housing and the piston rod, the dose dial sleeve having a helical thread of first lead;

a drive sleeve located between the dose dial sleeve and the piston rod, the drive sleeve having a helical groove of second lead;

characterised in that the first lead of the helical thread and the second lead of the helical groove are the same.

BEST AVAILABLE COPY

Mylan Exhibit - 1006 Mylan v. Sanofi

ISE

Preferably, the piston rod has a first threaded portion at a first end and a second threaded portion at a second end;

2

an insert or radially inwardly extending flange is located in the housing and

- 5 through which the first threaded portion of the piston rod may rotate; the dose dial sleeve being rotatable with respect to the housing and the insert; the drive sleeve being releasably connected to the dose dial sleeve and connected to the piston rod for rotation with respect thereto along the second threaded portion of the piston rod;
- 10 a button is located on the dose dial sleeve and rotatable with respect to the dose dial sleeve; and

clutch means are provided which upon depression of the button permit rotation between the dose dial sleeve and the drive sleeve.

15 Preferably, the injector further comprises a nut which is rotatable with respect to the drive sleeve and axially displaceable but not rotatable with respect to the housing.

More preferably, the drive sleeve is provided at a first end with first and second flanges with an intermediate thread between the first and second flanges, the nut being disposed between the first and second flanges and keyed to the housing by spline means. Additionally, a first radial stop may be provided on a second face of the nut and a second radial stop may be provided on a first face of the second flange.

25

Preferably, the first thread of the piston rod is oppositely disposed to the second thread of the piston rod.

Preferably, a second end of the clutch is provided with a plurality of dog teeth adapted to engage with a second end of the dose dial sleeve.

Preferably, the pen-type injector further includes clicker means disposed between the clutch means and spline means provided on the housing.



More preferably, the clicker means comprises a sleeve provided at a first end with a helically extending arm, a free end of the arm having a toothed member, and at a second end with a plurality of circumferentially directed saw teeth

3

5 adapted to engage a corresponding plurality of circumferentially saw teeth provided on the clutch means.

Alternatively, the clicker means comprises a sleeve provided at a first end with at least one helically extending arm and at least one spring member, a free end of the arm having a toothed member, and at a second end with a plurality of circumferentially directed saw teeth adapted to engage a corresponding plurality of circumferentially directed saw teeth provided on the clutch means.

Preferably, the main housing is provided with a plurality of maximum dose stops adapted to be abutted by a radial stop provided on the dose dial sleeve. More preferably, at least one of the maximum dose stops comprises a radial stop located between a helical rib and spline means provided at a second end of the housing. Alternatively, at least one of the maximum dose stops comprises a part of a raised window portion provided at a second end of the housing.

20

10

Preferably, the dose dial sleeve is provided with a plurality of radially extending members adapted to abut a corresponding plurality of radial stops provided at a second end of the housing.

25 The invention will now be described with reference to the accompanying drawings, in which:-

Figure 1 shows a sectional view of a pen-type injector in accordance with the present invention in a first, cartridge full, position;

Figure 2 shows a sectional view of the pen-type injector of Figure 1 in a second, 30 maximum first dose dialed, position;

Figure 3 shows a sectional view of the pen-type injector of Figure 1 in a third, first maximum first dose dispensed, position;

15

Figure 4 shows a sectional view of the pen-type injector of Figure 1 in a fourth, final dose dialed, position;

Figure 5 shows a sectional view of the pen-type injector of Figure 1 in a fifth, final dose dispensed, position;

5 Figure 6 shows a cut-away view of a first detail of the pen-type injector of Figure 1;

Figure 7 shows a partially cut-away view of a second detail of the pen-type injector of Figure 1;

Figure 8 shows a partially cut-away view of a third detail of the pen-type injector of Figure 1;

Figure 9 shows the relative movement of parts of the pen-type injector shown in Figure 1 during dialing up of a dose;

Figure 10 shows the relative movement of parts of the pen-type injector shown in Figure 1 during dialing down of a dose;

15

10

Figure 11 shows the relative movement of parts of the pen-type injector shown in Figure 1 during dispensing of a dose;

Figure 12 shows a partially cut-away view of the pen-type injector of Figure 1 in the second, maximum first dose dialed, position;

Figure 13 shows a partially cut-away view of the pen-type injector of Figure 1 in 20 the fourth, final dose dialed, position;

Figure 14 shows a partially cut-away view of the pen-type injector of Figure 1 in one of the first, third or fifth positions;

Figure 15 shows a cut-away view of a first part of a main housing of the pen-type injector of Figure 1; and

25 Figure 16 shows a cut-away view of a second part of the main housing of the pen-type injector of Figure 1.

Referring first to Figures 1 to 5, there may be seen a pen-type injector in accordance with the present invention in a number of positions.

30

The pen-type injector comprises a housing having a first cartridge retaining part 2, and second main housing part 4. A first end of the cartridge retaining means 2 and a second end of the main housing 4 are secured together by

retaining features 6. In the illustrated embodiment, the cartridge retaining means 2 is secured within the second end of the main housing 4.

5

A cartridge 8 from which a number of doses of medicinal product may be
5 dispensed is provided in the cartridge retaining part 2. A piston 10 is retained in a first end of the cartridge 8.

A removable cap 12 is releasably retained over a second end of the cartridge retaining part 2. In use the removable cap 12 can be replaced by a user with a suitable needle unit (not shown). A replacable cap 14 is used to cover the cartridge retaining part 2 extending from the main housing 4. Preferably, the outer dimensions of the replaceable cap 14 are similar or identical to the outer dimensions of the main housing 4 to provide the impression of a unitary whole when the replaceable cap 14 is in position covering the cartridge retaining part 2.

15

20

10

In the illustrated embodiment, an insert 16 is provided at a first end of the main housing 4. The insert 16 is secured against rotational or longitudinal motion. The insert 16 is provided with a threaded circular opening 18 extending therethrough. Alternatively, the insert may be formed integrally with the main housing 4 the form of a radially inwardly directed flange having an internal thread.

A first thread 19 extends from a first end of a piston rod 20. The piston rod 20 is of generally circular section. The first end of the piston rod 20 extends through the threaded opening 18 in the insert 16. A pressure foot 22 is located at the first end of the piston rod 20. The pressure foot 22 is disposed to abut a second end of the cartridge piston 10. A second thread 24 extends from a second end of the piston rod 20. In the illustrated embodiment the second thread 24 comprises a series of part threads rather than a complete thread. The illustrated embodiment is easier to manufacture and helps reduce the overall force required for a user to cause medicinal product to be dispensed.

25

30

The first thread 19 and the second thread 24 are oppositely disposed. The second end of the piston rod 20 is provided with a receiving recess 26.

A drive sleeve 30 extends about the piston rod 20. The drive sleeve 30 is generally cylindrical. The drive sleeve 30 is provided at a first end with a first radially extending flange 32. A second radially extending flange 34 is provided

б

5 spaced a distance along the drive sleeve 30 from the first flange 32. An intermediate thread 36 is provided on an outer part of the drive sleeve 30 extending between the first flange 32 and the second flange 34. A helical groove 38 extends along the internal surface of the drive sleeve 30. The second thread 24 of the piston rod 20 is adapted to work within the helical groove 38.

10

25

A first end of the first flange 32 is adapted to conform to a second side of the insert 16.

A nut 40 is located between the drive sleeve 30 and the main housing 2,

disposed between the first flange 32 and the second flange 34. In the illustrated embodiment the nut 40 is a half-nut. This assists in the assembly of the injector. The nut 40 has an internal thread matching the intermediate thread 36. The outer surface of the nut 40 and an internal surface of the main housing 4 are keyed together by splines 42 (see Figures 10, 11, 15 and 16) to prevent relative
rotation between the nut 40 and the main housing 4, while allowing relative

longitudinal movement therebetween.

A shoulder 37 is formed between a second end of the drive sleeve 30 and an extension 38 provided at the second end of the drive sleeve 30. The extension 38 has reduced inner and outer diameters in comparison to the remainder of the drive sleeve 30. A second end of the extension 38 is provided with a radially outwardly directed flange 39.

A clicker 50 and a clutch 60 are disposed about the drive sleeve 30, between the drive sleeve 30 and a dose dial sleeve $\frac{1}{70}$ (to be described below).

The clicker 50 is located adjacent the second flange 34 of the drive sleeve 30. The clicker 50 is generally cylindrical and is provided at a first end with a flexible

i

P96042

helically extending arm 52 (shown most clearly in Figure 6). A free end of the arm 52 is provided with a radially directed toothed member 54. A second end of the clicker 50 is provided with a series of circumferentially directed saw teeth 56 (cf Figure 7). Each saw tooth comprises a longitudinally directed surface and an inclined surface.

7

In an alternative embodiment (not shown) the clicker means further includes at least one spring member. The at least one spring member assists in the resetting of the clutch means 60 following dispense.

10

5

The clutch means 60 is located adjacent the second end of the drive sleeve 30. The clutch means 60 is generally cylindrical and is provided at a first end with a series of circumferentially directed saw teeth 66 (see Figure 7). Each saw tooth comprises a longitudinally directed surface and an inclined surface. Towards the

- 15 second end 64 of the clutch means 60 there is located a radially inwardly directed flange 62. The flange 62 of the clutch means 60 is disposed between the shoulder 37 of the drive sleeve 30 and the radially outwardly directed flange 39 of the extension 38. The second end of the clutch means 60 is provided with a plurality of dog teeth 65 (Figure 8). The clutch 60 is keyed to the drive sleeve 30 and by way of splines (not shown) to prevent relative station late.
- by way of splines (not shown) to prevent relative rotation between the clutch 60 and the drive sleeve 30.

In the illustrated embodiment, the clicker 50 and the clutch 60 each extend approximately half the length of the drive sleeve 30. However, it will be

25 understood that other arrangements regarding the relative lengths of these parts are possible.

The clicker 50 and the clutch means 60 are normally engaged, that is as shown in Figure 7.

30

A dose dial sleeve 70 is provided outside of the clicker 50 and clutch means 60 and radially inward of the main housing 4. A helical groove 74 is provided about an outer surface of the dose dial sleeve 70.

surrounding the window 44 in the main housing 4 (Figure 16).



NR. 177 · S. 11/24

P96042

The main housing 4 is provided with a window 44 through which a part of the outer surface of the dose dial sleeve may be seen. The main housing 4 is further provided with a helical rib 46, adapted to be seated in the helical groove 74 on the outer surface of the dose dial sleeve 70. The helical rib 46 extends for a single sweep of the inner surface of the main housing 4. A first stop 100 is provided between the splines 42 and the helical rib 46 (Figure 15). A second stop 102, disposed at an angle of 180° to the first stop 100 is formed by a frame

8

10

5

Conveniently, a visual indication of the dose that may be dialed, for example reference numerals (not shown), is provided on the outer surface of the dose dial sleeve 70. The window 44 conveniently only allows to be viewed a visual indication of the dose currently dialed.

15

20

A second end of the dose dial sleeve 70 is provided with an inwardly directed flange in the form of number of radially extending members 75. A dose dial grip 76 is disposed about an outer surface of the second end of the dose dial sleeve 70. An outer diameter of the dose dial grip 76 preferably corresponds to the outer diameter of the main housing 4. The dose dial grip 76 is secured to the

- dose dial sleeve 70 to prevent relative movement therebetween. The dose dial grip 76 is provided with a central opening 78. An annular recess 80 located in the second end of the dose dial grip 76 extends around the opening 78.
- 25 A button 82 of generally 'T' section is provided at a second end of the pen-type injector. A stem 84 of the button 82 may extend through the opening 78 in the dose dial grip 76, through the inner diameter of the extension 38 of the drive sleeve 30 and into the receiving recess 26 of the piston rod 20. The stem 84 is retained for limited axial movement in the drive sleeve 30 and against rotation
- 30 with respect thereto. A head 85 of the button 82 is generally circular. A skirt 86 depends from a periphery of the head 85. The skirt 86 is adapted to be seated in the annular recess 80 of the dose dial grip 76.

Operation of the pen-type injector in accordance with the present invention will now be described. In Figures 9, 10 and 11 arrows A, B, C, D, E, F and G represent the respective movements of the button 82, the dose dial grip 76, the dose dial sleeve 70, the drive sleeve 30, the clutch means 60, the clicker 50 and the nut 40.

To dial a dose (Figure 9) a user rotates the dose dial grip 76 (arrow A). With the clicker 50 and clutch means 60 engaged, the drive sleeve 30, the clicker 50, the clutch means 60 and the dose dial sleeve 70 rotate with the dose dial grip 76.

10

5

Audible and tactile feedback of the dose being dialed is provided by the clicker 50 and the clutch means 60. Torque is transmitted through the saw teeth 56,66 between the clicker 50 and the clutch means 60. The flexible arm 52 deforms and drags the toothed member 54 over the splines 42 to produce a click.

15 Preferably, the splines 42 are disposed such that each click corresponds to a unit dose.

The helical groove 74 on the dose dial sleeve 70 and the helical groove 38 in the drive sleeve 30 have the same lead. This allows the dose dial sleeve 70

20 (arrow C) to extend from the main housing 4 and the drive sleeve 30 (arrow D) to climb the piston rod 20 at the same rate. At the limit of travel, a radial stop 104 on the dose dial sleeve 70 engages either the first stop 100 or the second stop 102 provided on the main housing 4 to prevent further movement. Rotation of the piston rod 20 is prevented due to the opposing directions of the overhauled
25 and driven threads on the piston rod 20.

The nut 40, keyed to the main housing 4, is advanced along the intermediate thread 36 by the rotation of the drive sleeve 30 (arrow D). When the final dose dispensed position (Figures 4, 5 and 13) is reached, a radial stop 106 formed on a second surface of the nut 40 abuts a radial stop 108 on a first surface of the second flange 34 of the drive sleeve 30 preventing both the nut 40 and the drive sleeve 30 from rotating further.

Mylan Exhibit - 1006 Mylan v. Sanofi i

10

In an alternative embodiment (not shown) a first surface of the nut 40 is provided with a radial stop for abutment with a radial stop provided on a second surface of the first flange 32. This aids location of the nut 40 at the cartridge full position during assembly of the pen-type injector.

Should a user inadvertently dial beyond the desired dosage, the pen-type injector allows the dosage to be dialed down without dispense of medicinal product from the cartridge (Figure 10). The dose dial grip 76 is counter rotated. This causes the system to act in reverse. The flexible arm 52 now acts as a ratchet preventing the clicker from rotating. The torque transmitted through the clutch

means 60 causes the saw teeth 56,66 to ride over one another to create the clicks corresponding to dialed dose reduction. Preferably the saw teeth 56,66 are so disposed that the circumferential extent of each saw tooth corresponds to a unit dose.

15

20

25

10

5

When the desired dose has been dialed, the user may then dispense this dose by depressing the button 82 (Figure 11). This displaces the clutch means 60 axially with respect to the dose dial sleeve 70 causing the dog teeth 65 to disengage. However the clutch means 60 remains keyed in rotation to the drive sleeve 30. The dose dial sleeve 70 and associated dose dial grip 76 are now free to rotate (guided by the helical rib 46 located in helical groove 74).

The axial movement deforms the flexible arm 52 of the clicker 50 to ensure the saw teeth 56,66 cannot be overhauled during dispense. This prevents the drive sleeve 30 from rotating with respect to the main housing 4 though it is still free to move axially with respect thereto. This deformation is subsequently used to urge the clicker 50, and the clutch 60, back along the drive sleeve 30 to restore the connection between the clutch 60 and the dose dial sleeve 70 when pressure is removed from the button 82.

30

The longitudinal axial movement of the drive sleeve 30 causes the piston rod 20 to rotate though the opening 18 in the insert 16, thereby to advance the piston 10 in the cartridge 8. Once the dialed dose has been dispensed, the dose dial

5

P96042

11

sleeve 70 is prevented from further rotation by contact of a plurality of members 110 (Figure 14) extending from the dose dial grip 76 with a corresponding plurality of stops 112 formed in the main housing 4 (Figures 15 and 16). In the illustrated embodiment, the members 110 extend axially from the dose dial grip 76 and have an inclined end surface. The zero dose position is determined by the abutment of one of the axially extending edges of the members 110 with a corresponding stop 112,

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

□ FADED TEXT OR DRAWING

□ BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER:_____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox. 5



P96042 CLAIMS

1 A pen-type injector comprising a housing;

a piston rod adapted to operate through the housing;

a dose dial sleeve located between the housing and the piston rod, the dose dial sleeve having a helical thread of first lead;

12

a drive sleeve located between the dose dial sleeve and the piston rod, the drive sleeve having a helical groove of second lead;

characterised in that the first lead of the helical thread and the second lead of the 10 helical groove are the same.

2 A pen-type injector according to claim 1, characterised in that the piston rod has a first threaded portion at a first end and a second threaded portion at a second end;

15 an insert or radially inwardly extending flange is located in the housing and through which the first threaded portion of the piston rod may rotate; the dose dial sleeve being rotatable with respect to the housing and the insert; the drive sleeve being releasably connected to the dose dial sleeve and connected to the piston rod for rotation with respect thereto along the second

threaded portion of the piston rod;

a button is located on the dose dial sleeve and rotatable with respect to the dose dial sleeve; and

clutch means are provided which upon depression of the button permit rotation between the dose dial sleeve and the drive sleeve.

25

20

3 A pen-type injector according to claim 1 or claim 2, in which the injector further comprises a nut which is rotatable with respect to the drive sleeve and axially displaceable but not rotatable with respect to the housing.

30 4 A pen-type injector according to claim 3, in which the drive sleeve is provided at a first end with first and second flanges with an intermediate thread between the first and second flanges, the nut being disposed between the first and second flanges and keyed to the housing by spline means.

BEST AVAILABLE COPY

Mylan Exhibit - 1006 Mylan v. Sanofi

ISE

13

5 A pen-type injector according to claim 4, in which a first radial stop is provided on a second face of the nut and a second radial stop is provided on a first face of the second flange.

5

6 A pen-type injector according to any of claims 2 to 5, in which the first thread of the piston rod is oppositely disposed to the second thread of the piston rod.

- 10 7 A pen-type injector according to any of claims 2 to 6, in which a second end of the clutch is provided with a plurality of dog teeth adapted to engage with a second end of the dose dial sleeve.
- 8 A pen-type injector according to any of claims 2 to 7, in which the pen-type 15 injector further includes clicker means disposed between the clutch means and spline means provided on the housing

9 A pen-type injector according to claim 8, in which the clicker means comprises a sleeve provided at a first end with a helically extending arm, a free
20 end of the arm having a toothed member, and at a second end with a plurality of circumferentially directed saw teeth adapted to engage a corresponding plurality of circumferentially saw teeth provided on the clutch means.

10 A pen-type injector according to claim 8, in which the clicker means 25 comprises a sleeve provided at a first end with at least one helically extending arm and at least one spring member, a free end of the arm having a toothed member, and at a second end with a plurality of circumferentially directed saw teeth adapted to engage a corresponding plurality of circumferentially directed saw teeth provided on the clutch means.

30

A pen-type injector according to any previous claim, in which the main housing is provided with a plurality of maximum dose stops adapted to be abutted by a radial stop provided on the dose dial sleeve.

BEST AVAILABLE COPY

Mylan Exhibit - 1006 Mylan v. Sanofi

5

P96042

14

12 A pen-type injector according to claim 11, in which at least one of the maximum dose stops comprises a radial stop located between a helical rib and spline means provided at a second end of the housing.

13 A pen-type injector according to claim 11, in which at least one of the maximum dose stops comprises a part of a raised window portion provided at a second end of the housing.

10 14 A pen-type injector according to any previous claim, in which the dose dial sleeve is provided with a plurality of radially extending members adapted to abut a corresponding plurality of radial stops provided at a second end of the housing.

BEST AVAILABLE COPY

via .

1/7






Fig 1





BEST AVAILABLE COPY



k.

1

Mylan Exhibit - 1006 Mylan v. Sanofi

1. MAR. 2004 12:02

-

16

8

ISE UCK MANNH . 49 621 4227131

3/7

Fig 5

'NR. 177

76

60

50

30

2

40

22

10


S. 20/24

i

Mylan Exhibit - 1006 Mylan v. Sanofi

. .

-




· .


· · · · ·


•

Mylan Exhibit - 1006

Mylan v. Sanofi







Mylan Exhibit - 1006 Mylan v. Sanofi

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 10-1188-US-CON1)

In the Applica	ation of:)	
Rober	t Frederick Veasey et al.))	Examiner: Unassigned
Serial No.	Unassigned)	Group Art Unit: Unassigned
Filed:	Unassigned)	Confirmation No.: Unassigned
For: Pen-T	ype Injector)	Customer No.: 20306

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

PRELIMINARY AMENDMENT

Dear Sir:

Applicant submits the following preliminary amendment, and respectfully requests that it be entered prior to examination of this application.

Amendments to the specification begin on page 2.

Amendments to the claims begin on page 3.

Remarks begin of page 15.

Attachment includes an abstract.

Applicant generally authorizes the Office to charge any **General Authorization:** underpayment or credit any overpayment to Deposit Account No. 13-2490, and to treat any communication that requires an extension of time as incorporating a request for such an extension.

1

AMENDMENTS TO THE SPECIFICATION

1. Please insert the following heading and paragraph on page 1, line 2 of the specification:

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation application of US Patent Application No. 11/483,546, filed July 11, 2006, currently pending, which is a continuation application of US Patent Application No. 10/790,225, filed March 2, 2004, abandoned, and claims priority to GB Patent Application No. 0304822.0, filed March 3, 2003, the entire contents of each of which are incorporated herein by reference.

2. Please use the abstract on the attached page as the abstract for this application.

۰.,

0031

AMENDMENTS TO THE CLAIMS

1-14. (cancelled)

15. (new) A housing part for a medication dispensing apparatus, said housing part comprising:

a main housing, said main housing extending from a distal end to a proximal end;

a dose dial sleeve positioned within said housing, said dose dial sleeve comprising a helical groove configured to engage a threading provided by said main housing;

a dose knob disposed near a proximal end of said dose dial sleeve;

a piston rod provided within said housing, said piston rod is non-rotatable during a dose setting step relative to said main housing;

a driver extending along a portion of said piston rod, said driver comprising an internal threading near a distal portion of said driver, said internal threading adapted to engage an external thread of said piston rod; and,

a tubular clutch located adjacent a distal end of said dose knob, said tubular clutch operatively coupled to said dose knob,

wherein said dose dial sleeve extends circumferentially around at least a portion of said tubular clutch.

16. (new) The housing part of claim 15, wherein said tubular clutch is directly coupled to said dose knob.

17. (new) The housing part of claim 15, further comprising

0032

a container housing operatively coupled to said main housing, said container housing comprising a fluid container,

wherein said fluid container defines a medicament filled reservoir with a movable plunger at a proximal end and an outlet at a distal end,

said plunger movable by said piston rod to be advanced toward an outlet of said fluid container when said piston rod is moved distally.

18. (new) The housing part of claim 17, wherein during a dose setting step, said dose knob is rotated and moves away from said proximal end of said main housing so that a dose of said medicament contained within said medicament filled reservoir can be selected.

19. (new) The housing part of claim 18, wherein said dose knob is operatively configured to said tubular clutch so that, during said dose setting step, said tubular clutch, said dose dial sleeve, and said dose knob rotate out of said proximal end of said main housing.

20. (new) The housing part of claim 15, wherein said dose knob extends circumferentially around at least a portion of said tubular clutch.

21. (new) The housing part of claim 15, wherein during a dose dispensing step, said dose knob is activated in a distal direction and said tubular clutch disengages such that said dose dial sleeve rotates back towards said proximal end of said main housing.

Mylan Exhibit - 1006 Mylan v. Sanofi

22. (new) The housing part of claim 21, wherein during said dose dispensing step, said dose dial sleeve and said tubular clutch rotate together.

23. (new) The housing part of claim 17, wherein

during a dose dispensing step, said driver advances axially in a distal direction relative to said main housing, and

said driver advances said piston rod in said distal direction so as to dispense said medicament from said outlet at said distal end of said fluid container.

24. (new) The housing part of claim 15, wherein said dose setting knob is coupled in part by said clutch to said dose dial sleeve so as to prevent relative movement between said dose setting knob and said dose dial sleeve during a dose setting step.

25. (new) The housing part of claim 15, wherein said dose setting knob is partially secured to said dose dial sleeve so as to allow relative movement between said dose setting knob and said dose dial sleeve during a dose dispensing step.

26. (new) The housing part of claim 15, wherein said driver comprises at least one flange.

27. (new) The housing part of claim 26, wherein said at least one flange is located near a distal portion of said driver.

5

28. (new) The housing part of claim 15, further comprising a clicker, said clicker providing at least an audible feedback to a user when said dose knob is rotated.

29. (new) The housing part of claim 28, wherein said clicker provides tactile feedback to a user when said dose knob is rotated.

30. (new) The housing part of claim 28, wherein said clicker provides audible feedback when said dose knob is rotated in a dose increasing direction.

31. (new) The housing part of claim 28, wherein said clicker provides audible feedback when said dose knob is rotated in a dose decreasing direction.

32. (new) The housing part of claim 28, wherein said clicker comprises, at least one flexible arm, said flexible arm comprising at least one tooth member, and at least one spline,

wherein when said dose knob is rotated, said at least one flexible arm deforms and drags said tooth member over said at least one spline so as to provide said audible feedback.

33. (new) The housing part of claim 28, wherein said clicker is disposed between said clutch and a proximal end of said piston rod.

34. (new) The housing part of claim 28, wherein

said clicker generally comprises a cylindrical shape having a first and a second end, and

0035

said cylindrical shape is provided at said first end with at least one flexible extending arm.

35. (new) The housing part of claim 15, wherein

said tubular clutch comprises a plurality of teeth formed near an end of said tubular clutch,

said plurality of teeth remaining meshed during a dose setting step, and said plurality of teeth becoming unmeshed during a dose dispensing step.

36. (new) The housing part of claim 35, wherein said plurality of teeth comprise a plurality of dog teeth.

37. (new) The housing part of claim 15, wherein said piston rod comprises a generally circular cross section.

38. (new) The housing part of claim 15 wherein said external thread of said piston rod comprises a part thread.

39. (new) The housing part of claim 15,

wherein said piston rod comprises a first thread and a second thread, and

wherein at least one of said first or said second thread comprises at least one part threads rather than a complete thread.

7

40. (new) The housing part of claim 15, wherein said dose dial sleeve is provided outside said tubular clutch and radially inward of said main housing.

41. (new) The housing part of claim 15, wherein said main housing further comprises a helical rib, said helical rib adapted to be seated in said helical groove provided along an outer surface of said dose dial sleeve.

42. (new) The housing part of claim 41, wherein said helical rib extends for at least a single sweep of said inner surface of said main housing.

43. (new) The housing part of claim 41, wherein said helical rib comprises a single start helical rib.

44. (new) The housing part of claim 15, wherein said dose dial sleeve comprises at least one radial stop, said radial stop positioned near an end of said helical groove.

45. (new) The housing part of claim 44, wherein when said dose dial sleeve is rotated to set a maximum dose of said medication dispensing apparatus, said radial stop near said end of said helical groove abuts an end of said threading provided on said inner surface of said main housing and thereby prevents rotation of said dose dial sleeve.

46. (new) The housing part of claim 44, wherein said radial stop is positioned near a distal end of said helical groove.

47. (new) The housing part of claim 15, wherein if a user inadvertently dials said dose knob in one direction beyond a desired dose, said dose knob may be rotated in a second direction so as to allow said dialed dose to be reduced.

48. (new) The housing part of claim 15, wherein, to dispense a set dose, said dose knob is activated, and wherein activation of said dose knob disengages said tubular clutch in an axially direction with respect to said dose dial sleeve.

49. (new) The housing part of claim 17, wherein said housing part is configured such that a user is prevented from dialing a dose of medicament greater than said medicament remaining in said fluid container.

50. (new) The housing part of claim 15, wherein said housing part and said container comprises a disposable device.

51. (new) The housing part of claim 15, wherein said housing part and said container comprises a re-usable device.

52. (new) The housing part of claim 15, further comprising an insert, said insert provided at a distal end of the main housing, said insert secured against rotation.

9

53. (new) The housing part of claim 15, further comprising an insert, said insert provided at a distal end of the main housing, and said insert secured against longitudinal motion.

54. (new) The housing part of claim 53, wherein said insert comprises an opening extending therethrough, such that said piston rod is configured to extend through said opening.

55. (new) The housing part of claim 54, wherein said opening comprises a threaded opening, and wherein during a dose dispense step, an external thread of said piston rod threadingly engages said threaded opening so that said piston rod rotates during a dose dispense step.

56. (new) The housing part of claim 15, wherein said main housing comprises a window through which at least a portion of an outer surface of said dose dial sleeve may be viewable.

57. (new) The housing part of claim 56, wherein said window is located near a proximal end of said main housing and near a helical rib provided on an inner surface of said outer housing.

58. (new) The housing part of claim 15, wherein said helical groove of the dose dial sleeve has a first lead and said internal threading of said driver has a second lead, and wherein said first lead and said second lead are the same.

10

59. (new) The housing part of claim 15, wherein said helical groove of the dose dial sleeve has a first lead and said internal threading of said driver has a second lead, and wherein said first lead and said second lead are different.

60. (new) The housing part of claim 15, wherein said driver comprises a cylindrical shape.

61. (new) A pen type drug delivery device, said device comprising:

an external housing comprising a threading along a portion of an inner surface of said external housing, said external housing extending from a distal end to a proximal end;

a dialing element positioned within said housing, said dialing element comprising an outer surface extending from a distal end to a proximal end of said dialing element,

> wherein said outer surface comprises a helical threading that defines a groove configured to engage said threading provided on said inner surface of said external housing;

an actuator disposed about an outer surface of an end of said dialing element near said proximal end of said main housing;

a driver extending along at least a portion of a piston rod, said driver comprising a thread adapted to threadingly engage an external thread of a piston rod; and,

a clutch positioned at least partially within an open proximal end of said dialing element and located adjacent a distal end of said actuator and operatively coupled to said actuator,

wherein said dialing element extends circumferentially around at least a portion of said clutch;

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 SOUTH WACKER DRIVE, 32ND FLOOR CHICAGO, IL 60606 (312)913-0001 11

a tubular barrel retainer operatively coupled to said external housing, said tubular barrel retainer comprising a cartridge containing a medicament, said cartridge comprising a reservoir, a piston, a septum, and a cap;

said piston movable by said piston rod to be advanced toward an outlet of said cartridge when said piston rod is moved distally.

62. (new) The pen type drug delivery device of claim 61, wherein said tubular barrel retainer is permanently coupled to said external housing.

63. (new) The pen type drug delivery device of claim 61, wherein said tubular barrel retainer is removably coupled to said external housing.

64. (new) The pen type drug delivery device of claim 61, wherein said pen type drug delivery device comprises a prefilled, variable dose pen type drug delivery device.

65. (new) The pen type drug delivery device of claim 61, wherein said outer surface of said dialing element further comprises dosage indicator markings.

66. (new) The pen type drug delivery device of claim 61, wherein said external housing further comprises a housing window, and wherein said housing window allows said dosage indicator markings to be visible during use of said pen type drug delivery device.

0041

67. (new) The pen type drug delivery device of claim 61, wherein said driver comprises a cylindrical, tube-shaped body.

68. (new) The pen type drug delivery device of claim 61, wherein said clutch comprises a cylindrical clutch.

69. (new) A clutch for use within a pen type drug delivery device, said clutch comprising

a tubular body, said tubular body extending from a distal end to a proximal end; and said distal end of said tubular body having a diameter sized such that said distal end of said tubular body may be positioned within a proximal end of a dial member.

70. (new) The clutch of claim 69, wherein said proximal end of said tubular body is configured to reside within an inner space of a dose knob.

71. (new) The clutch of claim 69, further comprising a plurality of axially extending teeth formed in an interior of a flange of said clutch.

72. (new) The clutch of claim 69, wherein said clutch is positioned within an open proximal end of said dial member and located adjacent a distal end of said dose knob and operatively coupled to said dose knob, and wherein said dial member extends circumferentially around at least a portion of said clutch.

13

73. (new) The clutch of claim 70, wherein when said dose knob is activated to dispense a dose of a medicament contained within said pen type delivery device, said clutch is moved in a distal direction.

74. (new) The clutch of claim 70, wherein said pen type drug delivery device further comprises

a cartridge containing a medicament, said cartridge comprising a reservoir, a stopper, a septum and a ferrule.

75. (new) The clutch of claim 74, wherein said cartridge comprises a multidose cartridge.

0043

REMARKS

Prior to examination of this application on the merits, entry of the above amendments to the specification and claims are requested.

The specification is amended to include a cross-reference to related applications and an abstract, which is attached to this Preliminary Amendment.

Claims 1-14 are cancelled without prejudice or disclaimer, and new claims 15-75 are added. Support for the new claims is self-evident from the originally-filed disclosure, including the original claims, and therefore no new matter is added.

Also, attached to this Preliminary Amendment is an abstract.

If there are any matters that may be resolved or clarified through a telephone interview, the Examiner is respectfully requested to contact Applicant's undersigned representative at (312) 913-0001.

Respectfully submitted,

' McDonnell Boehnen Hulbert & Berghoff LLP

Date: November 11, 2010

By: <u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

Tab A

ABSTRACT

A housing for a dispensing apparatus. The housing comprising a main housing and a dose dial sleeve. The dose dial sleeve comprising a helical groove configured to engage a threading provided by the housing. A dose knob is disposed near a proximal end of the dose dial sleeve and a piston rod is provided within the housing. The piston rod is non-rotatable during a dose setting step. A driver comprises an internal threading near a distal portion of the driver and is adapted to engage an external thread of the piston rod. A tubular clutch is located adjacent a distal end of the dose knob and operatively coupled to the dose knob. The dose dial sleeve may extend circumferentially around at least a portion of the tubular clutch.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 10-1188-US-CON1)

In the Applica	ation of:)	
Robert Frederick Veasey et al.)	Examiner: Unassigned
Serial No.	Unassigned		Group Art Unit: Unassigned
Filed:	Unassigned		Confirmation No.: Unassigned
For: Pen-T	ype Injector)	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

SUBMISSION OF SUBSTITUTE SPECIFICATION

Subject to the approval of the Examiner, please replace the specification in the application filed herewith with the attached Substitute Specification. The Substitute Specification is the same as the originally-filed specification and is provided as a clean copy of the originally-filed specification. If for any reason the Substitute Specification is not in full compliance with the pertinent statutes and regulations, please so advise the undersigned.

If any fees are necessary for the submission of this Substitute Specification, please charge Deposit Account No. 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: November 11, 2010

By: <u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

Improvements in and relating to a pen-type injector

- 5 The present invention relates to pen-type injectors, that is to injectors of the kind that provide for administration by injection of medicinal products from a multidose cartridge. In particular, the present invention relates to such injectors where a user may set the dose.
- 10 Such injectors have application where regular injection by persons without formal medical training occurs. This is increasingly common amongst those having diabetes where self-treatment enables such persons to conduct effective management of their diabetes.
- 15 These circumstances set a number of requirements for pen-type injectors of this kind. The injector must be robust in construction, yet easy to use both in terms of the manipulation of the parts and understanding by a user of its operation. In the case of those with diabetes, many users will be physically infirm and may also have impaired vision. Where the injector is to be disposable rather than
- 20 reusable, the injector should be cheap to manufacture and easy to dispose of (preferably being suitable for recycling).

It is an advantage of the present invention that an improved pen-type injector is provided.

25

According to a first aspect of the present invention, a pen-type injector comprises a housing;

a piston rod adapted to operate through the housing;

30 a dose dial sleeve located between the housing and the piston rod, the dose dial sleeve having a helical thread of first lead;

a drive sleeve located between the dose dial sleeve and the piston rod, the drive sleeve having a helical groove of second lead;

characterised in that the first lead of the helical thread and the second lead of the

35 helical groove are the same.

5

2

Preferably, the piston rod has a first threaded portion at a first end and a second threaded portion at a second end;

an insert or radially inwardly extending flange is located in the housing and through which the first threaded portion of the piston rod may rotate;

- the dose dial sleeve being rotatable with respect to the housing and the insert; the drive sleeve being releasably connected to the dose dial sleeve and connected to the piston rod for rotation with respect thereto along the second threaded portion of the piston rod;
- 10 a button is located on the dose dial sleeve and rotatable with respect to the dose dial sleeve; and

clutch means are provided which upon depression of the button permit rotation between the dose dial sleeve and the drive sleeve.

15 Preferably, the injector further comprises a nut which is rotatable with respect to the drive sleeve and axially displaceable but not rotatable with respect to the housing.

More preferably, the drive sleeve is provided at a first end with first and second flanges with an intermediate thread between the first and second flanges, the nut being disposed between the first and second flanges and keyed to the housing by spline means. Additionally, a first radial stop may be provided on a second face of the nut and a second radial stop may be provided on a first face of the second flange.

25

Preferably, the first thread of the piston rod is oppositely disposed to the second thread of the piston rod.

Preferably, a second end of the clutch is provided with a plurality of dog teeth adapted to engage with a second end of the dose dial sleeve.

Preferably, the pen-type injector further includes clicker means disposed between the clutch means and spline means provided on the housing.

> Mylan Exhibit - 1006 Mylan v. Sanofi

More preferably, the clicker means comprises a sleeve provided at a first end with a helically extending arm, a free end of the arm having a toothed member, and at a second end with a plurality of circumferentially directed saw teeth

3

5 adapted to engage a corresponding plurality of circumferentially saw teeth provided on the clutch means.

Alternatively, the clicker means comprises a sleeve provided at a first end with at least one helically extending arm and at least one spring member, a free end of the arm having a toothed member, and at a second end with a plurality of circumferentially directed saw teeth adapted to engage a corresponding plurality of circumferentially directed saw teeth provided on the clutch means.

Preferably, the main housing is provided with a plurality of maximum dose stops adapted to be abutted by a radial stop provided on the dose dial sleeve. More preferably, at least one of the maximum dose stops comprises a radial stop located between a helical rib and spline means provided at a second end of the housing. Alternatively, at least one of the maximum dose stops comprises a part of a raised window portion provided at a second end of the housing.

20

30

10

Preferably, the dose dial sleeve is provided with a plurality of radially extending members adapted to abut a corresponding plurality of radial stops provided at a second end of the housing.

25 The invention will now be described with reference to the accompanying drawings, in which:-

Figure 1 shows a sectional view of a pen-type injector in accordance with the present invention in a first, cartridge full, position;

Figure 2 shows a sectional view of the pen-type injector of Figure 1 in a second, maximum first dose dialed, position;

Figure 3 shows a sectional view of the pen-type injector of Figure 1 in a third, first maximum first dose dispensed, position;

Mylan Exhibit - 1006 Mylan v. Sanofi

......

4

Figure 4 shows a sectional view of the pen-type injector of Figure 1 in a fourth, final dose dialed, position;

Figure 5 shows a sectional view of the pen-type injector of Figure 1 in a fifth, final dose dispensed, position;

5 Figure 6 shows a cut-away view of a first detail of the pen-type injector of Figure 1;

Figure 7 shows a partially cut-away view of a second detail of the pen-type injector of Figure 1;

Figure 8 shows a partially cut-away view of a third detail of the pen-type injector of Figure 1;

Figure 9 shows the relative movement of parts of the pen-type injector shown in Figure 1 during dialing up of a dose;

Figure 10 shows the relative movement of parts of the pen-type injector shown in Figure 1 during dialing down of a dose;

15

20

10

Figure 11 shows the relative movement of parts of the pen-type injector shown in Figure 1 during dispensing of a dose;

Figure 12 shows a partially cut-away view of the pen-type injector of Figure 1 in the second, maximum first dose dialed, position;

... Figure 13 shows a <u>partially</u> cut-away view of the pen-type injector of Figure 1 in the fourth, final dose dialed, position;

Figure 14 shows a partially cut-away view of the pen-type injector of Figure 1 in one of the first, third or fifth positions;

Figure 15 shows a cut-away view of a first part of a main housing of the pen-type injector of Figure 1; and

25 Figure 16 shows a cut-away view of a second part of the main housing of the pen-type injector of Figure 1.

Referring first to Figures 1 to 5, there may be seen a pen-type injector in accordance with the present invention in a number of positions.

30

The pen-type injector comprises a housing having a first cartridge retaining part 2, and second main housing part 4. A first end of the cartridge retaining means 2 and a second end of the main housing 4 are secured together by

retaining features 6. In the illustrated embodiment, the cartridge retaining means 2 is secured within the second end of the main housing 4.

5

A cartridge 8 from which a number of doses of medicinal product may be dispensed is provided in the cartridge retaining part 2. A piston 10 is retained in a first end of the cartridge 8.

A removable cap 12 is releasably retained over a second end of the cartridge retaining part 2. In use the removable cap 12 can be replaced by a user with a suitable needle unit (not shown). A replacable cap 14 is used to cover the cartridge retaining part 2 extending from the main housing 4. Preferably, the outer dimensions of the replaceable cap 14 are similar or identical to the outer dimensions of the main housing 4 to provide the impression of a unitary whole when the replaceable cap 14 is in position covering the cartridge retaining part 2.

15

20

25

10

5

In the illustrated embodiment, an insert 16 is provided at a first end of the main housing 4. The insert 16 is secured against rotational or longitudinal motion. The insert 16 is provided with a threaded circular opening 18 extending therethrough. Alternatively, the insert may be formed integrally with the main housing 4 the form of a radially inwardly directed flange having an internal thread.

A first thread 19 extends from a first end of a piston rod 20. The piston rod 20 is of generally circular section. The first end of the piston rod 20 extends through the threaded opening 18 in the insert 16. A pressure foot 22 is located at the first end of the piston rod 20. The pressure foot 22 is disposed to abut a second end of the cartridge piston 10. A second thread 24 extends from a second end of the piston rod 20. In the illustrated embodiment the second thread 24 comprises a series of part threads rather than a complete thread. The illustrated embodiment is easier to manufacture and helps reduce the overall force required for a user to cause medicinal product to be dispensed.

30

The first thread 19 and the second thread 24 are oppositely disposed. The second end of the piston rod 20 is provided with a receiving recess 26.

Mylan Exhibit - 1006 Mylan v. Sanofi

5

10

A drive sleeve 30 extends about the piston rod 20. The drive sleeve 30 is generally cylindrical. The drive sleeve 30 is provided at a first end with a first radially extending flange 32. A second radially extending flange 34 is provided

6

spaced a distance along the drive sleeve 30 from the first flange 32. An intermediate thread 36 is provided on an outer part of the drive sleeve 30 extending between the first flange 32 and the second flange 34. A helical groove 38 extends along the internal surface of the drive sleeve 30. The second thread 24 of the piston rod 20 is adapted to work within the helical groove 38.

A first end of the first flange 32 is adapted to conform to a second side of the insert 16.

A nut 40 is located between the drive sleeve 30 and the main housing 2,
disposed between the first flange 32 and the second flange 34. In the illustrated embodiment the nut 40 is a half-nut. This assists in the assembly of the injector. The nut 40 has an internal thread matching the intermediate thread 36. The outer surface of the nut 40 and an internal surface of the main housing 4 are keyed together by splines 42 (see Figures 10, 11, 15 and 16) to prevent relative rotation between the nut 40 and the main housing 4, while allowing relative longitudinal movement therebetween.

A shoulder 37 is formed between a second end of the drive sleeve 30 and an extension 38 provided at the second end of the drive sleeve 30. The

25 extension 38 has reduced inner and outer diameters in comparison to the remainder of the drive sleeve 30. A second end of the extension 38 is provided with a radially outwardly directed flange 39.

A clicker 50 and a clutch 60 are disposed about the drive sleeve 30, between the drive sleeve 30 and a dose dial sleeve 70 (to be described below).

The clicker 50 is located adjacent the second flange 34 of the drive sleeve 30. The clicker 50 is generally cylindrical and is provided at a first end with a flexible

> Mylan Exhibit - 1006 Mylan v. Sanofi

5

10

15

20

helically extending arm 52 (shown most clearly in Figure 6). A free end of the arm 52 is provided with a radially directed toothed member 54. A second end of the clicker 50 is provided with a series of circumferentially directed saw teeth 56 (cf Figure 7). Each saw tooth comprises a longitudinally directed surface and an inclined surface.

In an alternative embodiment (not shown) the clicker means further includes at least one spring member. The at least one spring member assists in the resetting of the clutch means 60 following dispense.

The clutch means 60 is located adjacent the second end of the drive sleeve 30. The clutch means 60 is generally cylindrical and is provided at a first end with a series of circumferentially directed saw teeth 66 (see Figure 7). Each saw tooth comprises a longitudinally directed surface and an inclined surface. Towards the second end 64 of the clutch means 60 there is located a radially inwardly directed flange 62. The flange 62 of the clutch means 60 is disposed between the shoulder 37 of the drive sleeve 30 and the radially outwardly directed flange 39 of the extension 38. The second end of the clutch means 60 is provided with a plurality of dog teeth 65 (Figure 8). The clutch 60 is keyed to the drive sleeve 30 by way of splines (not shown) to prevent relative rotation between the clutch 60 and the drive sleeve 30.

In the illustrated embodiment, the clicker 50 and the clutch 60 each extend approximately half the length of the drive sleeve 30. However, it will be understood that other arrangements regarding the relative lengths of these parts are possible.

The clicker 50 and the clutch means 60 are normally engaged, that is as shown in Figure 7.

30

25

A dose dial sleeve 70 is provided outside of the clicker 50 and clutch means 60 and radially inward of the main housing 4. A helical groove 74 is provided about an outer surface of the dose dial sleeve 70.

The main housing 4 is provided with a window 44 through which a part of the outer surface of the dose dial sleeve may be seen. The main housing 4 is further provided with a helical rib 46, adapted to be seated in the helical groove 74 on
the outer surface of the dose dial sleeve 70. The helical rib 46 extends for a single sweep of the inner surface of the main housing 4. A first stop 100 is provided between the splines 42 and the helical rib 46 (Figure 15). A second stop 102, disposed at an angle of 180° to the first stop 100 is formed by a frame

8

10

Conveniently, a visual indication of the dose that may be dialed, for example reference numerals (not shown), is provided on the outer surface of the dose dial sleeve 70. The window 44 conveniently only allows to be viewed a visual indication of the dose currently dialed.

surrounding the window 44 in the main housing 4 (Figure 16).

15

20

A second end of the dose dial sleeve 70 is provided with an inwardly directed flange in the form of number of radially extending members 75. A dose dial grip 76 is disposed about an outer surface of the second end of the dose dial sleeve 70. An outer diameter of the dose dial grip 76 preferably corresponds to the outer diameter of the main housing 4. The dose dial grip 76 is secured to the dose dial sleeve 70 to prevent relative movement therebetween. The dose dial grip 76 is provided with a central opening 78. An annular recess 80 located in the second end of the dose dial grip 76 extends around the opening 78.

A button 82 of generally 'T' section is provided at a second end of the pen-type injector. A stem 84 of the button 82 may extend through the opening 78 in the dose dial grip 76, through the inner diameter of the extension 38 of the drive sleeve 30 and into the receiving recess 26 of the piston rod 20. The stem 84 is retained for limited axial movement in the drive sleeve 30 and against rotation

30 with respect thereto. A head 85 of the button 82 is generally circular. A skirt 86 depends from a periphery of the head 85. The skirt 86 is adapted to be seated in the annular recess 80 of the dose dial grip 76.

Mylan Exhibit - 1006 Mylan v. Sanofi

Operation of the pen-type injector in accordance with the present invention will now be described. In Figures 9, 10 and 11 arrows A, B, C, D, E, F and G represent the respective movements of the button 82, the dose dial grip 76, the dose dial sleeve 70, the drive sleeve 30, the clutch means 60, the clicker 50 and the nut 40.

9

To dial a dose (Figure 9) a user rotates the dose dial grip 76 (arrow A). With the clicker 50 and clutch means 60 engaged, the drive sleeve 30, the clicker 50, the clutch means 60 and the dose dial sleeve 70 rotate with the dose dial grip 76.

10

5

Audible and tactile feedback of the dose being dialed is provided by the clicker 50 and the clutch means 60. Torque is transmitted through the saw teeth 56,66 between the clicker 50 and the clutch means 60. The flexible arm 52 deforms and drags the toothed member 54 over the splines 42 to produce a click.

15 Preferably, the splines 42 are disposed such that each click corresponds to a unit dose.

The helical groove 74 on the dose dial sleeve 70 and the helical groove 38 in the drive sleeve 30 have the same lead. This allows the dose dial sleeve 70

20 (arrow C) to extend from the main housing 4 and the drive sleeve 30 (arrow D) to climb the piston rod 20 at the same rate. At the limit of travel, a radial stop 104 on the dose dial sleeve 70 engages either the first stop 100 or the second stop 102 provided on the main housing 4 to prevent further movement. Rotation of the piston rod 20 is prevented due to the opposing directions of the overhauled and driven threads on the piston rod 20.

The nut 40, keyed to the main housing 4, is advanced along the intermediate thread 36 by the rotation of the drive sleeve 30 (arrow D). When the final dose dispensed position (Figures 4, 5 and 13) is reached, a radial stop 106 formed on

30 a second surface of the nut 40 abuts a radial stop 108 on a first surface of the second flange 34 of the drive sleeve 30, preventing both the nut 40 and the drive sleeve 30 from rotating further.

10

In an alternative embodiment (not shown) a first surface of the nut 40 is provided with a radial stop for abutment with a radial stop provided on a second surface of the first flange 32. This aids location of the nut 40 at the cartridge full position during assembly of the pen-type injector.

5

Should a user inadvertently dial beyond the desired dosage, the pen-type injector allows the dosage to be dialed down without dispense of medicinal product from the cartridge (Figure 10). The dose dial grip 76 is counter rotated. This causes the system to act in reverse. The flexible arm 52 now acts as a ratchet

10 preventing the clicker from rotating. The torque transmitted through the clutch means 60 causes the saw teeth 56,66 to ride over one another to create the clicks corresponding to dialed dose reduction. Preferably the saw teeth 56,66 are so disposed that the circumferential extent of each saw tooth corresponds to a unit dose.

15

When the desired dose has been dialed, the user may then dispense this dose by depressing the button 82 (Figure 11). This displaces the clutch means 60 axially with respect to the dose dial sleeve 70 causing the dog teeth 65 to disengage. However the clutch means 60 remains keyed in rotation to the drive sleeve 30.

20 The dose dial sleeve 70 and associated dose dial grip 76 are now free to rotate (guided by the helical rib 46 located in helical groove 74).

The axial movement deforms the flexible arm 52 of the clicker 50 to ensure the saw teeth 56,66 cannot be overhauled during dispense. This prevents the drive sleeve 30 from rotating with respect to the main housing 4 though it is still free to move axially with respect thereto. This deformation is subsequently used to urge the clicker 50, and the clutch 60, back along the drive sleeve 30 to restore the connection between the clutch 60 and the dose dial sleeve 70 when pressure is removed from the button 82.

30

25

The longitudinal axial movement of the drive sleeve 30 causes the piston rod 20 to rotate though the opening 18 in the insert 16, thereby to advance the piston 10 in the cartridge 8. Once the dialed dose has been dispensed, the dose dial

Mylan Exhibit - 1006 Mylan v. Sanofi

5

sleeve 70 is prevented from further rotation by contact of a plurality of members 110 (Figure 14) extending from the dose dial grip 76 with a corresponding plurality of stops 112 formed in the main housing 4 (Figures 15 and 16). In the illustrated embodiment, the members 110 extend axially from the dose dial grip 76 and have an inclined end surface. The zero dose position is

11

dose dial grip 76 and have an inclined end surface. The zero dose position is determined by the abutment of one of the axially extending edges of the members 110 with a corresponding stop 112.

Mylan Exhibit - 1006 Mylan v. Sanofi

P96042 CLAIMS

1 A pen-type injector comprising a housing;

a piston rod adapted to operate through the housing;

5 a dose dial sleeve located between the housing and the piston rod, the dose dial sleeve having a helical thread of first lead;

a drive sleeve located between the dose dial sleeve and the piston rod, the drive sleeve having a helical groove of second lead;

characterised in that the first lead of the helical thread and the second lead of the helical groove are the same.

2 A pen-type injector according to claim 1, characterised in that the piston rod has a first threaded portion at a first end and a second threaded portion at a second end;

- 15 an insert or radially inwardly extending flange is located in the housing and through which the first threaded portion of the piston rod may rotate; the dose dial sleeve being rotatable with respect to the housing and the insert; the drive sleeve being releasably connected to the dose dial sleeve and connected to the piston rod for rotation with respect thereto along the second
- 20 threaded portion of the piston rod;

a button is located on the dose dial sleeve and rotatable with respect to the dose dial sleeve; and

clutch means are provided which upon depression of the button permit rotation between the dose dial sleeve and the drive sleeve.

25

10

3 A pen-type injector according to claim 1 or claim 2, in which the injector further comprises a nut which is rotatable with respect to the drive sleeve and axially displaceable but not rotatable with respect to the housing.

30 4 A pen-type injector according to claim 3, in which the drive sleeve is provided at a first end with first and second flanges with an intermediate thread between the first and second flanges, the nut being disposed between the first and second flanges and keyed to the housing by spline means.

0059

Mylan Exhibit - 1006 Mylan v. Sanofi

5

13

5 A pen-type injector according to claim 4, in which a first radial stop is provided on a second face of the nut and a second radial stop is provided on a first face of the second flange.

6 A pen-type injector according to any of claims 2 to 5, in which the first thread of the piston rod is oppositely disposed to the second thread of the piston rod.

10 7 A pen-type injector according to any of claims 2 to 6, in which a second end of the clutch is provided with a plurality of dog teeth adapted to engage with a second end of the dose dial sleeve.

8 A pen-type injector according to any of claims 2 to 7, in which the pen-type 15 injector further includes clicker means disposed between the clutch means and spline means provided on the housing.

9 A pen-type injector according to claim 8, in which the clicker means comprises a sleeve provided at a first end with a helically extending arm, a free
20 end of the arm having a toothed member, and at a second end with a plurality of circumferentially directed saw teeth adapted to engage a corresponding plurality of circumferentially saw teeth provided on the clutch means.

10 A pen-type injector according to claim 8, in which the clicker means comprises a sleeve provided at a first end with at least one helically extending arm and at least one spring member, a free end of the arm having a toothed member, and at a second end with a plurality of circumferentially directed saw teeth adapted to engage a corresponding plurality of circumferentially directed saw teeth provided on the clutch means.

30

11 A pen-type injector according to any previous claim, in which the main housing is provided with a plurality of maximum dose stops adapted to be abutted by a radial stop provided on the dose dial sleeve.

> Mylan Exhibit - 1006 Mylan v. Sanofi

0060

5

14

12 A pen-type injector according to claim 11, in which at least one of the maximum dose stops comprises a radial stop located between a helical rib and spline means provided at a second end of the housing.

13 A pen-type injector according to claim 11, in which at least one of the maximum dose stops comprises a part of a raised window portion provided at a second end of the housing.

10 14 A pen-type injector according to any previous claim, in which the dose dial sleeve is provided with a plurality of radially extending members adapted to abut a corresponding plurality of radial stops provided at a second end of the housing.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 10-1188-US-CON1)

In the Applic	ation of:)	
Robe	rt Frederick Veasey et al.)	Examiner: Unassigned
Serial No.	Unassigned)	Group Art Unit: Unassigned
Filed:	Unassigned)	Confirmation No.: Unassigned
For: Pen-7	Type Injector)	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

SUBMISSION OF REPLACEMENT DRAWINGS

Subject to the approval of the Examiner, please replace the drawings in the application filed herewith with the drawings in the seven (7) attached Replacement Sheets (which include Figures 1-16). These Replacement Sheets include cleaner versions of the originally-filed drawings. If for any reason the Replacement Sheets are not in full compliance with the pertinent statutes and regulations, please so advise the undersigned.


If any fees are necessary for the submission of these Replacement Sheets, please charge Deposit Account No. 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP


Date: November 11, 2010

By: <u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523




Mylan Exhibit - 1006 Mylan v. Sanofi

Replacement Sheet





Mylan Exhibit - 1006 Mylan v. Sanofi



.

· · · ·











Fig. 8








e. . .









Mylan Exhibit - 1006 Mylan v. Sanofi

Replacement Sheet


. . . .







Mylan Exhibit - 1006 Mylan v. Sanofi

۰. ۰







Mylan Exhibit - 1006 Mylan v. Sanofi

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

In re Application of:)
Robert Frederick Veasey et al. Serial No.: Unassigned Filed: Unassigned)) Examiner: Unassigned)) Group Art Unit: Unassigned) Confirmation No.: Unassigned
For: Pen-Type Injector Commissioner for Patents P.O. Box 1450)

GENERAL AUTHORIZATION UNDER 37 C.F.R. § 1.136(a)(3)

Sir:

The Commissioner is hereby generally authorized under 37 C.F.R. § 1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 C.F.R. § 1.53 requiring an extension of time as incorporating a request therefore, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 13-2490 for any fee that may be due in connection with such a request for an extension of time.

By:

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: November 11, 2010

Alexandria, VA 22313-1450

<u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

Electronic Patent Application Fee Transmittal					
Application Number:					
Filing Date:					
Title of Invention:	Pen-Type Injector				
First Named Inventor/Applicant Name:	Rol	Robert Frederick Veasey			
Filer:	Thomas E. Wettermann				
Attorney Docket Number: 10-1188-US-CON1					
Filed as Large Entity					
Utility under 35 USC 111(a) Filing Fees					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Utility application filing		1011	1	330	330
Utility Search Fee		1111	1	540	540
Utility Examination Fee		1311	1	220	220
Pages:					
Claims:					
Claims in excess of 20		1202	41	52	2132
Miscellaneous-Filing:					
Petition:					
			N	Ivlan Exhibi	it - 1006

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
	Total in USD (\$) 3222			

Electronic Ac	knowledgement Receipt
EFS ID:	8817075
Application Number:	12944544
International Application Number:	
Confirmation Number:	5949
Title of Invention:	Pen-Type Injector
First Named Inventor/Applicant Name:	Robert Frederick Veasey
Customer Number:	20306
Filer:	Thomas E. Wettermann
Filer Authorized By:	
Attorney Docket Number:	10-1188-US-CON1
Receipt Date:	11-NOV-2010
Filing Date:	
Time Stamp:	18:03:06
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes				
Payment Type	Deposit Account				
Payment was successfully received in RAM	\$3222				
RAM confirmation Number	14579				
Deposit Account	132490				
Authorized User					
The Director of the USPTO is hereby authorized to charge	e indicated fees and credit any overpayment as follows:				
Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)					
Charge any Additional Fees required under 37 C.F.R. Se	ction 1.20 (Post Issuance fees) 00772 Mylan Exhibit - 1006				
	00/3				

Mylan v. Sanofi

File Listing	:				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.
		10_1188_US_CON1_Utility_Tra	159799		
1	Transmittal of New Application	nsmittal_2010_11_11.pdf	5a0fab92a83362b83776ad95850d26d465c a30b3	no	1
Warnings:		•		'	
Information:					
2	Miscellaneous Incoming Letter	10_1188_US_CON1_Fee_Trans	141239	no	1
		mittal_2010_11_11.pdf	a036d828823d5c5ce09069919e3f9622809 e0ae8		
Warnings:					
Information:		1	I		
3	Application Data Sheet	10_1188_US_CON1_ADS_2010	3568688	no	5
5	Application Data Sheet	_11_11.pdf	96a167a16b3c30e27c738cee4a41f11ef2bf 3c90	10	5
Warnings:					
Information:			· · · · · ·		
4		10_1188_US_CON1_Specificati	1518028	yes	15
		on_2010_11_11.pdf	c3a7c2d93887b47e03fd1d18f613bf27d897 c381		10
	Multip	oart Description/PDF files in .	zip description		
	Document De	scription	Start	Eı	nd
	Specifica	tion	1	12	
	Claim	;	13	1	5
Warnings:					
Information:			986403		
Information:	Drawings-only black and white line	10_1188_US_CON1_Figures_2	900+03	no	7
_	Drawings-only black and white line drawings	10_1188_US_CON1_Figures_2 010_11_11.pdf	df9ea3eb4389d1ede0b183134451080cd77 aca24	no	7
Information:			df9ea3eb4389d1ede0b183134451080cd77	no	7
Information:			df9ea3eb4389d1ede0b183134451080cd77	no	7
Information: 5 Warnings:			df9ea3eb4389d1ede0b183134451080cd77	no	7
Information: 5 Warnings: Information:	drawings	010_11_11.pdf 10_1188_US_CON1_Preliminar	df9ea3eb4389d1ede0b183134451080cd77 aca24		
Information: 5 Warnings: Information: 6	drawings	010_11_11.pdf 10_1188_US_CON1_Preliminar y_Amendment_2010_11_11.	df9ea3eb4389d1ede0b183134451080cd77 aca24 1049898 59e691816bdd774fe3443a0505342d35c84		
Information: 5 Warnings: Information:	drawings	010_11_11.pdf 10_1188_US_CON1_Preliminar y_Amendment_2010_11_11.	df9ea3eb4389d1ede0b183134451080cd77 aca24 1049898 59e691816bdd774fe3443a0505342d35c84		
Information: 5 Warnings: Information: 6 Warnings: Information:	drawings Preliminary Amendment	010_11_11.pdf 10_1188_US_CON1_Preliminar y_Amendment_2010_11_11. pdf 10_1188_US_CON1_Submissio	df9ea3eb4389d1ede0b183134451080cd77 aca24 1049898 59e691816bdd774fe3443a0505342d35c84	no	17
Information: 5 Warnings: Information: 6 Warnings:	drawings	010_11_11.pdf 10_1188_US_CON1_Preliminar y_Amendment_2010_11_11. pdf	df9ea3eb4389d1ede0b183134451080cd77 aca24 1049898 59e691816bdd774fe3443a0505342d35c84 43e2e		

Warnings:					
Information	:				
8		10_1188_US_CON1_Substitute	1383458	yes	14
0		_Specification_2010_11_11.pdf	26054764e65c83bee299ba82af8fcfc5fa228 26a	yes	14
	Multip	art Description/PDF files in .	zip description		
	Document Des	scription	Start	Er	nd
	Specificati	ion	1	1	1
	Claims	12	1	4	
Warnings:			·		
Information	:				
9	Miscellaneous Incoming Letter	10_1188_US_CON1_Submissio n_of_Replacement_Drawings_	82031	no	1
		2010_11_11.pdf	06b52f55c9ed3ba85d68d23dc9dce0d4bec 7e3a0		
Warnings:					
Information	:				
10	Drawings-only black and white line	10_1188_US_CON1_Replacem	591552	no	7
	drawings	ent_Drawings_2010_11_11.pdf	27dae9a34063b206f682cd0984f514e57f35 4a69		
Warnings:	<u> </u>			1	
Information	:				
11	Authorization for Extension of Time all	10_1188_US_CON1_General_A	62253	no	1
	replies	uthorization_2010_11_11.pdf	e36f082293cdd48c545028291345b00b226 e7f45	110	•
Warnings:					
Information	:				
12	Fee Worksheet (PTO-875)	fee-info.pdf	36001	no	2
_			622e50f743553cfbc97055b1dfcb90c5ba9f 9530	-	
Warnings:					
Information	:				
		Total Files Size (in bytes)	965	9939	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (07-06)

Approved for use through 1/31/2007. OMB 0651-0032 ILC Detention

Under the Paperwork Reduction Act of 1995, no persons are required to respond to PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						_		Docket Number	Filing Date Filing Date		OMB control number.
	AF	PLICATION					12,01	1,011	,		HER THAN
	(Column 1) (Column 2)							ENTITY	OR	SMA	LL ENTITY
FOR NUMBER FILED NUMBER EXTRA					RATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)		
\boxtimes	BASIC FEE (37 CFR 1.16(a), (b), c	or (c))	N/A		N/A		N/A			N/A	330
\boxtimes	SEARCH FEE (37 CFR 1.16(k), (i), c	or (m))	N/A		N/A		N/A			N/A	540
Χ	EXAMINATION FE (37 CFR 1.16(o), (p), o		N/A		N/A		N/A			N/A	220
	AL CLAIMS CFR 1.16(i))		14 mir	us 20 = * 0			X \$ =		OR	X \$52 =	0
	EPENDENT CLAIM CFR 1.16(h))	S	1 m	inus 3 = * 0			X \$ =			X \$220 =	0
APPLICATION SIZE FEE (37 CFR 1.16(s)) If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).											
_	MULTIPLE DEPEN				2		TOTAL			TOTAL	1090
111							TOTAL			TOTAL	1090
	APPI	LICATION AS	AMENL	JED – PARI	1 11					OTHE	ER THAN
		(Column 1) CLAIMS		(Column 2) HIGHEST) (Column 3)		SMAL	L ENTITY	OR	SMA	LL ENTITY
AMENDMENT	11/11/2010	REMAINING AFTER AMENDMENT		NUMBER PREVIOUSL PAID FOR	PRESENT Y EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
DME	Total (37 CFR 1.16(i))	* 61	Minus	** 20	= 41		X \$ =		OR	X \$52=	2132
ENI	Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0		X \$ =		OR	X \$220=	0
AM	Application Si	ze Fee (37 CFR ·	.16(s))								
	FIRST PRESEN	ITATION OF MULTI	PLE DEPEN	DENT CLAIM (37	′ CFR 1.16(j))				OR		
							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	2132
		(Column 1)		(Column 2)) (Column 3)						
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSL PAID FOR	PRESENT _Y EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
ENT	Total (37 CFR 1.16(i))	*	Minus	Nevie	=		X \$ =		OR	X \$ =	
ENDM	Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =		OR	X \$ =	
1EN	Application Si	ze Fee (37 CFR ⁻	.16(s))								
AM	FIRST PRESEN	ITATION OF MULTI	PLE DEPEN	DENT CLAIM (37	' CFR 1.16(j))				OR		
							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
** lf *** lf											

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875							Application or Docket Number 12/944,544			
APPLICATION AS FILED - PART I (Column 1) (Column 2)						SMAL	SMALL ENTITY		OTHER THAN OR SMALL ENTITY	
	FOR	NUMBE	R FILE	D NUMBE	R EXTRA	RATE(\$)	FEE(\$)		RATE(\$)	FEE(\$)
	SIC FEE FR 1.16(a), (b), or (c))	N	/A	١	J/A	N/A		1	N/A	330
	ARCH FEE FR 1.16(k), (i), or (m))	N	/A	١	J/A	N/A		1	N/A	540
	MINATION FEE FR 1.16(0), (p), or (q))	N	/A	Ν	J/A	N/A		1	N/A	220
TOT	AL CLAIMS FR 1.16(i))	61	minus	20= *	41			OR	× 52 =	2132
	EPENDENT CLAI	^{MS} 3	minus	3 = *				1	× 220 =	0.00
APPLICATION SIZE FEE (37 CFR 1.16(s)) (37 CFR 1.16(s)) (37 CFR 1.16(s)) (37 CFR 1.16(s))			e application si all entity) for ea on thereof. See	ze fee due is ch additional					0.00	
Μυι	_TIPLE DEPENDE	ENT CLAIM PRE	SENT (3	7 CFR 1.16(j))				1		0.00
*lft	he difference in co	olumn 1 is less th	an zero,	enter "0" in colur	mn 2.	TOTAL		1	TOTAL	3222
		CATION AS A			1					
		(Column 1)		(Column 2)	(Column 3)	SMAL	OTHER THAN SMALL ENTITY OR SMALL ENTITY			
NT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
ΜĒ	Total (37 CFR 1.16(i))	*	Minus	**	=	x	=	OR	x =	
AMENDMENT	Independent (37 CFR 1.16(h))	*	Minus	***	=	x	=	OR	x =	
AMI	Application Size Fe	ee (37 CFR 1.16(s))								
	FIRST PRESENT	ATION OF MULTIPI	E DEPEN	DENT CLAIM (37 C	CFR 1.16(j))			OR		
	1					TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
		(Column 1)		(Column 2)	(Column 3)			_		
NT B		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
ΜĒ	Total (37 CFR 1.16(i))	*	Minus	**	=	x	=	OR	x =	
AMENDMENT	Independent (37 CFR 1.16(h))	*	Minus	***	=	x	=	OR	x =	
AM	Application Size Fe	ee (37 CFR 1.16(s))			•					
	FIRST PRESENT	TION OF MULTIPI	E DEPEN	DENT CLAIM (37 C	CFR 1.16(j))			OR		
	1					TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
*	 If the entry in cc If the "Highest N If the "Highest Num The "Highest Num 	lumber Previous umber Previously	ly Paid Fo Paid For"	or" IN THIS SPA IN THIS SPACE is	CE is less thar s less than 3, er	n 20, enter "20".	ox in column 1.			

United St	ates Patent and Trademar	UNITED STA' United States Address: COMMI PO. Box I	a, Virginia 22313-1450		
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE		
12/944,544	11/11/2010	Robert Frederick Veasey	10-1188-US-CON1		
			CONFIRMATION NO. 5949		
20306		FORMALITIES LETTER			
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606			CC000000044663932*		

Date Mailed: 11/26/2010

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

• The oath or declaration is missing.

A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.

Note: If a petition under 37 CFR 1.47 is being filed, an oath or declaration in compliance with 37 CFR 1.63 signed by all available joint inventors, or if no inventor is available by a party with sufficient proprietary interest, is required.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Replacement drawings in compliance with 37 CFR 1.84 and 37 CFR 1.121(d) are required. The drawings submitted are not acceptable because:
 - The drawings must be reasonably free from erasures and must be free from alterations, overwriting, interlineations, folds, and copy marks. See Figure(s) 1-16.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

The applicant needs to satisfy supplemental fees problems indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

• A surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.16(f) of \$130 for a non-small entity, must be submitted.

page 1 of 2

SUMMARY OF FEES DUE:

Total fee(s) required within **TWO MONTHS** from the date of this Notice is **\$130** for a non-small entity • **\$130** Surcharge.

Replies should be mailed to:

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <u>https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</u>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <u>http://www.uspto.gov/ebc.</u>

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

/sgorems/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 2 of 2

UNITED STATES PATENT AND TRADEMARK OFFICE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Advandria, Virginia 22313-1450 www.uspto.gov										
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS					
12/944,544	11/11/2010	3767	3222	10-1188-US-CON1	61 3					
				C	ONFIRMATION NO. 5949					
20306				FILING RE	CEIPT					
MCDONNELL	BOEHNEN HU	JLBERT &	BERGHOFF LL	P						
300 S. WACKER DRIVE					C000000044663931*					
32ND FLOOR				*0	C000000044663931*					
CHICAGO, IL	CHICAGO, IL 60606									

Date Mailed: 11/26/2010

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Robert Frederick Veasey, Warwickshire, UNITED KINGDOM; Robert Perkins, Warwickshire, UNITED KINGDOM; David Aubrey Plumptre, Worcestershire, UNITED KINGDOM;

Assignment For Published Patent Application

DCA DESIGN INTERNATIONAL LTD, Warwick, UNITED KINGDOM

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 11/483,546 07/11/2006 and is a CON of 10/790,225 03/02/2004 ABN

Foreign Applications

UNITED KINGDOM 0304822.0 03/03/2003

Request to Retrieve - This application either claims priority to one or more applications filed in an intellectual property Office that participates in the Priority Document Exchange (PDX) program or contains a proper **Request to Retrieve Electronic Priority Application(s)** (PTO/SB/38 or its equivalent). Consequently, the USPTO will attempt to electronically retrieve these priority documents.

If Required, Foreign Filing License Granted: 11/23/2010

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/944,544**

Projected Publication Date: To Be Determined - pending completion of Missing Parts **Non-Publication Request:** No

page 1 of 3

Mylan Exhibit - 1006 Mylan v. Sanofi

Early Publication Request: No Title

Pen-Type Injector

Preliminary Class

604

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where

page 2 of 3

the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

page 3 of 3

		PTO/SB/81 (01-09) Approved for use through 11/30/2011. OMB 0661-0035
	U.S. Patent	and Tradomark Officer U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required	Application Numbe	r 12/944,544
POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY	Filing Date	November 11, 2010
	First Named Invent	
	Title	Pen-Type Injector
AND	Art Unit	Unassigned
CHANGE OF CORRESPONDENCE ADDRESS	Examiner Name	Unassigned
CHANGE OF CONNECT ON DELIVER THE	Attorney Docket Ni	imber 10-1188-US-CON1
I hereby revoke all previous powers of attorney given i		
A Power of Attorney is submitted herewith.		
OR I hereby appoint Practitioner(s) associated with the following Number as my/our attorney(s) or agent(s) to prosecute the identified above, and to transact all business in the United s and Trademark Office connected therewith:	application	20306

	DR I hereby appoint Practitioner(s) named below as my/our attorn to transact all business in the United States Patent and Trader	ey(s) or agent(s) to prosecute the application identified above, and nark Office connected therewith:
	Practitioner(s) Name	Registration Number
		·
Ļ		

Address

City Country

Please recogni:

X The add

OR		
The add	iress associated with Customer N	lumb
OR		

recognize or chai	nge the correspondence address for the above-Identific	ed applic	ation to:		
The address ass	ociated with the above-mentioned Customer Number.				
?			[
The address ass	ociated with Customer Number:				
Firm or Individual Name					.
iS					
		State		Zip	
·····					

Email

Telephone			Eman	
Telephone				
I am the:				
Appli	ant/inventor.			
OR				
Assic	nee of record of the entire interes	t. See 37 CFR 3.71.		
Ctata	nent under 37 CFR 3.73(b) (Forn	n PTO/SB/96) submitted herewi	th or filed on	
01816		IGNATURE of Applicant or A	ssignee of F	Record
		SIGNATORE OF Applicate of the		Date
Signature	1 Vlase	~		
Gignatalo				T-1

	TP VA - 2	Date	14/2/2011			
Signature	L. Vlasen	Telephone	144 1926 499461			
Name	Robert Frederick Veasey					
Title and Company	Inventor					
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.						

*Total of 3 forms are submitted.

.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33, The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, end submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork	Reduction Act of 1995, no persons are required	to respond to a collection	on of Info	rmation unless	it displays a valid	OMB control number.
		Application Numb	er	12/044,044		
POWER OF ATTORNEY OR	R OF ATTORNEY	Filing Date		November '	11, 2010 Jerick Veasey e	
	First Named Inver	ntor	Robert Fred	Jerick veasey e	L dl.	
REVOCATION O	POWER OF ATTORNEY POWER OF ATTORNEY	Title		Pen-Type li	njector	
	AND	Art Unit		Unassigned	1	
	RESPONDENCE ADDRESS	Examiner Name		Unassigned	t	
MANGE OF COM		Attorney Docket	umber	10-1188-U	S-CON1	
·····						
hereby revoke all p	revious powers of attorney given	in the above-lder	ntified a	application).	
A Power of Attorn	ney is submitted herewith.		·			
I hereby appoint I Number as my/ou identified above, and Trademark C	Practitioner(s) associated with the followin ur attorney(s) or agent(s) to prosecute the and to transact all business in the United Office connected therewith:	states Patent	2030			
I hereby appoint	Practitioner(s) named below as my/our alt siness in the United States Patent and Tra	torney(s) or agent(s) ademark Office conne	to prose ected the	cute the app erewith:	lication identifie	above, and
	Praclitioner(s) Name			legistration N	lumber	
	, isottoricity raine					
	· · · · · · · · · · · · · · · · · · ·					
					······	
OR The address ass OR	sociated with Customer Number:					
Firm or Individual Name			<u></u>			
Address						
		State	1		Zip	
City					<u></u>	
Country		Email				
Telephone		Email				
I am the: Applicant/Invent OR Assignee of rec Statement under	ord of the entire interest. See 37 CFR 3.7 or 37 CFR 3 73(b) (Form PTO/SB/96) subr	mitted herewith or file	d on	ord		
	SIGNATURE of Ap	oplicant or Assignee	OI Kec	Date	15-FE3-	7-54
Signature	10ct			Telephone	12 125	
Name	Robert Perkins		L		I	
Title and Company	Inventor			<u> </u>	Cuberalit	me if more then one
NOTE: Signatures of all th signature is required, see	Inventor ne Inventors or assignees of record of the entire below*.	Interest or their represe	ntallve(s)	are required.	Submit multiple for	
	ns are submitted.				nefit by the nublin	which is to file (and by the
USPTO in process) an ap-	on is required by 37 CFR 1.31, 1.32 and 1.33; The plication. Confidentiality is governed by 35 U.S.C. aring, and submitting the completed application equire to complete this form and/or suggestions			a deserved on the	unon the individua	Lease Any comments of

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork I	Reduction Act of 1995, no persons are required	to respond to a collection	on of Infor	mation unless	it displays a	valid OMB contr	ol number.
<i>(</i>		Application Numb	ier	16044,044			
POWER OF ATTORNEY		Filing Date First Named Inver	tor	November 11, 2010 Robert Frederick Veasey et al.			
1	OR			Robell Flee	Jellen vega	ey ot al.	
REVOCATION O	F POWER OF ATTORNEY POWER OF ATTORNEY	Title		Pen-Type I	njector		
	AND	Art Unit		Unassigne	d		
CHANGE OF COR	RESPONDENCE ADDRESS	Examiner Name		Unassigne	d		
CHANGE OF CON		Attorney Docket	lumber	10-1188-U	S-CON1		
				11 11			
I hereby revoke all pr	revious powers of attorney given	In the above-ider	ntified a	application	1.	;	
	ey is submitted herewith.				•		
OR			[<u>.</u>	
Number as my/ou identified above, a and Trademark O	Practitioner(s) associated with the followir ir attorney(s) or agent(s) to prosecute the and to transact all business in the United iffice connected therewith:	States Patent	2030				
	Practitioner(s) named below as my/our at siness in the United States Patent and Tra	torney(s) or agent(s) ademark Office conne	to prose acted the	cute the app erewith:	lication ide	atified above, a	ind
	Practitioner(s) Name		R	egistration N	lumber		
						an a	
	·						
	in a second s	above-identified appli	cation to				
	nge the correspondence address for the a						
The address ass	oclated with the above-mentioned Custor	ner Number.					
OR							
	ociated with Customer Number:						
Firm or							
Address							
		State			Zip	>	
City							
Country		Emall					
Telephone							
I am the: Applicant/Invent OR Assignee of rec	ord of the entire interest. See 37 CFR 3.7	1.					
Statement unde	r 37 CEB 3 73(b) (Form PTO/SB/96) sub	mitted herewith or tile	ed on	1			
······	ASIGNATURE of A	oplicant or Assigned	s of their	ord Date	14/21	2011	
Signature	1/ NVVID			Date Telephone		26 4994	61
Name	David Aubrey Plumptre			1 cichilolle	1441 171		
Title and Company	Inventor				Oubmit	nlo forms if more	than one
NOTE: Signatures of all th signature is required, see	Inventors or assignees of record of the entire below*.	Interest or their represe	entative(s)	are required.			
	ns are submitted.						file (and by th
USPTO to process) an ap including gathering, prepa the amount of time you re	on is required by 37 CFR 1.31, 1.32 and 1.33, T plication, Confidentiality is governed by 35 U.S.(iring, and submitting the completed application aquire to complete this form and/or suggestions Department of Commerce, P.O. Box 1450, A ommissioner for Patents, P.O. Box 145	form to the USPTO. The s for reducing this burde lexandria, VA 22313-14 50, Alexandria, VA 2	me will va en, shouic 160, DO 2313-14	ry depending i be sent to th NOT SEND i 50.	upon the Ind e Chief Infor EES OR C	Ividual case. Any mation Officer, L OMPLETED FO	J.S. Patent an RMS TO THI LegelNel, Inc.
	If you need assistance in completing	the form, call 1-800-	PTO-91	99 and selec	ot option 2.	. www.Forn	nsWorkflow.com

0086

. .

Mylan v. Sanofi

PTO/SB/22 (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDE FY 2009		Docket Number (0 10-1188-US-CO	
(Fees pursuant to the Consolidated Appropriations A Application Number 12/944,544	401, 2003 (H.K. 4818).)	Filed November	11, 2010
For Pen-Type Injector			
Art Unit 3767		Examiner Unass	signed
This is a request under the provisions of 37 CFR 1.13 application.	86(a) to extend the period	d for filing a reply in	the above identified
The requested extension and fee are as follows (chee	ck time period desired ar	nd enter the approp	riate fee below):
	<u>Fee</u> <u>Sn</u>	nall Entity Fee	
One month (37 CFR 1.17(a)(1))	\$130	\$65	\$
Two months (37 CFR 1.17(a)(2))	\$490	\$245	\$490.00
Three months (37 CFR 1.17(a)(3))	\$1110	\$555	\$
Four months (37 CFR 1.17(a)(4))	\$1730	\$865	\$
Five months (37 CFR 1.17(a)(5))	\$2350	\$1175	\$
Applicant claims small entity status. See 37 CFF	R 1.27.		
A check in the amount of the fee is enclose	d.		
Payment by credit card. Form PTO-2038 is	attached.		
The Director has already been authorized to	o charge fees in this a	pplication to a De	eposit Account.
The Director is hereby authorized to charge Deposit Account Number 13-2490.	any fees which may	be required, or cr	edit any overpayment, to
WARNING: Information on this form may become Provide credit card information and authorization		ation should not be	included on this form.
I am the 🔲 applicant/inventor.			
assignee of record of the entire Statement under 37 CFR 3.7			
attorney or agent of record. Reg	istration Number <u>41,5</u>	<u>23</u>	
attorney or agent under 37 CFR Registration number if acting und			
/Thomas E. Wettermann/		Mar	rch 21, 2011
Signature Thomas E. Wettermann		311	Date 2-913-2138
Typed or printed name		phone Number	
NOTE: Signatures of all the inventors or assignees of record of the en signature is required, see below.	ntire interest or their representa	tive(s) are required. Sub	mit multiple forms if more than one
Total of <u>1</u> forms are submitted.			
This collection of information is required by 37 CFR 1.136(a). The info USPTO to process) an application. Confidentiality is governed by 35 U complete, including gathering, preparing, and submitting the complete comments on the amount of time you require to complete this form and U.S. Patent and Trademark Office, U.S. Department of Commerce, P. FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents	S.C. 122 and 37 CFR 1.11 and d application form to the USPT d/or suggestions for reducing th O. Box 1450, Alexandria, VA 22	d 1.14. This collection is O. Time will vary depend is burden, should be sen 2313-1450. DO NOT SEN	estimated to take 6 minutes to ing upon the individual case. Any it to the Chief Information Officer,
If you need assistance in comp	bleting the form, call 1-800-PTC 0087		2. an Exhibit - 1006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

)

In re A _l	n re Application of:				
	Robert Frederick Veasey et al.				
Serial N	Serial No.: 12/944,544				
Filed:	Filed: November 11, 2010				
For: Pen-Type Injector					
Commi	Commissioner for Patents				

Examiner: Unassigned Group Art Unit: 3767 Confirmation No.: 5949

GENERAL AUTHORIZATION UNDER 37 C.F.R. § 1.136(a)(3)

Sir:

P.O. Box 1450

Alexandria, VA 22313-1450

The Commissioner is hereby generally authorized under 37 C.F.R. § 1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 C.F.R. § 1.53 requiring an extension of time as incorporating a request therefore, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 13-2490 for any fee that may be due in connection with such a request for an extension of time.

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: March 21, 2011

By:

<u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

Mylan Exhibit - 1006 Mylan v. Sanofi

Electronic Patent Application Fee Transmittal						
Application Number:	12944544					
Filing Date:	11-	Nov-2010				
Title of Invention:	Pen-Type Injector					
First Named Inventor/Applicant Name:	Rol	bert Frederick Vease	еу			
Filer:	The	omas E. Wetterman	n			
Attorney Docket Number:	10-	1188-US-CON1				
Filed as Large Entity						
Utility under 35 USC 111(a) Filing Fees						
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)	
Basic Filing:						
Pages:						
Claims:						
Miscellaneous-Filing:						
Late filing fee for oath or declaration		1051	1	130	130	
Petition:						
Patent-Appeals-and-Interference:						
Post-Allowance-and-Post-Issuance:						
Extension-of-Time:	-0	089	N	Aylan Exhibi Mylan v.		

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension - 2 months with \$0 paid	1252	1	490	490
Miscellaneous:				
Total in USD (\$) 6				620

Electronic Ac	Electronic Acknowledgement Receipt				
EFS ID:	9703674				
Application Number:	12944544				
International Application Number:					
Confirmation Number:	5949				
Title of Invention:	Pen-Type Injector				
First Named Inventor/Applicant Name:	Robert Frederick Veasey				
Customer Number:	20306				
Filer:	Thomas E. Wettermann				
Filer Authorized By:					
Attorney Docket Number:	10-1188-US-CON1				
Receipt Date:	21-MAR-2011				
Filing Date:	11-NOV-2010				
Time Stamp:	18:14:03				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted with Payment	yes				
Payment Type	Deposit Account				
Payment was successfully received in RAM	\$620				
RAM confirmation Number	5898				
Deposit Account	132490				
Authorized User					
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:					
Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)					
Charge any Additional Fees required under 37 C.F.R. Se	ction 1.20 (Post Issuance fees) 0001 Mylan Exhibit - 1006				
	0091				

File Listing	j :				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	10_1188_US_CON1_Missing_P arts_Transmittal_2011_03_21.	140310	no	1
•		pdf	592f5b328ebfcfacd0850a194fe8a7011fc29 0c1		,
Warnings:					
Information:					
2	Miscellaneous Incoming Letter	10_1188_US_CON1_Missing_P arts_Response_2011_03_21.	50673	no	1
		pdf	5c9e69f50a09b599328872cef30ecd5b9a03 3cf9		
Warnings:					
Information:					
3	Oath or Declaration filed	10_1188_US_CON1_Declaratio	703937	no	5
J	outror Decidiation nica	n_2011_03_21.pdf	9fe5651e66ba41d5f2b3aef4a260f52aaf4b1 6d1	no	
Warnings:					
Information:					
4	Power of Attorney	10_1188_US_CON1_Power_Of	420245	no	3
т	Tower of Automey	_Attorney_2011_03_21.pdf	79c5528a8df5d5a6f497e40a5970244b8f64 6564	110	
Warnings:	·			<u> </u>	
Information:					
5	Extension of Time	10_1188_US_CON1_2Mo_Ext_	128429	no	1
5		Time_2011_03_21.pdf	8b3761cb40979d8c28175f07b32b9ad2a68 24080	110	I
Warnings:	·			<u> </u>	
Information:					
6	Authorization for Extension of Time all	10_1188_US_CON1_General_A	58750		1
0	replies	uthorization_2011_03_21.pdf	a4e018ea2ef3c7073faff010b162004f2391c 4de	no	
Warnings:	· · ·		L		
Information:					
7	Fee Worksheet (PTO-875)	fee-info.pdf	32070	50	2
,		iee mo.pu	bf2fe387dae4b60c5e08e067a0bb6fb50f43 d8ba	no	۷
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/21 (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

	Application Number	12/944,544				
TRANSMITTAL	Filing Date	November 11, 2010				
FORM	First Named Inventor	Robert Frederick Veasey et al.				
	Art Unit	3767				
(to be used for all correspondence after initial	filing) Examiner Name	Unassigned				
Total Number of Pages in This Submission	12 Attorney Docket Number	er 10-1188-US-CON1				
	ENCLOSURES (Check al	all that apply)				
Fee Transmittal Form	Drawing(s)	After Allowance Communication to TC				
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences				
Amendment/Reply	Petition	Appeal Communication to TC (Appeal				
After Final	Petition to Convert to a Provisional Application	Notice, Brief, Reply Brief) Proprietary Information				
Affidavits/declaration(s)	Power of Attorney, Revocat Change of Correspondence	ation				
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please Identify below):				
Express Abandonment Request	Request for Refund	Executed Declaration and				
Information Disclosure Statement	CD, Number of CD(s)					
 Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 	Remarks					
SIGNA	TURE OF APPLICANT, ATT	ORNEY, OR AGENT				
Firm Name McDonnell Boehnen	Hulbert & Berghoff LLP					
Signature /Thomas E. Wetterm	nann/					
Printed name Thomas E. Wetterma	ann					
Date March 21, 2011		Reg. No. 41,523				
CERTIFICATE OF TRANSMISSION/MAILING						
		e USPTO or deposited with the United States Postal Service ssioner for Patents, P.O. Box 1450, Alexandria, VA 22313-				
Signature /Thomas E. V	Nettermann/					
Typed or printed name Thomas E. W	Vettermann	Date March 21, 2011				
This collection of information is required by 37 CFI	This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USP1O to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USP1O. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Mylan Exhibit - 1000

Mylan v. Sanofi

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

)

In re Application of: Robert Frederick Veasey et al. Serial No.: 12/944,544 Filed: November 11, 2010

For: Pen-Type Injector

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Examiner: Unassigned Group Art Unit: 3767 Confirmation No.: 5949

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

In accordance with the Notice to File Missing Parts dated November 26, 2010, we are filing

herewith an executed Declaration and Power of Attorney, together with the requisite fees, pursuant

to 37 C.F.R. §§ 1.16(e).

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: March 21, 2011

Ву: <u>/Т</u> т

/Thomas E. Wettermann/ Thomas E. Wettermann Reg. No. 41,523

PATENT APPLICATION (37 CFR 1.63) Declaration Submitted With Initial Filing OR Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (f)) required) Declaration Submitted after Initial Filing Date November 11, 2010 Art Unit Unassigned Art Unit Unassigned Examiner Name Unassigned Mathematication (2) I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and or which a patent is sought on the invention entitled: Pen-Type Injector (Title of the Invention) The application of which is attached hereto	Under the Panerwork Reduction	Act of 1995, no persons are required to	U.S. Patent and Trader respond to a collection of information	nark Office; U.S. DEPARTMENT OF COMMERC tion unless it contains a valid OMB control number
DESIGN PATENT APPLICATION (37 CFR 1.63) Declaration With initial With initial With initial With initial With initial With initial With initial (2) believer the inventor's isolence, mailing address, and citizenship are as stated below next to their name diagonal diagonal diagonal diagonal diagonal diagonal diagonal diagonal (2) believe the inventor's residence, mailing address, and citizenship are as stated below next to their name diagonal diagonal diagonal diagonal diagonal diagonal diagonal diagonal diagonal diagonal diagonal which a patent is sought on the invention entitled: Pen-Type Injector (Title of the Invention) Is attached hereto (Title of the contents of the above identified applicable). hereby state that 1 have reviewed and understand the contents of the above identified application, including the claims, mended by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including 1 ontimution-in-part application, material information which became available between the filing date of the prior application. Application To Permit Access To Application by Participating Offices (EPO), the Krean intelledual Property Office (NPO), the wore-identified patent application	-		Attorney Docket	
(37 CFR 1.63) Application Declaration Declaration With initial OR Declaration Submitted Submitted after Initial Filing Date November 11, 2010 Art Unit Unassigned Filing Examiner Name Unassigned Initial (2) believe the inventor's made below to be the original and first inventor(s) of the subject matter which is claimed and rwhich a patent is sought on the invention entitled. Pen-Type Injector (7itle of the Invention) is attached hereto (7itle of the Invention) is attached hereto (7itle of the Invention) was filed on (MM/DD/YYYY) 11/11/2010 as United States Application Number or PCT International Application Number 12/944,544 Application Number 12/944,544 and was amended on (MM/DD/YYYY) (11/11/2010 as United States Application Number or PCT International Application Number 12/944,544 Application Number 12/944,544 State and the contents of the above identified application, including the claims, mendel by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including 1 on orbitruation-in-part application. Muthorization To Permit Access To Application by Participating Offices If checked, the undersigned hereby grants the USPT0 authority to provide the European Patent Office (EPO),			First Named Inventor	Robert Frederick Veasey et al.
Declaration Declaration Tryperadon (Value) Tryperadon (Value) Bing Date November 11, 2010 With Initial Image Submitted after Initial Filing Date November 11, 2010 Art Unit Unassigned Examiner Name Unassigned example Examiner Name Unassigned (2) I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and which a patent is sought on the invention entitled: Pen-Type Injector (Title of the Invention) e application of which is attached hereto Was filed on (MM/DD/YYYY) <u>11/11/2010</u> as United States Application Number or PCT International Application Number 12/944,544 and was amended on (MM/DD/YYYY)			CON	IPLETE IF KNOWN
Sommitted With Initial Filing submitted after Initial Filing excertance (37 CFR1.16 (f)) required) Initial Submitted after Initial Filing excertance (37 CFR1.16 (f)) required) Initial Consistence Art Unit Unassigned hereby declare that: (1) Each Inventor's residence, mailing address, and citizenship are as stated below next to their name dt (2) believe the Inventor(s) named below to be the original and first Inventor(s) of the subject matter which is claimed and r which a patient is sought on the Invention entitled: Pen-Type Injector (Title of the Invention) eapplication of which is attached hereto Is attached hereto (R) Was filed on (MM/DD/YYYY) 11/11/2010 as United States Application Number or PCT International Application Number 12/944,544 and was amended on (MM/DD/YYYY) (if applicable). hereby state that I have reviewed and understand the contents of the above identified application, including the claims, imended by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including 1 ontinuation-h-part applications, material Information which became available between the filing date of the prior application inductorin-h-part applications, material Information which became available between the filing date of the prior application inductorin-trapart applications, material Information which became available between the filing date of the prior application inductorin-trapart applications. hereby diffice (JPO), the apan Patent Office (JPO), the Korcen Intellectual Propery Office (MPO), the apan Patent Office (JPO), t			Application Number	12/944,544
With Initial UR Enling (surcharge (37 CFR 1.16 (ft)) required) Art Unit Unassigned Hereby declare that: (1) Each inventor's residence, mailing address, and citizenship are as stated below next to their name di (2) I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and rwhich a patent is sought on the invention entitled: Pen-Type Injector (Title of the Invention) eapplication of which is statched hereto Was filed on (MM/DD/YYYY) 11/1/1/2010 as United States Application Number or PCT International Application Number 12/944,544 and was amended on (MM/DD/YYYY) (ft applicable). hereby state that I have reviewed and understand the contents of the above identified application, including the claims, mended by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including 1 ontinuation-in-part applications, material information which became available between the filing date of the prior application application in the national or PCT international filing date of the continuation-in-part application. Authorization To Permit Access To Application by Participating Offices If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (IPO), the apan Patent Office (JPO), KIPO, wiPO, or other intellectual property office in which a foreign application calming priority to the above-identified patent application. nuclear cost with the EPO, JPO, KIPO, WIPO, or other intellectual property office inventor application admit priorit	Submitted OD Submitted after Initial	Filing Date	November 11, 2010	
required) Examiner Name Unassigned hereby declare that: (1) Each Inventor's residence, mailing address, and citizenship are as stated below next to their name d(2) believe the inventor(s) named below to be the original and first Inventor(s) of the subject matter which is claimed and or which a patent is sought on the invention entitled: Pen-Type Injector (Title of the Invention) is attached hereto (Title of the Invention) was filed on (MM/DD/YYYY) 11/11/2010 as United States Application Number or PCT International Application Number 12/944,544 and was amended on (MM/DD/YYYY) (if applicable). hereby state that I have reviewed and understand the contents of the above identified application, including the claims, a mended by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including 1 ontinuation-in-part applications, material information which became available between the filing date of the prior application in the national or PCT international filing date of the continuation-in-part application. Authorization To Permit Access To Application by Participating Offices	With Initial OR 2	Filing (surcharge	Art Unit	Unassigned
nd (2) believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and re which a patent is sought on the invention entitled: Pen-Type Injector (Title of the Invention) he application of which is attached hereto Is attached hereto (Title of the Invention) was filed on (MM/DD/YYYY) <u>11/11/2010</u> as United States Application Number or PCT International Application Number <u>12/944,544</u> and was amended on (MM/DD/YYYY) (if applicable). hereby state that I have reviewed and understand the contents of the above identified application, including the claims, is mended by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including 1 ontinuation-in-part applications, material information which became available between the filing date of the prior application of the above-identified patent application. Authorization To Permit Access To Application by Participating Offices If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the forean intellectual property Offices in which a foreign application claiming priority to the above-identified patent application. naccordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above-identified patent application. naccordance with 37 CFR 1.14(h)(3), access may be provided to a foreign application to which be above-identified patent application. naccordance with 37 CFR 1.14(c), a	1 11113		Examiner Name	Unassigned
ne application of which is attached hereto was filed on (MM/DD/YYYY) <u>11/11/2010</u> as United States Application Number or PCT International Application Number <u>12/944,544</u> and was amended on (MM/DD/YYYY)	and (2) I believe the inventor(s) or which a patent is sought on t Pen-Type Injector	named below to be the original he invention entitled:	and first inventor(s) of the	
ne application of which is attached hereto was filed on (MM/DD/YYYY) <u>11/11/2010</u> as United States Application Number or PCT International Application Number <u>12/944,544</u> and was amended on (MM/DD/YYYY)		/Title of t	he Invention)	
A was filed on (MM/DD/YYYY) <u>11/11/2010</u> as United States Application Number or PCT International Application Number <u>12/944,544</u> and was amended on (MM/DD/YYYY) (if applicable). hereby state that I have reviewed and understand the contents of the above identified application, including the claims, is mended by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for ontinuation-in-part applications, material information which became available between the filing date of the prior application if the national or PCT international filing date of the continuation-in-part application. Authorization To Permit Access To Application by Participating Offices	he application of which			
 was filed on (MM/DD/YYYY) <u>11/11/2010</u> as United States Application Number or PCT International Application Number <u>12/944,544</u> and was amended on (MM/DD/YYYY)	is attached hereto			
Application Number <u>12/944,544</u> and was amended on (MM/DD/YYYY) (if applicable). hereby state that I have reviewed and understand the contents of the above identified application, including the claims, is mended by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for ontinuation-in-part applications, material information which became available between the filing date of the prior application ind the national or PCT international filing date of the continuation-in-part application. Authorization To Permit Access To Application by Participating Offices 	OR			· · · ·
hereby state that I have reviewed and understand the contents of the above identified application, including the claims, is mended by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for ontinuation-in-part applications, material information which became available between the filing date of the prior application of the national or PCT international filing date of the continuation-in-part application. Authorization To Permit Access To Application by Participating Offices If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the lapan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and iny other intellectual property offices in which a foreign application claiming priority to the above-identified patent application see 37 CFR 1.14(c) and (h). This box should not be checked if the inpplicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application property office in which a foreign application claiming priority to the above-identified patent application claiming riority to the above-identified patent application is filed to have access to the above-identified patent application claiming riority to the above-identified patent application with respection. In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above-identified patent application which benefits on the above-identified patent application. In accordance with 37 CFR 1.14(c) if a copy of the foreign application that satisfies the certified copy requirement of CFR 1.55 has been filed in the above-identified patent application. In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices. [Page 1 of 3]	was filed on (MM/DD/YYY	(Y) <u>11/11/2010</u> as United Stat	es Application Number or	PCT International
mended by any amendment specifically referred to above. acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including f ontinuation-in-part applications, material information which became available between the filing date of the prior application ind the national or PCT international filing date of the continuation-in-part application. Authorization To Permit Access To Application by Participating Offices If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the lapan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and inv other intellectual property offices in which a foreign application claiming priority to the above-identified patent application lied access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the piplicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming rriority to the above-identified patent application is filed to have access to the above-identified patent application claiming rriority to the above-identified patent application is filed to have access to the above-identified patent application claiming rriority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application to which the above-identified patent application. In accordance with 37 CFR 1.14(h)(3), access may be provided to a copy of the above-identified patent application atoms priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application to which the above-identified patent application. In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices. [Page 1 of 3]	Application Number <u>12/9</u>	44,544 and was amended on	(MM/DD/YYYY) (if	applicable).
ontinuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. Authorization To Permit Access To Application by Participating Offices If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the lapan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and iny other intellectual property offices in which a foreign application claiming priority to the above-identified patent application led access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming riority to the above-identified patent application is filed to have access to the above-identified patent application. In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above-identified patent application with respe to: 1) the above-identified patent application-as-filed; 2) any foreign application to which the above-identified patent application application the above-identified patent application as-filed; 2) any foreign application to which the above-identified patent application application is filed to have access to the above-identified copy requirement of 77 CFR 1.55 has been filed in the above-identified patent application; and 3) any U.S. application-as-filed from which benefit sought in the above-identified patent application. In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices. [Page 1 of 3]	hereby state that I have revie amended by any amendment sp	wed and understand the conte pecifically referred to above.	ents of the above identified	d application, including the claims, as
If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the apan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and invy other intellectual property offices in which a foreign application claiming priority to the above-identified patent application lied access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified patent application is filed to have access to the above-identified patent application. In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above-identified patent application with respe to: 1) the above-identified patent application-as-filed; 2) any foreign application to which the above-identified patent application chains priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of cought in the above-identified patent application. The above-identified patent application. The above-identified patent application. The above-identified patent application. The above-identified patent application has a copy of the foreign application that satisfies the certified copy requirement of the above-identified patent application. The	continuation-in-part applications	s, material information which b	ecame available between	lefined in 37 CFR 1.56, including for the filing date of the prior application
apan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and inv other intellectual property offices in which a foreign application claiming priority to the above-identified patent application iled access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claimin priority to the above-identified patent application is filed to have access to the above-identified patent application. In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above-identified patent application with respe to: 1) the above-identified patent application-as-filed; 2) any foreign application to which the above-identified patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application; and 3) any U.S. application-as-filed from which benefit cought in the above-identified patent application. In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices. [Page 1 of 3]	Authorization To Permit A	ccess To Application by F	Participating Offices	
 o: 1) the above-identified patent application-as-filed; 2) any foreign application to which the above-identified patent applicatio claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of CFR 1.55 has been filed in the above-identified patent application; and 3) any U.S. application-as-filed from which benefit cought in the above-identified patent application. n accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices. 	Japan Patent Office (JPO), the any other intellectual property o filed access to the above-identif applicant does not wish the EPC	Korean Intellectual Property Of iffices in which a foreign applica fied patent application. See 37 O, JPO, KIPO, WIPO, or other i	fice (KIPO), the World Inte ation claiming priority to the CFR 1.14(c) and (h). This intellectual property office	Ilectual Property Office (WIPO), and a above-identified patent application is s box should not be checked if the in which a foreign application claiming
Permit Access to Application by Participating Offices. [Page 1 of 3]	to: 1) the above-identified pate claims priority under 35 U.S.C. 37 CFR 1.55 has been filed in t	nt application-as-filed; 2) any fo 119(a)-(d) if a copy of the foreig he above-identified patent appl	preign application to which gn application that satisfies	the above-identified patent application the certified copy requirement of
	In accordance with 37 CFR 1.1 Permit Access to Application by	/ Participating Offices.	· · · · · · · · · · · · · · · · · · ·	ne date of filing the Authorization to
	· · · · · ·	,		

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing the form, call 1-800-PTO-9199 and select option 2

Mylan Exhibit - 1006

Mylan v. Sanofi

DECLARATION — Utility or Design Patent Application

Claim of Foreign Priority Benefits

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Co YES	py Attached? NO
0304822.0	GB	03/03/2003			\boxtimes
Additional foreign app	lication number	s are listed on a supplemental	priority data sheet PTC)/SB/02B attacł	ned hereto.


[Page 2 of 3]



PTO/SB/01 (04-09) Approved for use through 09/30/2010. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all assoc	ddress slated with omer Number:	20304	OR	Correspondence address below					
Name									
Address		anna a sa anna anna anna anna anna anna							
011		State		ZIP					
City		Onaro							
Country	Telephone		Email						
contribute to identity theft. Person (other than a check or credit card USPTO to support a petition or an USPTO, petitioners/applicants sho to the USPTO. Petitioner/applicant the application (unless a non-publ patent. Furthermore, the record fir referenced in a published applicat PTO-2038 submitted for payment Petitioner/applicant is advised tha into the Privacy Act system of recor <i>Files</i> . Documents not retained in COMMERCE/PAT-TM-10, System	WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicant should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application is insuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application forms PTO-2038 submitted for payment purposes are not retained in the application (such as the PTO/SB/01) are placed into the Privacy Act system of records DEPARTMENT OF COMMERCE, COMMERCE-PAT-7, System name: <i>Patent Application Files</i> . Documents not retained in an application file (such as the PTO-2038) are placed into the Privacy Act system of COMMERCE/PAT-TM-10, System name: <i>Deposit Accounts and Electronic Funds Transfer Profiles</i> .								
NAME OF SOLE OR FIRS		A petitio	n has been file	d for this unsigned inventor					
Given Name (first and middle [if a		Family Name or Surr	Family Name or Surname						
Robert Frederick		Veasey							
Inventor's Signature	Veasey.	Da	l8	3/11					
Residence: City	State	Country		Citizenship					
Warwickshire		UK		UK					
Mailing Address 31 Lonsdale Road Leamington Spa									
City Warwickshire	State	Zip CV32 T	'EP	Country UK					
Additional inventors or a legal repr	resentative are being nan	ned on the <u>1</u> supplemental shee [Page 3 of 3]	(s) PTO/SB/02A or	02LR attached hereto.					



PTO/SB/02A (07-07) Approved for use through 06/30/2010. OMB 0851-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. A -1 -1 1000

DECLARATION	ADDITIC Supplement	DNAL INVENT	OR(S) Page <u>1</u> of <u>1</u>		
Name of Additional Joint Inventor, if any:		A pet	ition has been filed f	or this unsigned in	ventor
Given Name (first and middle (if any)		Family Nan	ne or Sumame		
Robert 110		Perkins	99 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1		
Inventor's Signature				and the second	HMARCH 2011
Oxfordshire			UK	. UK	
Residence: City	State		Country	Citizens	hip
6 Printers Court Abingdon					
Mailing Address			OX14 SB	z uk	800011131011000110410440440440441011011011011011
Oxfordshire City	State		Zip	Country	
Name of Additional Joint Inventor, if any:		A pe	lition has been filed f	or this unsigned inv	ventor
Given Name (first and middle (if any)		Family Name or Sumame			
David Aubrey		Plumptre)		
Inventor's Signature	95940000 400 000 900 900 900 000 000 000 0			Date	a na se
Worcestershire			υκ		UK
Residence: City	State		Country		Citizenship
36 Shire Way Droitwich Mailing Address	10117510-00-00-00-00-00-00-00-00-00-00-00-00-0	Valgeture partners and Product Flowers and a St			
Worcestershire	0		WR9 7	UK Count	n/
City	State		Zlp	<u> </u>	: y
Name of Additional Joint Inventor, if any:	1990) (1991) - 1990) - 1990) - 1990) - 1990) - 1990) - 1990) - 1990) - 1990) - 1990) - 1990) - 1990) - 1990) -		tition has been filed		and a second
Given Name (first and middle (if any)		000200977777777777777777777777777777777	Fami	y Name or Sumam	10
Inventor's Signature				Date	ر می اور این می اور این می اور این می اور این می این این این می اور این می اور این می اور این می اور این می اور این می این می
Residence: City	State		Country	SEANONE DE LOS CONTRACTORIS CONTRACTORIS CONTRACTORIS CONTRACTORIS CONTRACTORIS CONTRACTORIS CONTRACTORIS CONT	Citizenship
Malling Address		11112100000000000000000000000000000000	2001		
City This collection of Information is required by 35 U.S.C. 115 and 37 C	State		Zip	Coun	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.53. The information is required to obtain on reliant a benefit of the police which is the field of the police which is do not a constrained to be an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

American LegalNet, Inc. www.FormsWorkflow.com

PTO/SB/02A (07-07) Approved for use through 06/30/2010. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE required to respond to a colleolion of information unless it contains a valid OMB control number. Underth

DECLARATION				VENTOR(S	5) Page <u>1</u> of <u>1</u>	
				P1		
Name of Additional Joint Inventor, if any:	en filed for this u	insigned in	IVENIOF			
Given Name (first and middle (if any)		Family Na	ne or Suman	าย		
Robert		Perkins				
Inventor's Signalure					Date	an de la de la casa de
Warwickshire	and the second design of the s		UK	antisti ya kata na kata	UK	
Residence: City	State	•	Country		Citizens	hlp
67 Erica Drive Leamington Spa						• .
Mailing Address	ana mana ana ana ana ana ana ana ana ana				UK	
Warwickshire	State		Zip	31 2RW	Country	,
City Name of Additional Joint Inventor, if any:		A pe	and a second	en filed for this u	nsigned in	ventor
Given Name (first and middle (if any)				Family Name	or Suman	18
David Aubrey		Plumptre	9		-1	
Inventor's Signature			a and a state of the local state of	29 600 Jakata 10 10 10 20 20 20 20 20 20 20 20 20 20 20 20 20	Date	14/2/2011
Worcestershire			UK			UK
Residence: City	State		Country	and and a second se		Citizenship
36 Shire Way Droitwich						
Mailing Address						- Constant of the State
Worcestershire		August	WR9 7	,	UK	
City	State		Zip		Count	ry .
Name of Additional Joint Inventor, if any:		Ар	etition has be	en filed for this	unsigned	inventor
Given Name (first and middle (if any)				Family Name	or Suman	18
		an a		na decentrative point of the sector of a sector of the sec	1	Ţĸĸġĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ
Inventor's Signature					Date	22.000.000.000.000.000.000.000.000.000.
Residence: City	State	19-19-19-19-19-19-19-19-19-19-19-19-19-1	Country		12 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Citizenship
				e		
Mailing Address	<u> </u>	and a subscription of the		and an a stand of the stand of	agua provinsi se	#1.1997.00 FEROID 41.41.41.41.41.41.41.41.41.41.41.41.41.4
City	State		Zip		Coun	
This collection of information is required by 35 U.S.C. 115 and 37 O (and by the USPTO to process) an application. Confidentiality is go minutes to complete, including gathering, preparing, and submitting case. Any comments on the amount of time you require to complete Officer, U.S. Patent and Trademark Office, U.S. Department of Con FORMS TO THIS ADDRESS. SEND TO: Commissioner for Pat	overned by 30 the complete this form an	ed application d/or suggestio Box 1450, Ale	form to the l ns for reducin xandria, VA 2	JSPTO, Time w Ig this burden, s 22313-1450, DO	ll vary dep hould be so NOT SEN	ending upon the individual

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

American LegalNel, Inc. www.FormsWorkflow.com

	UNITED STATES PATENT AND TRADEMARK OFFICE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov							
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS		
12/944,544	11/11/2010	3767	3352	10-1188-US-CON1	61	3		
				CC	NFIRMATION	NO. 5949		
20306				FILING REC	EIPT			
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP								
300 S. WACKER DRIVE								
32ND FLOOR				*000	000000049232315	*		
CHICAGO, IL	60606							

Date Mailed: 08/11/2011

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Robert Frederick Veasey, Warwickshire, UNITED KINGDOM; Robert Perkins, Oxfordshire, UNITED KINGDOM; David Aubrey Plumptre, Worcestershire, UNITED KINGDOM;

Assignment For Published Patent Application

DCA DESIGN INTERNATIONAL LTD, Warwick, UNITED KINGDOM **Power of Attorney:** The patent practitioners associated with Customer Number <u>20306</u>

Domestic Priority data as claimed by applicant

This application is a CON of 11/483,546 07/11/2006 PAT 7,918,833 and is a CON of 10/790,225 03/02/2004 ABN

Foreign Applications (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <u>http://www.uspto.gov</u> for more information.) UNITED KINGDOM 0304822.0 03/03/2003

Request to Retrieve - This application either claims priority to one or more applications filed in an intellectual property Office that participates in the Priority Document Exchange (PDX) program or contains a proper **Request to Retrieve Electronic Priority Application(s)** (PTO/SB/38 or its equivalent). Consequently, the USPTO will attempt to electronically retrieve these priority documents.

If Required, Foreign Filing License Granted: 11/23/2010

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/944,544**

Projected Publication Date: To Be Determined - pending completion of Corrected Papers

page 1 of 3

Non-Publication Request: No

Early Publication Request: No Title

Pen-Type Injector

Preliminary Class

604

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

page 2 of 3

Mylan Exhibit - 1006 Mylan v. Sanofi

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

page 3 of 3

UNITED ST	UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMEN United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PC Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov						
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE				
12/944,544	11/11/2010	Robert Frederick Veasey	10-1188-US-CON1				
			CONFIRMATION NO. 5949				
20306		FORMALI	TIES LETTER				
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606			DC000000049232356*				

Date Mailed: 08/11/2011

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

An application number and filing date have been accorded to this application. The application is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given TWO MONTHS from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- Replacement drawings in compliance with 37 CFR 1.84 and 37 CFR 1.121(d) are required. The drawings submitted are not acceptable because:
 - The drawings must be reasonably free from erasures and must be free from alterations, overwriting, interlineations, folds, and copy marks. See Figure(s) 1 to 16.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

page 1 of 2

Replies should be mailed to:

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <u>https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</u>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <u>http://www.uspto.gov/ebc.</u>

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

/ctuazon/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 2 of 2

UNITED ST	UNITED STATES PATENT AND TRADEMARK OFFICE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Virginia 22313-1450 www.usdio.gov								
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE						
12/944,544	11/11/2010	Robert Frederick Veasey	10-1188-US-CON1						
20306 MCDONNELL BOEHNEN 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606	I HULBERT & BERGHOFF LLP		CONFIRMATION NO. 5949 WAL NOTICE						

Letter Regarding a New Notice and/or the Status of the Application

If a new notice or Filing Receipt is enclosed, applicant may disregard the previous notice mailed on 11/26/2010. The time period for reply runs from the mail date of the new notice. Within the time period for reply, applicant is required to file a reply in compliance with the requirements set forth in the new notice to avoid abandonment of the application.

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <u>https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</u>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <u>http://www.uspto.gov/ebc.</u>

If the reply is not filed electronically via EFS-Web, the reply must be accompanied by a copy of the new notice.

If the Office previously granted a petition to withdraw the holding of abandonment or a petition to revive under 37 CFR 1.137, the status of the application has been returned to pending status.

/ctuazon/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1

Mylan Exhibit - 1006 Mylan v. Sanofi

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875									Application or Docket Number 12/944,544		
APPLICATION AS FILED - PART I (Column 1) (Column 2) SMALL ENTITY								OR	OTHER THAN ORSMALL ENTITY		
	FOR	NUMBE	R FILE	D NUMBE	R EXTRA		RATE(\$)	FEE(\$)		RATE(\$)	FEE(\$)
	SIC FEE FR 1.16(a), (b), or (c))	N	/A	١	J/A		N/A		1	N/A	330
	ARCH FEE FR 1.16(k), (i), or (m))	N	/A	١	J/A		N/A		1	N/A	540
	MINATION FEE FR 1.16(0), (p), or (q))	N	/A	١	J/A		N/A		1	N/A	220
TOT	AL CLAIMS FR 1.16(i))	61	minus	20= *	41				OR	× 52 =	2132
	EPENDENT CLAII FR 1.16(h))	^{MS} 3	minus	3 = *					1	× 220 =	0.00
FEE	PLICATION SIZ E CFR 1.16(s))	E sheets of p \$270 (\$13 50 sheets	oaper, th 5 for sm or fractio	and drawings e e application si all entity) for ea on thereof. See CFR 1.16(s).	ze fee due is ch additional						0.00
MUL	_TIPLE DEPENDE	ENT CLAIM PRE	SENT (3	7 CFR 1.16(j))]		0.00
*lft	he difference in co	olumn 1 is less th	an zero,	enter "0" in colur	mn 2.		TOTAL		1	TOTAL	3222
	APPLIC	CATION AS A	MEND	ED - PART I	I				•	•	
		(Column 1)		(Column 2)	(Column 3)		SMALL	ENTITY	OTHER THAN OR SMALL ENTITY		
NT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
Ν	Total (37 CFR 1.16(i))	*	Minus	**	=	x	=		OR	x =	
AMENDMENT	Independent (37 CFR 1.16(h))	*	Minus	***	=	x	=		OR	x =	
AM	Application Size Fe	ee (37 CFR 1.16(s))	•		•						
	FIRST PRESENT	TION OF MULTIPI	E DEPEN	DENT CLAIM (37 C	CFR 1.16(j))				OR		
	I					·	TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
		(Column 1)		(Column 2)	(Column 3)						
NT B		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
ΜË	Total (37 CFR 1.16(i))	*	Minus	**	=	×	=		OR	x =	
AMENDMENT	Independent (37 CFR 1.16(h))	*	Minus	***	=	×	=		OR	x =	
Application Size Fee (37 CFR 1.16(s))								1			
	FIRST PRESENT	TION OF MULTIPI	E DEPEN	DENT CLAIM (37 C	CFR 1.16(j))				OR		
							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
*	* If the entry in cc * If the "Highest N * If the "Highest Nu The "Highest Num	Jumber Previous	ly Paid Fo Paid For"	or" IN THIS SPA IN THIS SPACE is	CE is less thar s less than 3, er	n 20, er nter "3".		in column 1.	_		

UNITED ST	UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P. Dox 1450 Alexandria Virginia 22313-1450 www.usipa.ov							
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE					
12/944,544	11/11/2010	Robert Frederick Veasey	10-1188-US-CON1					
			CONFIRMATION NO. 5949					
20306		ΡΟΑ ΑΟΟΙ	EPTANCE LETTER					
MCDONNELL BOEHNEN 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606	I HULBERT & BERGHOFF LLP		CC000000049231891*					

Date Mailed: 08/11/2011

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 03/21/2011.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/lchau/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

))

In re Application of: Robert Frederick Veasey et al. Serial No.: 12/944,544 Filed: November 11, 2010 For: Pen-Type Injector

Examiner: Unassigned

Group Art Unit: 3352

Confirmation No.: 5949

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

By:

In accordance with the Notice to file Corrected Application Papers dated August 11, 2011,

we are filing herewith Replacement Drawings.

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: December 21, 2011

/Thomas E. Wettermann/ Thomas E. Wettermann Reg. No. 41,523





FIG. 1













FIG. 5








FIG. 7






FIG. 8







5/7





Mylan Exhibit - 1006 Mylan v. Sanofi









FIG. 14



7/7

FIG. 15




FIG. 16

PTO/SB/22 (09-11) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136		ocket Number (Opt -1188-US-CON1	
Application Number 12/944,544		ed November 11	
For Pen-Type Injector	·		
Art Unit 3767	Ex	aminer Unassigi	ned
This is a request under the provisions of 37 CFR 1.136(a) to extend the application.	period fo	r filing a reply in th	e above identified
The requested extension and fee are as follows (check time period desi	red and e	nter the appropria	te fee below):
<u>Fee</u>	<u>Small</u>	<u>Entity Fee</u>	
One month (37 CFR 1.17(a)(1)) \$150		\$75 \$	i
Two months (37 CFR 1.17(a)(2)) \$560		\$280 \$	
Three months (37 CFR 1.17(a)(3)) \$1270		\$635 \$	1,270.00
Four months (37 CFR 1.17(a)(4)) \$1980		\$990 \$	
Five months (37 CFR 1.17(a)(5)) \$2690	Ş	\$1345 \$	<u> </u>
Applicant claims small entity status. See 37 CFR 1.27.			
A check in the amount of the fee is enclosed.			
Payment by credit card. Form PTO-2038 is attached.			
The Director has already been authorized to charge fees in t	this appli	cation to a Depo	osit Account.
The Director is hereby authorized to charge any fees which Deposit Account Number <u>13-2490</u> .		-	
WARNING: Information on this form may become public. Credit card i Provide credit card information and authorization on PTO-2038.	informatio	n should not be inc	cluded on this form.
I am the applicant/inventor.			
assignee of record of the entire interest. See 37 Statement under 37 CFR 3.73(b) is enclosed			
attorney or agent of record. Registration Number	<u>41,523</u>		
attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34	<u> </u> .		
/Thomas E. Wettermann/		Decemb	er 21, 2011
Signature Thomas E. Wettermann			Date 913 2138
Typed or printed name			one Number
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their reprisignature is required, see below.	resentative(s) are required. Submit	multiple forms if more than one
Total of <u>1</u> forms are submitted.			
This collection of information is required by 37 CFR 1.136(a). The information is required to ob USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1 complete, including gathering, preparing, and submitting the completed application form to the comments on the amount of time you require to complete this form and/or suggestions for redu U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexand	1.11 and 1.1 USPTO. Til ucing this bu a, VA 22313-	4. This collection is esti ne will vary depending rden, should be sent to 1450. DO NOT SEND	imated to take 6 minutes to upon the individual case. Any the Chief Information Officer,
If you need assistance in completing the form, call 1-80	00-PTO-919	9 and select option 2.	
0117		Mylar	American LegalNet, Inc. www.FormsWorkFlow.com

Mylan v. Sanofi

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

In re Application of:)
Robert Frederick Veasey et al.	
Serial No.: 12/944,544) Examiner: Unassigned
Filed: November 11, 2010) Group Art Unit: 3767)) Confirmation No.: 5949
For: Pen-Type Injector) Commination No.: 3949

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

GENERAL AUTHORIZATION UNDER 37 C.F.R. § 1.136(a)(3)

Sir:

The Commissioner is hereby generally authorized under 37 C.F.R. § 1.136(a)(3) to treat the present and any future related filings in this or any related application filed pursuant to 37 C.F.R. § 1.53 requiring an extension of time as incorporating a request therefore, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 13-2490 for any fee that may be due in connection with such a request for an extension of time.

> Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: December 21, 2011

By:

/Thomas E. Wettermann/ Thomas E. Wettermann Reg. No. 41,523

0118

Electronic Patent /	App	lication Fee	e Transmi	ittal			
Application Number:	129	944544					
Filing Date:	11-Nov-2010						
Title of Invention:	Pen-Type Injector						
First Named Inventor/Applicant Name:	Robert Frederick Veasey						
Filer:	Thomas E. Wettermann						
Attorney Docket Number:	10-	-1188-US-CON1					
Filed as Large Entity							
Utility under 35 USC 111(a) Filing Fees							
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)		
Basic Filing:							
Pages:							
Claims:							
Miscellaneous-Filing:							
Petition:							
Patent-Appeals-and-Interference:							
Post-Allowance-and-Post-Issuance:							
Extension-of-Time:							
Extension - 3 months with \$0 paid		1253) 119	1	Aylan ¹²²⁰ Exhibi	$t - 1006^{1270}$		
	U			Mylan v.	Sanofi		

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)	
Miscellaneous:					
	Total in USD (\$)			1270	

Electronic Ac	knowledgement Receipt
EFS ID:	11678485
Application Number:	12944544
International Application Number:	
Confirmation Number:	5949
Title of Invention:	Pen-Type Injector
First Named Inventor/Applicant Name:	Robert Frederick Veasey
Customer Number:	20306
Filer:	Thomas E. Wettermann
Filer Authorized By:	
Attorney Docket Number:	10-1188-US-CON1
Receipt Date:	21-DEC-2011
Filing Date:	11-NOV-2010
Time Stamp:	18:14:54
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1270
RAM confirmation Number	7951
Deposit Account	132490
Authorized User	
The Director of the USPTO is hereby authorized to charge	e indicated fees and credit any overpayment as follows:
Charge any Additional Fees required under 37 C.F.R. Se	ction 1.19 (Document supply fees)
Charge any Additional Fees required under 37 C.F.R. Se	ction 1.20 (Post Issuance fees) Mylan Exhibit - 1006
	0121 Mijian Exiliar 7000

File Listin	y.				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	T	10_1188_US_CON1_Response_	140358		
1	Transmittal Letter	Transmittal_2011_12_21.pdf	111498c02c73350e08beed9e1e977351b02 58f06	no	1
Warnings:			I <u> I</u>		
Information:					
2	Miscellaneous Incoming Letter	10_1188_US_CON1_Corrected _Papers_Response_2011_12_2	54494	no	1
-		1.pdf	6517f86eedf1c08baa7cc81388c27936b9a0 0a8f		·
Warnings:	·		·		
Information:					
3	Drawings-only black and white line	10_1188_US_CON1_Replacem	518544	no	7
drawings	drawings	ent_Drawings_2011_12_21.pdf	d9f42732e6294dba55d6309a8b5603c66fe e577e	110	,
Warnings:			L	· · · ·	
Information:					
4		10_1188_US_CON1_3Mo_Ext_	112298	no	1
		Time_2011_12_21.pdf	9745c57364a6bdc5903449b5b600cd4a06c b439a	110	
Warnings:					
Information:					
5	Authorization for Extension of Time all	10_1188_US_CON1_General_A	58823	no	1
_	replies	uthorization_2011_12_21.pdf	02e5a43202476683fc1937cdf68625b2ece1 fa28		
Warnings:					
Information:					
6	Fee Worksheet (SB06)	fee-info.pdf	30279	no	2
-			da9e5bd7ddaf2f4cd0c20925c04eaa7adad 15ce4		-
Warnings:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/21 (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the	Paperwork R	eduction Act of 1995,	no persor	ns are required to respond to a	collec	ction of info	ormation	unless it	displays a valid OMB control number.
(Application Number		12/944,	544		
Т	RANS	MITTAL		Filing Date		Novem	ber 11	, 2010	
	FO	RM		First Named Inventor		Robert I	Fredei	rick Ve	easey et al.
				Art Unit		3352			
(to be used for all correspondence after initial filing)				Examiner Name		Unassig	gned		
Total Numbe	er of Pages in	This Submission	11	Attorney Docket Numbe	er	10-1188	8-US-0	CON1	
			ENC	LOSURES (Check	all th	nat apply))		
Fee Tr	ransmittal F	orm		Drawing(s)				After A	Allowance Communication to TC
	Fee Attac	hed		Licensing-related Papers					l Communication to Board
	dment/Reply	ý		Petition Petition to Convert to a				Appea	ll Communication to TC (Appeal , Brief, Reply Brief)
	After Fina	Ι		Provisional Application					etary Information
	Affidavits/	declaration(s)		Power of Attorney, Revoca Change of Correspondence				-	Letter
Extens	sion of Time	Request		Terminal Disclaimer				Other	Enclosure(s) (please Identify
Expres	ss Abandon	ment Request		Request for Refund				below): oonse to Notice to File
	nation Disclo	sure Statement		CD, Number of CD(s)				Corre	ected Application Papers,
				Landscape Table on CD					ected Drawings and eral Authorization
	ed Copy of I nent(s)	Priority	Rem	arks					
	to Missing F								
Incom	plete Applic	ation ⁄lissing Parts							
	under 37	CFR 1.52 or 1.53							
		SIGNA		OF APPLICANT, ATT			RAG	ENT	
Firm Name	McDo			& Berghoff LLP					
Signature	_	as E. Wetterm							
Printed name		as E. Wetterma							
Date	Decer	nber 21, 2011			R	eg. No.	41,52	3	
					I				
(С	ERTIFI	CATE OF TRANSMIS	SSIC	ON/MAI	LING		
	postage as	first class mail in							e United States Postal Service (1450, Alexandria, VA 22313-
Signature		/Thomas E. W	/etterm	ann/					
Typed or printe	ed name	Thomas E. W	etterma	ann				Date	December 21, 2011
~									

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Mylan v. Sanofi

	PAT	ENT APPLI		DN FEE DE titute for Form		TION REC	ORD		Applica 12/94	tion or Docket Num 4,544	ber
	APP	LICATION A			umn 2)	SM	ALL E	NTITY	OR	OTHER SMALL	
FOR NUMBER FILED NUMBER EXTRA						RATE(\$)	FEE(\$)		RATE(\$)	FEE(\$)
	SIC FEE FR 1.16(a), (b), or (c))	N	/A	١	J/A	N/A				N/A	380
	ARCH FEE FR 1.16(k), (i), or (m))	N	/A	Ν	J/A	N/A				N/A	620
EXA	MINATION FEE FR 1.16(0), (p), or (q))	N	/A	Ν	J/A	N/A				N/A	250
TOT	AL CLAIMS FR 1.16(i))	61	minus	20= *	41				OR	× 60 =	2460
	EPENDENT CLAI	^{NS} 3	minus	3 = *						× 250 =	0.00
FEE	PLICATION SIZ E CFR 1.16(s))	and drawings e e application si all entity) for ea on thereof. See CFR 1.16(s).	ze fee due is ch additional						0.00		
Μυι	_TIPLE DEPENDE	ENT CLAIM PRE	SENT (3	7 CFR 1.16(j))							0.00
*lft	he difference in co	olumn 1 is less th	an zero,	enter "0" in colur	nn 2.	TOTAL				TOTAL	3710
	APPLIC	CATION AS A	MEND	ED - PART I	I		-		•	•	
		(Column 1)		(Column 2)	(Column 3)	SM	ALL E	NTITY	OR	OTHER SMALL	
NT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)		ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
μ	Total (37 CFR 1.16(i))	*	Minus	**	=	x	=		OR	X =	
AMENDMENT	Independent (37 CFR 1.16(h))	*	Minus	***	=	x	=		OR	x =	
AM	Application Size Fe	ee (37 CFR 1.16(s))	•								
	FIRST PRESENT	TION OF MULTIPI	E DEPEN	DENT CLAIM (37 C	CFR 1.16(j))				OR		
	1					TOTAL ADD'L FE	E		OR	TOTAL ADD'L FEE	
		(Column 1)		(Column 2)	(Column 3)				_		
NT B		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)		ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
μ	Total (37 CFR 1.16(i))	*	Minus	**	=	x	=		OR	x =	
AMENDMENT	Independent (37 CFR 1.16(h))	*	Minus	***	=	x	=		OR	x =	
AM	Application Size Fe	ee (37 CFR 1.16(s))			•						
	FIRST PRESENT	TION OF MULTIPI	E DEPEN	DENT CLAIM (37 C	CFR 1.16(j))				OR		
						TOTAL ADD'L FE	E		OR	TOTAL ADD'L FEE	
*	 If the entry in cc If the "Highest N If the "Highest Nu The "Highest Num 	Jumber Previous	ly Paid Fo Paid For"	or" IN THIS SPA IN THIS SPACE is	CE is less thar s less than 3, er	1 20, enter "20". hter "3".	e box in	column 1.	-		

	United State	<u>s Patent</u>	and Tradema	UNITED STAT United States Address: COMMIS PO Box 14	Virginia 22313-1450
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS
12/944,544	11/11/2010	3767	3352	10-1188-US-CON1	61 3
					CONFIRMATION NO. 5949
20306				UPDATE	D FILING RECEIPT
MCDONNELL	BOEHNEN HU	JLBERT &	BERGHOFF LL	Р	
300 S. WACKE	ER DRIVE				OC000000051711281*
32ND FLOOR				*	OC000000051711281*
CHICAGO, IL	60606				

Date Mailed: 01/04/2012

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Robert Frederick Veasey, Warwickshire, UNITED KINGDOM; Robert Perkins, Oxfordshire, UNITED KINGDOM; David Aubrey Plumptre, Worcestershire, UNITED KINGDOM;

Assignment For Published Patent Application

DCA DESIGN INTERNATIONAL LTD, Warwick, UNITED KINGDOM **Power of Attorney:** The patent practitioners associated with Customer Number <u>20306</u>

Domestic Priority data as claimed by applicant

This application is a CON of 11/483,546 07/11/2006 PAT 7918833 and is a CON of 10/790,225 03/02/2004 ABN

Foreign Applications (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <u>http://www.uspto.gov</u> for more information.) UNITED KINGDOM 0304822.0 03/03/2003

Request to Retrieve - This application either claims priority to one or more applications filed in an intellectual property Office that participates in the Priority Document Exchange (PDX) program or contains a proper **Request to Retrieve Electronic Priority Application(s)** (PTO/SB/38 or its equivalent). Consequently, the USPTO will attempt to electronically retrieve these priority documents.

If Required, Foreign Filing License Granted: 11/23/2010

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/944,544**

Projected Publication Date: 04/12/2012

page 1 of 3

Non-Publication Request: No

Early Publication Request: No Title

Pen-Type Injector

Preliminary Class

604

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

page 2 of 3

Mylan Exhibit - 1006 Mylan v. Sanofi

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage, facilitate, and accelerate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit <u>SelectUSA.gov</u>.

page 3 of 3

Mylan Exhibit - 1006 Mylan v. Sanofi

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12944544				
Filing Date		2010-11-11				
First Named Inventor	Rober	t Frederick Veasey et al.				
Art Unit		3763				
Examiner Name						
Attorney Docket Number		10-1188-US-CON1				

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Da	ate		name of Patentee or Applicant		s,Columns,Lines where ant Passages or Relev es Appear	
	1	5304152		1994-04-	-19	Sams				
	2	5626566		1997-05-	-06	Petersen et al				
If you wisl	n to ad	d additional U.S. Pate	nt citatio	n informa	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT A	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*			Kind Code ¹			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20020052578	A1	2002-05-	-02	Moller				
lf you wisl	n to ad	d additional U.S. Publ	_∣ ished Ap	plication	citatio	ı n information ı	please click the Ade	l d buttor	n. Add	
_									Remove	
Examiner Initial*				Country K Code² j C		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T⁵
	1	0937471	EP		A2	1999-08-25	Becton, Dickinson a Company	and		
lf you wisl	n to ad	d additional Foreign P	atent Do	ocument o	citation	information p	lease click the Add	button	Add	
			NON	I-PATEN		RATURE DO	CUMENTS		Remove	

INFORMATION DISCLOSURE Application Number 12944544 Filing Date 2010-11-11 First Named Inventor Robert Frederick Veasey et al. Art Unit 3763 Examiner Name Attorney Docket Number 10-1188-US-CON1

Examiner Initials*	Cite No	(book	nclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.			
	1					
If you wis	h to ao	dd add	itional non-patent literature document citation information please click the Add k	outton Add	1	
			EXAMINER SIGNATURE			
Examiner	Signa	ture	Date Considered			
			reference considered, whether or not citation is in conformance with MPEP 609 mance and not considered. Include copy of this form with next communication	-		
Standard S ⁻¹ ⁴ Kind of do	Г.З). ^з F cument	^F or Japa by the a	O Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the docume nese patent documents, the indication of the year of the reign of the Emperor must precede the ser appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applic n is attached.	rial number of the patent doo	ument.	

	Application Number		12944544	
	Filing Date		2010-11-11	
INFORMATION DISCLOSURE	First Named Inventor	Robei	rt Frederick Veasey et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3763	
	Examiner Name			
	Attorney Docket Number		10-1188-US-CON1	

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas E. Wettermann/	Date (YYYY-MM-DD)	2012-01-20
Name/Print	Thomas E. Wettermann	Registration Number	41,523

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.


The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

(19)	Europäisches Patentamt European Patent Office Office européen des brevets	(11) EP 0 937 471 A2
(12)	EUROPEAN PATE	INT APPLICATION
(43)	Date of publication: 25.08.1999 Bulletin 1999/34	(51) Int. Cl. ⁶ : A61M 5/00
(21)	Application number: 99102372.2	
(22)	Date of filing: 08.02.1999	
(30)	Designated Contracting States: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE Designated Extension States: AL LT LV MK RO SI Priority: 20.02.1998 US 26938 Applicant: Becton Dickinson and Company	 (72) Inventors: Walters, Daniel A. Dover, New Jersey 07801-1918 (US) Brooks, Christopher J. Glen Head, New York (US) Fontayne, Diego Y. Teaneck, New Jersey (US) (74) Representative:
	Becton, Dickinson and Company Franklin Lakes, New Jersey 07417 (US)	von Kreisler, Alek, DiplChem. et al Patentanwälte, von Kreisler-Selting-Werner, Bahnhofsvorplatz 1 (Deichmannhaus) 50667 Köln (DE)

(54) Medication delivery pen

(57) A medication delivery pen having a repeatdose feature that limits motion of the dose control mechanism using an adjustable repeat-dose stop on the dose knob. In addition, the medication delivery pen also provides the user a simple mechanism for setting and correcting the dose and a drive mechanism that makes the dispensing operation as easy as possible requiring as little force as necessary.



15

40

45

Description

BACKGROUND OF THE INVENTION

1. FIELD OF THE INVENTION

[0001] The present invention relates to a medication delivery pen having a variety of features and, more particularly, a medication delivery pen that provides a mechanical advantage that uses less force to delivery the selected dose than would be needed to push directly on a plunger within a vial, a re-settable and/or repeatable dosing feature, and a self-priming feature all within the device using relatively few components.

1

2. DESCRIPTION OF RELATED ART

Hypodermic syringes are used to deliver [0002] selected doses of medication to patients. The prior art hypodermic syringe includes a syringe barrel having 20 opposed proximal and distal ends. A cylindrical chamber wall extends between the ends and defines a fluid receiving chamber. The proximal end of the prior art syringe barrel is substantially open and receives a plunger in sliding fluid tight engagement. The distal end 25 of the prior art syringe barrel includes a passage communicating with the chamber. A needle cannula may be mounted to the distal end of the prior art syringe barrel, such that the lumen of the needle cannula communicates with the passage and the chamber of the syringe 30 barrel. Movement of the plunger in a proximal direction draws fluid through the lumen of the needle cannula and into the chamber. Movement of the plunger in a proximal-to-distal direction urges fluid from the chamber and through the lumen of the needle cannula. 35

Medication to be injected with the prior art [0003] hypodermic syringe often is stored in a vial having a pierceable elastomeric seal. Medication in the prior art vial is accessed by piercing the elastomeric seal with the needle cannula. A selected dose of the medication may be drawn into the chamber of the syringe barrel by moving the plunger a selected distance in a proximal direction. The needle cannula may be withdrawn from the vial, and the medication may be injected into a patient by moving the plunger in a distal direction.

[0004] Some medication, such as insulin is selfadministered. The typical diabetes patient will require injections of insulin several times during the course of the day. The required dose of insulin will vary from patient to patient, and for each patient may vary during 50 the course of the day and from day to day. Each diabetes patient will establish a regimen that is appropriate for his or her own medical condition and for his or her lifestyle. The regimen typically includes some combination of a slow or medium acting insulin and a faster act-55 ing insulin. Each of these regimens may require the diabetes patient to periodically self-administer insulin in public locations, such as places of employment or restaurants. The required manipulation of the standard prior art hypodermic syringe and vial can be inconvenient and embarrassing in these public environments.

[0005] Medication delivery pens have been developed to facilitate the self-administration of medication. One prior art medication delivery pen includes a vial holder into which a vial of insulin or other medication may be received. The vial holder is an elongate generally tubular structure with proximal and distal ends. The distal 10 end of the prior art vial holder includes mounting means for engaging a double-ended needle cannula. The proximal end also includes mounting means for engaging a driver and dose setting apparatus as explained further below. A disposable vial for use with the prior art vial holder includes a distal end having a pierceable elastomeric seal that can be pierced by one end of a doubleended needle cannula. The proximal end of this prior art vial includes a plunger slidably disposed in fluid tight engagement with the cylindrical wall of the vial. This prior art medication delivery pen is used by inserting the vial of medication into the vial holder. A prior art pen body then is connected to the proximal end of the vial holder. The pen body includes a dose setting apparatus for designating a dose of medication to be delivered by the pen and a driving apparatus for urging the plunger of the vial distally for a distance corresponding to the selected dose.

[0006] The user of the pen mounts a prior art doubleended needle cannula to the distal end of the vial holder such that the proximal point of the needle cannula pierces the elastomeric seal on the vial. The patient then selects a dose and operates the pen to urge the plunger distally to deliver the selected dose. The dose selecting apparatus returns to zero upon injection of the selected dose with this prior art medication delivery pen. The patient then removes and discards the needle cannula, and keeps the prior art medication delivery pen in a convenient location for the next required medication administration. The medication in the vial will become exhausted after several such administrations of medication. The patient then separates the vial holder from the pen body. The empty vial may then be removed and discarded. A new vial can be inserted into the vial holder, and the vial holder and pen body can be reassembled and used as explained above.

[0007] The above described medication delivery pen is effective and much more convenient for self-administration of medication than the hypodermic syringes that use separate medication vials. However, the abovedescribed medication delivery pens require the user to continually set or reset the desired dose before each injection. As a result, users with impaired vision and fine motor skills have found it difficult to readily set the dose on such pens especially when using a medication delivery pen having a wide range of dosage settings available. Since it is particularly common among patients with diabetes to have complications of the disease causing impaired vision and fine motor skills even more of a

10

15

20

25

30

40

50

55

need has been found to address this problem. Hence, it is necessary to provide a medication delivery pen having a simple mechanism for setting the desired dose, repeating the dose when necessary, and priming the medication delivery pen prior to use. It is also important to provide a medication delivery pen that makes the dispensing operation as easy as possible requiring as little force as necessary.

SUMMARY OF THE INVENTION

[0008] The present invention relates to a medication delivery pen that addresses the above-identified problems. The medication delivery pen has a repeat-dose feature that limits motion of the dose control mechanism using an adjustable repeat-dose stop on the dose knob. In addition, the medication delivery pen also provides the user a simple mechanism for setting and correcting the dose and a drive mechanism that makes the dispensing operation as easy as possible requiring as little force as necessary.

[0009] Another feature of the present invention is that the medication delivery pen provides a simple means for retracting the plunger when reloading the medication delivery pen with a new vial.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010]

Fig. 1 is an exploded perspective view of a medication delivery pen according to the present invention.

Fig. 2 is a cross-sectional view of the medication delivery pen shown in Fig. 1 fully assembled and in *35* a ready for use condition.

Fig. 3 is a cross-sectional view of the medication delivery pen shown in Fig. 2 in a set dose condition and ready for dispense of medication.

Fig. 4 is a cross-sectional view of the rod barrel tube shown in Fig. 1.

Fig. 5 is a cross-sectional view of the medication 45 delivery pen shown in Fig. 2 along line A-A.

Fig. 6 is a cross-sectional view of a portion of an alternative medication delivery pen that has a feature that it allows it to be reloadable.

Fig. 7 is a cross-sectional view of yet another medication delivery according to the present invention having means for setting a desired dose and repeating delivery of that desired dose in consecutive injections.

DETAILED DESCRIPTION OF THE INVENTION

[0011] A multi-feature medication delivery pen 10 according to the present invention is shown in Fig. 1. Medication delivery pen 10 includes a cap 11 removably attached to a body 40 so to cover a vial retainer 35 containing a vial 30. As shown in Fig. 2 vial 30 includes a proximal end 31 and a distal end 32 having a vial cap 33 that securely holds a vial septum 34 on distal end 32. Vial 30 also includes a vial piston 39 therein to form a sterile sliding seal within vial 30 to hold medication therein. As shown in Fig. 2 a pen-needle assembly 20 is releasably engaged to a distal end 36 of vial retainer 35. Pen-needle assembly 20 includes a double-ended needle cannula 21 having a distal point 24 and a proximal point (not shown). Double-ended needle cannula 21 is mounted on a hub 23 including means for attaching hub 23 to distal end 36 of vial retainer 35. A proximal end 37 of vial retainer 35 is snap-fit onto a distal end 42 of body 40 or can be mounted thereto by other means, e.g., threads.

[0012] As shown in Figs. 1-3, medication delivery pen 10 includes a rod barrel tube 70, a clicker 90, a lens and ring assembly 60, and a dose knob 50. Rod barrel tube 70 includes a distal end 71 and a proximal end 72, with an outer barrel 73 extending from distal end 71 and surround a rod barrel 74. As shown in Fig. 1 outer barrel 73 may have a pair of openings 75 through its outer surface. Rod barrel 74 includes a set of external threads 76 that mate with a set of internal threads 53 within dose knob 50, described below, and a set of internal threads 77 that mate with a threaded shaft 101 on a plunger 100 having a distal face 102 and a proximal end 105. Plunger 100 also includes a pair of keyways 104 extending from distal face 102 to a keyway stop 103 near proximal end 105. Rod barrel tube 70 also include a plurality of ratchet pawls 78 at distal end 71 that are received within body 40 and engage with ratchet 41 located within body 40 near its distal end 42. Distal end 42 of body 40 also includes a pair of keys 43, shown in Fig. 2, that extend into body 40 to engage with the pair of keyways 104 on plunger shaft 101 of plunger screw 100. Rod barrel tube 70 also includes a window 79 located near its proximal end 72 through which a plurality of dosage numerals 51 printed on dose knob 50 are visible to a user for setting of the desired dose. Dose knob 50 also includes a dose knob cap 54 that is permanently attached to a proximal end 55 of dose knob 50. Dose knob 50 also includes internal threads 53 that engage rod barrel outer diameter threads 76 on rod barrel 74 so that dose knob 50 is threaded out of rod barrel tube 70 as a dose is being set, as shown in Fig. 3. During the dose setting operation rod barrel tube 70 is prevented from rotating within body 40 by interaction of ratchet pawl 78 on rod barrel tube 70 and ratchet 41 within body 40.

[0013] Dose knob 50 also includes a plurality of key slots 52 arranged axially on the outer surface of dose

10

knob 50 so to receive a matched plurality of keys 91 on the inside of clicker 90 as clicker 90 is mounted onto dose knob 50. Clicker 90 also includes a plurality of clicker fingers 92 on its outer circumference that interacts with a plurality of slots 61 within lens and ring assembly 60. Interaction between clicker fingers 92 and slots 61 occur during the dose setting operation to provide the user with audible and/or tactile feedback during this operation. Lens and ring assembly 60 provide a feature of magnifying the dosage numeral 51 on the outside surface of dose knob 50 to aide the user in setting the dose during the setting operation using lens 62 integrated thereto.

[0014] Dose knob 50 has an enlarged proximal end 55 onto which dose knob cap 54 has been attached and ¹⁵ may have a textured surface and/or an indentation to provide easy operator manipulation of dose knob 50 during dose setting of medication delivery pen 10. In addition, it should be appreciated that dose knob cap 54 could be integrally molded at proximal end 55 of dose ²⁰ knob 50.

[0015] Fig. 5 is a cross-sectional view of medication delivery pen 10 shown in Fig. 2 along lines A-A and more clearly show the interaction between the ratchet 41 within body 40 and ratchet pawl 78 at distal end 71 of 25 rod barrel tube 70. Fig. 5 also shows that ratchet pawl 78 at ratchet surface 41 only prevent rotation in one direction so that after a dose has been set as shown in Fig. 3 and pressure is applied to dose knob cap 54 rod barrel tube 70 is free to rotate within body 40. As rod 30 barrel tube 70, rotates interaction between rod barrel internal threads 77 and threaded shaft 101 of plunger screw 100 occurs to move plunger screw 100 in the distal direction a distance corresponding to the desired dose that was set. Plunger screw 100 moves in the dis-35 tal direction because it is prevented from rotation by interaction of keys 43 in body 40 and keyways 104 on plunger screw 100.

[0016] Fig. 6 is a cross-sectional view of a section of an alternative medication delivery pen that provides the 40 pen with the ability to be reloaded when vial has been filly used and must be replaced. This embodiment is substantially similar to the earlier embodiment except that key 43 within body 40 has been replaced with a plunger screw key 200 that is free to rotate when vial 45 retainer 235 is removed from body 240, but when vial retainer 235 is filly threaded to pen body 240 plunger screw key 200 is prevented from rotating. Plunger screw key 200 includes a proximal face 201 having a plurality of teeth that engage with matching plurality of teeth 244 50 within body 240. Plunger screw key 200 also includes a shoulder 202 around the circumference that is received in a circumferencial internal diameter clearance slot 245 within body 240 to retain plunger screw key 200 within body 240. Plunger screw 200 also includes a pair of 55 keys 203 that engage keyway 104 and plunger screw 100, discussed above. Interaction between key 203 and keyway 104 prevent plunger screw 100 from rotating

when plunger screw key 200 is prevented from rotating because of the interaction between key 204 on plunger screw key 200 and key 244 within body 240 when a proximal end 237 of vial retainer 235 applies sufficient pressure on shoulder 202.

[0017] Fig. 7 is yet another embodiment of a medication delivery pen according to the present invention and, more particularly, shows a feature that allows the user to set a desired dose for repeated delivery. As shown in Fig. 7 this feature is provided by the incorporation into the first embodiment of a dose knob having a distal end 301 and a proximal end 302, wherein proximal end 302 includes a well about its outer surface and a plurality of stop adjuster rotation detents 304 are located within proximal end 302 of dose knob 300. A stop adjuster 310 includes a distal end 311 and a proximal end 312 with distal end 311 being inserted into circumferencial well 303 in dose knob 300. Stop adjuster 310 also includes a set of external threads 313 and a plurality of stop adjuster rotational detents 314 within an inner surface that engage with corresponding stop adjuster rotational detents 304 on dose knob 300. Stop adjuster rotation detents 304 and 314 provide the user with tactile feedback during the operation of setting the repeat dose.

[0018] A dose stop 320 includes a plurality of dose stop keys 321 extending radially from dose stop 320 and a set of internal threads 322 that engage with outer threads 313 on stop adjuster 310. A dose knob cap 330 is attached to dose knob 300 after stop adjuster 310 has been mounted on dose knob 300 to retain stop adjuster 310 thereon. In addition, dose knob cap 330 can provide a textured surface and/or indentations for use during dose setting, as described above.

[0019] After a dose has been set by the user, the user would rotate stop adjuster 310 to move dose stop 320 in a proximal direction until a proximal face 323 of dose stop 320 comes into contact with a distal face 393 on a clicker 390. Of course, clicker 390 provides the same features and functions as clicker 90 in the earlier embodiment. Rotation of stop adjuster 310 cause dose stop 320 to move because of interaction between internal threads 322 and stop adjuster outer diameter thread 313 and interaction between dose stop key 321 and a dose knob keyway 305 on dose knob 300. When dose stop is in the position desired by the user further proximal movement of the dose knob is prevented beyond the set desired dose. Dose stop 320 remains in the position it has been set to until change at a later point by the user via stop adjuster 310.

[0020] While the present invention has been described with respect to a preferred and a number of alternative embodiments, it is apparent that various changes can be made without departing from the scope of the invention as defined by the appended claims.

Claims

1. A medication delivery pen comprising:

4

a pen-needle assembly;

a vial retainer including a vial containing a medication to be delivered and having said penneedle removably attached to a distal end; a housing having said vial retainer mounted to 5 a distal end and including;

a dose control mechanism for setting a desired dose to be delivered from the vial; a drive mechanism for dispensing the *10* desired dose from the; and a rod barrel tube for interfacing said dose control mechanism with said drive mechanism.

- 2. A medication delivery pen according to Claim 1, wherein said rod barrel tube includes an outer thread for engaging said dose control mechanism and an inner thread for engaging said drive mechanism.
- **3.** A medication delivery pen according to Claim 1, further comprising means for preventing rotation of said rod barrel tube and said drive mechanism when said dose control mechanism is being used to 25 set the desired dose.
- 4. A medication delivery pen according to Claim 3, wherein said means for preventing rotation of said rod barrel tube and said drive mechanism includes 30 a ratchet mechanism between said housing and said rod barrel tube to prevent rotation of said rod barrel tube and said drive mechanism within said housing when said dose control mechanism is being used to set the desired dose. 35
- A medication delivery pen according to Claim 1, further comprising a means on said rod barrel tube for displaying the dose set by said dose control mechanism.
- 6. A medication delivery pen according to Claim 5, wherein said means for displaying the dose includes a window within said rod barrel tube.
- 7. A medication delivery pen according to Claim 1, further comprising means within said housing for resetting said drive mechanism when a new vial is loaded into said vial retainer.
- 8. A medication delivery pen according to Claim 1, further comprising means for repeating the desired dose.
- **9.** A medication delivery pen according to Claim 8, *55* wherein said means for repeating the desired dose includes an adjustable repeat dose stop in said dose control mechanism that limits axial motion of

said dose control mechanism when setting the desired dose.

10. A medication delivery pen according to Claim 9,

wherein said dose control mechanism includes a dose knob, and


wherein said adjustable repeat dose stop is mounted in said dose knob to limit motion of said dose knob when repeating the desired dose.


15


20


40


45











IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

In re Application of:)
Robert Frederick Veasey et al.))) Exeminer Unessigned
Serial No.: 12/944,544) Examiner: Unassigned)) Group Art Unit: 3763
Filed: November 11, 2010) Confirmation No.: 5949
For: Pen-Type Injector)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

GENERAL AUTHORIZATION UNDER 37 C.F.R. § 1.136(a)(3)

Sir:

The Commissioner is hereby generally authorized under 37 C.F.R. § 1.136(a)(3) to treat the present and any future related filings in this or any related application filed pursuant to 37 C.F.R. § 1.53 requiring an extension of time as incorporating a request therefore, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 13-2490 for any fee that may be due in connection with such a request for an extension of time.

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: January 20, 2012

By:

<u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

Electronic Acknowledgement Receipt				
EFS ID:	11882006			
Application Number:	12944544			
International Application Number:				
Confirmation Number:	5949			
Title of Invention:	Pen-Type Injector			
First Named Inventor/Applicant Name:	Robert Frederick Veasey			
Customer Number:	20306			
Filer:	Thomas E. Wettermann			
Filer Authorized By:				
Attorney Docket Number:	10-1188-US-CON1			
Receipt Date:	20-JAN-2012			
Filing Date:	11-NOV-2010			
Time Stamp:	18:22:04			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment			no				
File Listing:							
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1	Transmittal Letter	10_1188_US_CON1_IDS_Trans mittal_2012_01_20.pdf	140443	no	1		
1			66afc602aa9da1fd2e3754a1a59310861962 62e8				
Warnings:		-		· · ·			
Information:			0144	Mylan Exł	nibit - 100)6	

2	Information Disclosure Statement (IDS) Form (SB08)	10_1188_US_CON1_IDS_2012_ 01_20.pdf	612300	no	4		
			0bb				
Warnings:							
Information		i	I	1			
3	Foreign Reference	10_1188_US_CON1_Foreign_R ef_1.pdf		no	10		
			b3ca6f0311b92921f29bf7e9d823c62927c9 bc02				
Warnings:							
Information			1				
4	4 Authorization for Extension of Time all 10_1188_US_CON1_General_ replies uthorization_2012_01_20.pd	10_1188_US_CON1_General_A	58960	no	1		
			299ebdf18fd305d37a4203d65c22e7efd4ae 1340				
Warnings:							
Information							
		Total Files Size (in bytes)	13	308333			
characterize Post Card, as <u>New Applica</u> If a new appl 1.53(b)-(d) a	ledgement Receipt evidences receip d by the applicant, and including pag described in MPEP 503. <u>tions Under 35 U.S.C. 111</u> lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin	ge counts, where applicable. tion includes the necessary o R 1.54) will be issued in due	It serves as evidence components for a filir	e of receipt : ng date (see	similar to a 37 CFR		
<u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.							
<u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.							

PTO/SB/21 (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pa	aperwork Re	eduction Act of 1995,	no persor	ns are required to respond to a o	colleo	ction of info	rmation u	unless it	displays a valid OMB control number.
(Application Number		12/944,	544		
TR	RANSI	MITTAL		Filing Date		Novemb	oer 11,	2010	
	FO	RM		First Named Inventor		Robert I	Freder	ick Ve	easey et al.
				Art Unit		3763	3763		
(to be used for	all corresp	ondence after initial fi	ling)	Examiner Name		Unassig	gned		
Total Number of Pages in This Submission 16			Attorney Docket Number	r	10-1188	3-US-C	CON1		
			ENC	CLOSURES (Check a	all th	nat apply))		
Fee Trar	nsmittal Fo	orm		Drawing(s)				After A	Allowance Communication to TC
				Licensing-related Papers					I Communication to Board eals and Interferences
	nent/Reply After Final			Petition Petition to Convert to a Provisional Application					Il Communication to TC (Appeal , Brief, Reply Brief)
	Affidavits/	declaration(s)		Power of Attorney, Revoca Change of Correspondenc					etary Information
Extensio	on of Time	Request		Terminal Disclaimer			\square		Letter Enclosure(s) (please Identify)
		ment Request						Сору	, of Cited Reference and eral Authorization
🛛 Informati	ion Disclo	sure Statement							
Certified Docume	Copy of F nt(s)	Priority	Rem	narks		E			
	Missing F ete Applica								
	Reply to N	/lissing Parts CFR 1.52 or 1.53							
		SIGNA	TURE (OF APPLICANT, ATT	OR	NEY, O	R AGI	ENT	
Firm Name	McDo	nnell Boehnen	Hulbert	t & Berghoff LLP					
Signature	/Thom	as E. Wetterma	ann/						
Printed name	Thoma	as E. Wetterma	Inn						
Date	Janua	ry 20, 2012			Re	eg. No.	41,52	3	
		С	ERTIFI	CATE OF TRANSMIS	SSIC	ON/MAI	LING		
	stage as	first class mail in							e United States Postal Service (1450, Alexandria, VA 22313-
Signature		/Thomas E. W	/etterm	ann/					
Typed or printed	name	Thomas E. W	etterma	ann				Date	January 20, 2012
			_						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED ST	ates Patent and Trademar	UNITED STA' United States Address: COMMIS P.O. Box I	a, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
12/944,544	11/11/2010	Robert Frederick Veasey	10-1188-US-CON1
			CONFIRMATION NO. 5949
20306		PUBLICAT	
MCDONNELL BOEHNEN 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606	HULBERT & BERGHOFF LLP		DC000000053687151*

Title:Pen-Type Injector

Publication No.US-2012-0089100-A1 Publication Date:04/12/2012

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Office of Public Records. The Office of Public Records can be reached by telephone at (703) 308-9726 or (800) 972-6382, by facsimile at (703) 305-8759, by mail addressed to the United States Patent and Trademark Office, Office of Public Records, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently http://pair.uspto.gov/. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12944544
Filing Date		2010-11-11
First Named Inventor Robe		t Frederick Veasey
Art Unit		3763
Examiner Name MEN		DEZ, MANUEL A
Attorney Docket Number		10-1188-US-CON1

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5674204		1997-10-07	Chanoch	
	2	5688251		1997-11-18	Chanoch	
	3	6083197		2000-07-04	Umbaugh	
	4	6221046		2001-04-24	Burroughs, et al.	
	5	6899698		2005-05-31	Sams	
lf you wisl	n to add	additional U.S. Paten	t citatio	n information pl	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040059299		2004-03-25	Moller	
lf you wisl	n to add	additional U.S. Publis	hed Ap	plication citatio	n information please click the Ad	d button. Add
				FOREIGN PAT	TENT DOCUMENTS	Remove

Mylan Exhibit - 1006 Mylan v. Sanofi

INFORMATION DISCLOSURE Application Number 12944544 Filing Date 2010-11-11 First Named Inventor Robert Frederick Veasey Art Unit 3763 Examiner Name MENDEZ, MANUEL A Attorney Docket Number 10-1188-US-CON1

Examiner Initial*	Cite No	Forei Num	ign Document ber ³	Country Code² j	Kind Code⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	09374	476	EP		1999-08-25	BECTON DICKINSON CO		
	2	91/14	467	WO		1991-10-03	SAMS BERNARD		
	3	99/38	554	WO		1999-08-05	NOVO NORDISK AS		
If you wisl	h to ac	d add	litional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor	Add	
				NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No	(bool		nal, serial, symp	osium,	catalog, etc), c	the article (when approp late, pages(s), volume-is		T⁵
	1								
If you wisl	h to ac	d add	litional non-paten	t literature docur	ment cit	ation informati	on please click the Add I	outton Add	
				EX	AMINE	R SIGNATUR	E		
Examiner	Signa	iture					Date Considered		
							ormance with MPEP 609 with next communication		
Standard ST ⁴ Kind of doo	¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								

	Application Number		12944544	
	Filing Date		2010-11-11	
INFORMATION DISCLOSURE	First Named Inventor	Robei	rt Frederick Veasey	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3763	
	Examiner Name	MEN	DEZ, MANUEL A	
	Attorney Docket Numb	er	10-1188-US-CON1	

CERTIFICATION STATEM	ENT
----------------------	-----

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas E. Wettermann/	Date (YYYY-MM-DD)	2012-10-15
Name/Print	Thomas E. Wettermann	Registration Number	41523

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic A	cknowledgement Receipt
EFS ID:	13981779
Application Number:	12944544
International Application Number:	
Confirmation Number:	5949
Title of Invention:	Pen-Type Injector
First Named Inventor/Applicant Name:	Robert Frederick Veasey
Customer Number:	20306
Filer:	Thomas E. Wettermann
Filer Authorized By:	
Attorney Docket Number:	10-1188-US-CON1
Receipt Date:	17-OCT-2012
Filing Date:	11-NOV-2010
Time Stamp:	15:58:04
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment			no					
File Listing	g:							
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
1	Information Disclosure Statement (IDS)		D-1188-US-CON1_Supp_IDS.	612524	no	4		
I	Form (SB08)	pdf	692d1091dcd41ad53c6d960ca3ffb7535f1d 5fc5					
Warnings:								
Information:			0152	Mylan Exł	nibit - 10()6		

2	Foreign Reference	EP0937476A2.pdf	421015	no	9					
			5c34134e0b35c9dbf01af4bdba9f434730ee 0851							
Warnings:										
Information:										
3	Foreign Reference	WO9114467A1.pdf	1212033	no	27					
		19	19d72d3e0ac8f33d0bf23fa8aa6fb9b6eb7b 0f21							
Warnings:		-								
Information										
			1423176		20					
4	Foreign Reference	WO9938554A1.pdf	b40583b8fc8e8ab064417db16a7f745a2e9f 436f	no	30					
Warnings:										
Information			1							
		Total Files Size (in bytes)	: 36	68748						
characterize	ledgement Receipt evidences receip d by the applicant, and including pag described in MPEP 503.	•			-					
	<u>tions Under 35 U.S.C. 111</u> ication is being filed and the applica	tion includes the necessary	omnononte for a filir	a data (coo	27 CEP					
	nd MPEP 506), a Filing Receipt (37 CF		-	-						
Acknowledg	ement Receipt will establish the filin	g date of the application.								
	<u>ge of an International Application ur</u>	National Stage of an International Application under 35 U.S.C. 371								
	bmission to enter the national stage	of an international applicati	•							
U.S.C. 371 ar	bmission to enter the national stage id other applicable requirements a F ge submission under 35 U.S.C. 371 w	of an international applicati orm PCT/DO/EO/903 indicati	ng acceptance of the	application						
U.S.C. 371 ar national stag	nd other applicable requirements a F	of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the	ng acceptance of the	application						
U.S.C. 371 ar national stag <u>New Interna</u> If a new inter	nd other applicable requirements a F ge submission under 35 U.S.C. 371 wi tional Application Filed with the USP rnational application is being filed an	of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u> nd the international applicat	ng acceptance of the e Filing Receipt, in du ion includes the nece	applicatior e course. ssary comp	n as a ponents for					
U.S.C. 371 ar national stag <u>New Interna</u> If a new inter an internatio	nd other applicable requirements a F ge submission under 35 U.S.C. 371 wi tional Application Filed with the USP rnational application is being filed a onal filing date (see PCT Article 11 an	of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u> nd the international applicat d MPEP 1810), a Notification	ng acceptance of the e Filing Receipt, in du ion includes the nece of the International	applicatior e course. ssary comp Application	n as a conents for Number					
U.S.C. 371 ar national stag <u>New Interna</u> If a new inter an internatic and of the In	nd other applicable requirements a F ge submission under 35 U.S.C. 371 wi tional Application Filed with the USP rnational application is being filed an onal filing date (see PCT Article 11 an ternational Filing Date (Form PCT/RG urity, and the date shown on this Ack	of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u> nd the international applicat d MPEP 1810), a Notification D/105) will be issued in due c	ng acceptance of the e Filing Receipt, in du ion includes the nece of the International ourse, subject to pres	application e course. ssary comp Application scriptions c	n as a conents for Number oncerning					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 10-1188-US-CON1)

In the Applica	ation of:)	
Rober	t Frederick Veasey et al.)	Examiner: Manuel A. MENDEZ
Serial No.	12/944,544)	Group Art Unit: 3763
Filed:	November 11, 2010)	Confirmation No.: 5949
For: Pen-T	ype Injector)	Customer No.: 20306

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

SUPPLEMENTAL PRELIMINARY AMENDMENT

Dear Sir:

Applicant submits the following supplemental preliminary amendment, and respectfully requests that it be entered prior to examination of this application.

Amendments to the claims begin on page 2.

Remarks begin of page 4.

General Authorization: Applicant generally authorizes the Office to charge any underpayment or credit any overpayment to Deposit Account No. 13-2490, and to treat any communication that requires an extension of time as incorporating a request for such an extension.

Mylan Exhibit - 1006 Mylan v. Sanofi

AMENDMENTS TO THE CLAIMS

1-14. (Canceled)

15. (Previously presented) A housing part for a medication dispensing apparatus, said housing part comprising:

a main housing, said main housing extending from a distal end to a proximal end;

a dose dial sleeve positioned within said housing, said dose dial sleeve comprising a helical groove configured to engage a threading provided by said main housing;

a dose knob disposed near a proximal end of said dose dial sleeve;

a piston rod provided within said housing, said piston rod is non-rotatable during a dose setting step relative to said main housing;

a driver extending along a portion of said piston rod, said driver comprising an internal threading near a distal portion of said driver, said internal threading adapted to engage an external thread of said piston rod; and,

a tubular clutch located adjacent a distal end of said dose knob, said tubular clutch operatively coupled to said dose knob,

wherein said dose dial sleeve extends circumferentially around at least a portion of said tubular clutch.

16. (Canceled)

2

17. (Currently amended) The housing part of claim 15, further comprising

a container housing operatively coupled to said main housing, said container housing comprising a fluid container,

wherein said fluid container defines a medicament filled reservoir with a movable plunger at a proximal end and an outlet at a distal end,

said plunger movable by said piston rod to be advanced toward an outlet of said fluid container when said piston rod is moved distally, wherein during a dose setting step, said dose knob is rotated and moves away from said proximal end of said main housing so that a dose of said medicament contained within said medicament filled reservoir can be selected.

18. (Canceled)

19. (Currently amended) The housing part of claim [[18]]<u>17</u>, wherein said dose knob is operatively configured to said tubular clutch so that, during said dose setting step, said tubular clutch, said dose dial sleeve, and said dose knob rotate out of said proximal end of said main housing.

20-75. (Canceled)

Mylan Exhibit - 1006 Mylan v. Sanofi

REMARKS

Prior to examination of this application on the merits, entry of the above amendments to the specification and claims are requested.

In this supplemental preliminary amendment, Applicant has (i) amended claim 17 to include the features of claim 18, (ii) amended claim 19 to make it dependent on claim 17 rather than claim 18, and (iii) canceled claims 16, 18, and 20-75. As a result, claims 15, 17, and 19 are pending.

Applicant reserves the right to pursue in a continuation application the subject matter of any of the claims without the present amendments, and any other subject matter disclosed by this application.

If there are any matters that may be resolved or clarified through a telephone interview, the Examiner is respectfully requested to contact Applicant's undersigned representative at (312) 913-0001.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: April 16, 2013

By: <u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

In re Application of: Robert Frederick Veasey et al. Serial No.: 12/944,544 Filed: November 11, 2010 For: Pen-Type Injector

Examiner: Manual A. Mendez Group Art Unit: 3763 Confirmation No.: 5949

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

GENERAL AUTHORIZATION UNDER 37 C.F.R. § 1.136(a)(3)

Sir:

The Commissioner is hereby generally authorized under 37 C.F.R. § 1.136(a)(3) to treat the present and any future related filings in this or any related application filed pursuant to 37 C.F.R. § 1.53 requiring an extension of time as incorporating a request therefore, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 13-2490 for any fee that may be due in connection with such a request for an extension of time.

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: April 16, 2013

By:

<u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

Electronic Acknowledgement Receipt					
EFS ID:	15532169				
Application Number:	12944544				
International Application Number:					
Confirmation Number:	5949				
Title of Invention:	Pen-Type Injector				
First Named Inventor/Applicant Name:	Robert Frederick Veasey				
Customer Number:	20306				
Filer:	Thomas E. Wettermann				
Filer Authorized By:					
Attorney Docket Number:	10-1188-US-CON1				
Receipt Date:	16-APR-2013				
Filing Date:	11-NOV-2010				
Time Stamp:	18:57:52				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted with P	ayment		no				
File Listing:							
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1			10_1188_US_CON1_Suppleme ntal_Prelim_Amendment_Tram		no	1	
			smittal_2013_04_16.pdf	801b8908a7f3462d61cc4ef1d7d4da94c30 609b6		I	
Warnings:							
Information:				Mylan Fyl	nihit - 100)6	

		Total Files Size (in bytes)	28	37553	
Information	:				
Warnings:					
3	Authorization for Extension of Time all replies	10_1188_US_CON1_General_A uthorization_2013_04_16.pdf	58792 cb1fd3b3a0cd03f35cea1b1d2d8587424eff 5ae1	no	1
Information	:				
Warnings:					
2	Preliminary Amendment	ntal_Preliminary_Amendment_ 2013_04_16.pdf	5a107c6cc20b843ae6ab67c7bba74137a78 4fe68	no	4
2		10_1188_US_CON1_Suppleme	88516		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/21 (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pa	perwork Reduction Act of 1995,	no persons are required to respond to a	a collection of infe	ormation unless it	displays a valid OMB control number.
(Application Number	12/944	,544	
TR	ANSMITTAL	Filing Date	Novem	ber 11, 2010	
	FORM	First Named Inventor		Frederick Ve	easey
		Art Unit	3763		
(to be used for	all correspondence after initial f	iling) Examiner Name	Manua	I A. Mendez	
Total Number o	f Pages in This Submission	6 Attorney Docket Numb	^{er} 10-118	8-US-CON1	
		ENCLOSURES (Check	all that apply)	
Fee Trar	nsmittal Form	Drawing(s)		After A	Allowance Communication to TC
	Fee Attached	Licensing-related Papers			l Communication to Board
Amendm	nent/Reply	Petition Petition to Convert to a		Appea	I Communication to TC (Appeal
	After Final	Provisional Application			, Brief, Reply Brief) etary Information
	Affidavits/declaration(s)	Power of Attorney, Revoo Change of Corresponder			Letter
Extensio	n of Time Request	Terminal Disclaimer		Other	Enclosure(s) (please Identify
Express	Abandonment Request	Request for Refund		below Gene	eral Authorization
Informati	ion Disclosure Statement	CD, Number of CD(s)			
	Convert Driverity		in CD		
Docume	Copy of Priority nt(s)	Remarks			
	Missing Parts/ ete Application				
	Reply to Missing Parts				
l	under 37 CFR 1.52 or 1.53				
	SIGNA	I TURE OF APPLICANT, AT	TORNEY, C	OR AGENT	
Firm Name	McDonnell Boehnen	Hulbert & Berghoff LLP			
Signature	/Thomas E. Wetterm	ann/			
Printed name	Thomas E. Wetterma	ann			
Date	April 16, 2013		Reg. No.	41,523	
	С	ERTIFICATE OF TRANSM	SSION/MA	ILING	
	stage as first class mail in	eing electronically transmitted to th an envelope addressed to: Comm			
Signature	/Thomas E. W	Vettermann/			
Typed or printed	name Thomas E. W	/ettermann		Date	April 16, 2013
	formation is required by 27 CEE	2.4.5. The information is required to abt	ain an mtain a ha	nofit by the public	which is to file (and by the LISPTO to

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



							to a collection of informatio		alid OMB control number.
P	ATENT APPL	Substitute f			I RECORD		n or Docket Number 2/944,544	Filing Date 11/11/2010	To be Mailed
							ENTITY: 🛛 L	ARGE 🗌 SMA	
					ATION AS FIL		РТ I		
			(Column ⁻		(Column 2)	LU - FAN			
	500			·	. ,			1 .	
	FOR BASIC FEE			_ED	NUMBER EXTRA		RATE (\$)	ŀ	EE (\$)
	(37 CFR 1.16(a), (b),	or (c))	N/A		N/A		N/A		
	SEARCH FEE (37 CFR 1.16(k), (i), (or (m))	N/A		N/A		N/A		
	EXAMINATION FE (37 CFR 1.16(o), (p),		N/A		N/A		N/A		
	ΓAL CLAIMS CFR 1.16(i))		mir	nus 20 = *			X \$ =		
	EPENDENT CLAIM CFR 1.16(h))	S	m	inus 3 = *			X \$ =		
	APPLICATION SIZE (37 CFR 1.16(s))	FEE of p for f frac CFI	aper, the a small entity tion thereo R 1.16(s).	ation and drawing application size f y) for each additi of. See 35 U.S.C	ee due is \$310 (onal 50 sheets o	\$155 or			
	MULTIPLE DEPEN								
* If I	he difference in colu	umn 1 is less tha	n zero, ente	r "0" in column 2.			TOTAL		
		(Column 1)		(Column 2)	ION AS AMEN (Column 3)		ART II		
AMENDMENT	04/16/2013 CLAIMS REMAINING AFTER AMENDMENT			HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EX	TRA	RATE (\$)	ADDITIC	ONAL FEE (\$)
ME	Total (37 CFR 1.16(i))	* 3	Minus	** 20	= 0		x \$80 =		0
EN N	Independent (37 CFR 1.16(h))	* 1	Minus	***3	= 0		x \$420=		0
AMI	Application Si	ze Fee (37 CFR	1.16(s))						
	FIRST PRESEN	TATION OF MULT	IPLE DEPEN	DENT CLAIM (37 CFF	R 1.16(j))				
							TOTAL ADD'L FEI	Ξ	0
		(Column 1)	_	(Column 2)	(Column 3))	_		
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EX	TRA	RATE (\$)	ADDITIC	ONAL FEE (\$)
N. EN.	Total (37 CFR 1.16(i))	*	Minus	**	=		X \$ =		
AMENDMENT	Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =		
1EN	Application Si	ze Fee (37 CFR	1.16(s))						
A	FIRST PRESEN	TATION OF MULT	IPLE DEPEN	DENT CLAIM (37 CFF	R 1.16(j))				
							TOTAL ADD'L FEI	=	
** lf	the entry in column the "Highest Numbe f the "Highest Numb	er Previously Pai	d For" IN TH	HIS SPACE is less	than 20, enter "20"		LIE /VICTORIA BF	ROWN/	
	-	-			-		ppropriate box in colum		
proce prepa requir Depa	ss) an application. (ring, and submitting e to complete this fo	Confidentiality is the completed a orm and/or sugge e, P.O. Box 1450 Commissione	governed by pplication for estions for re Alexandria for Pate	/ 35 U.S.C. 122 and orm to the USPTO. educing this burden a, VA 22313-1450. I nts, P.O. Box 1 4	d 37 CFR 1.14. Thi Time will vary dep n, should be sent to DO NOT SEND FE 150, Alexandria	s collection is ending upon the Chief Inf ES OR CON , VA 22313	a benefit by the public v s estimated to take 12 the individual case. An formation Officer, U.S. IPLETED FORMS TO -1450.	minutes to complete y comments on the Patent and Tradem THIS	e, including gathering, amount of time you

0162

Mylan Exhibit - 1006 Mylan v. Sanofi

	ed States Patent	TAND TRADEMARK OFFICE	UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 22: www.uspto.gov	Trademark Office FOR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/944,544	11/11/2010	Robert Frederick Veasey	10-1188-US-CON1	5949
	7590 08/30/2013 L BOEHNEN HULBERT ER DRIVE	EXAM MENDEZ, N		
32ND FLOOR CHICAGO, IL			ART UNIT	PAPER NUMBER
			3763	
			MAIL DATE	DELIVERY MODE
			08/30/2013	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No. 12/944,544	Applicant(s) VEASEY ET AL.	
Office Action Summary	Examiner MANUEL MENDEZ	Art Unit 3763	AIA (First Inventor to File) Status No
The MAILING DATE of this communication app	l pears on the cover sheet w	ith the corresponde	
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNIC 36(a). In no event, however, may a r will apply and will expire SIX (6) MON b, cause the application to become AE	CATION. reply be timely filed ITHS from the mailing date BANDONED (35 U.S.C. §	of this communication. 133).
Status			
1) Responsive to communication(s) filed on <u>4/16</u> A declaration(s)/affidavit(s) under 37 CFR 1.1		<u>.</u>	
2a) This action is FINAL . 2b) This	action is non-final.		
3) An election was made by the applicant in resp	•		ring the interview on
 the restriction requirement and election 4) Since this application is in condition for alloward closed in accordance with the practice under E 	nce except for formal matt	ers, prosecution as	
Disposition of Claims			
 5) ∑ Claim(s) <u>15,17 and 19</u> is/are pending in the ap 5a) Of the above claim(s) is/are withdraw 6) □ Claim(s) is/are allowed. 7) ∑ Claim(s) <u>15, 17, and 19</u> is/are rejected. 8) □ Claim(s) is/are objected to. 9) □ Claim(s) are subject to restriction and/o * If any claims have been determined <u>allowable</u>, you may be eleparticipating intellectual property office for the corresponding a <u>http://www.uspto.gov/patents/init_events/pph/index.jsp</u> or send Application Papers 10) □ The specification is objected to by the Examine 11) ∑ The drawing(s) filed on <u>11/11/2010</u> is/are: a) ∑ Applicant may not request that any objection to the 	wn from consideration. r election requirement. ligible to benefit from the Pat pplication. For more informat I an inquiry to <u>PPHfeedback@</u> r. accepted or b) objected drawing(s) be held in abeyar	ion, please see @uspto.gov. ed to by the Examir nce. See 37 CFR 1.8	ner. 5(a).
Replacement drawing sheet(s) including the correct Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign		., .	9 37 GFR 1.121(a).
Certified copies: a) All b) Some * c) None of the: 1. Certified copies of the priority documen 2. Certified copies of the priority documen 3. Copies of the certified copies of the priority documen * See the attached detailed Office action for a list of	ts have been received. ts have been received in A prity documents have beer u (PCT Rule 17.2(a)).	Application No	
Attachment(s) 1) X Notice of References Cited (PTO-892)		Summary (PTO-413)	
2) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>10/17/2012 and 1/20/2012</u> . U.S. Patent and Trademark Office	Paper No(: 4) 🗌 Other:	s)/Mail Date ·	

U.S. Patent and Trademark	-
PTOL-326 (Rev. 08-13)	

Office Action Summary 0164

DETAILED ACTION

Claim Rejections - 35 USC § 112

The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.

The following is a quotation of 35 U.S.C. 112 (pre-AIA), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 15, 17, and 19 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112

(pre-AIA), first paragraph, as failing to comply with the written description requirement.

The claim(s) contains subject matter which was not described in the specification in

such a way as to reasonably convey to one skilled in the relevant art that the inventor or

a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had

possession of the claimed invention.

The specification does not describe a "dose knob". There is no mention in the

specification of a "dose knob" disposed near a proximal end of the dose dial sleeve.

Accordingly, the phrase "dose knob" disclosed in line 6 of claim 15 appears to have no

support in the specification.

The specification also fails to disclose the term "driver" referring to the "driver extending along a portion of the piston rod" disclosed in line 9 of claim 15. Clarification concerning the support of the phrases "dose knob" and "driver" is respectfully requested.

> Mylan Exhibit - 1006 Mylan v. Sanofi

0165

In view of the 35 U.S.C. 112 (first paragraph) problems disclosed above, the

examiner of record cannot determine the exact scope of the pending claims, and

therefore, presents the following Section 103 rejection.

Claim Rejections - 35 USC § 103

The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis

for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 15, 17, and 19 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Walters et al. (EP 0937471A2; hereinafter "Walters").

The Walters publication discloses a housing, a dose dial sleeve, a piston rod, and a drive sleeve. Since it appears that the "dose knob" and the "driver" elements have no support in the specification and the "tubular clutch" is located at the distal end of the "dose job", it is impossible to properly discern the exact function of the "tubular clutch" in the pending claims. Therefore, for a person of ordinary skill in the art, designing a dispensing apparatus having a housing, a dose dial sleeve, a piston rod, and a drive sleeve would have been considered an obvious design choice.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent

and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to

http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-l.jsp.

0167

Claims 15, 17, and 19 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14 of U.S. Patent No. 7,918,833. Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims identified above disclose similar structural elements with minor variations that a person of ordinary skill in the art would have considered as obvious design choices.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MANUEL MENDEZ whose telephone number is (571)272-4962. The examiner can normally be reached on 0730-1800 hrs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Nicholas D. Lucchesi can be reached on 571-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

0168

Respectfully submitted,

/Manuel A. Mendez/

Primary Examiner, Art Unit 3763

Mylan Exhibit - 1006 Mylan v. Sanofi

Notice of References Cited	Application/Control No. 12/944,544	Applicant(s)/Patent Under Reexamination VEASEY ET AL.				
Notice of Melefences Cheu	Examiner	Art Unit				
	MANUEL MENDEZ	3763	Page 1 of 1			

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	А	US-7,918,833	04-2011	Veasey et al.	604/209
	В	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	Ι	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	Ν					
	0					
	Р					
	Q					
	R					
	s					
	Т					

NON-PATENT DOCUMENTS

* Image: Ima

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Part of Paper No. 20130824

Mylan Exhibit - 1006 Mylan v. Sanofi

0170

Doc description: Information Disclosure Statement (IDS) Filed

12944544 - GALL:037063 Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		12944544		
	Filing Date		2010-11-11		
	First Named Inventor	Robei	t Frederick Veasey et al.		
	Art Unit Examiner Name Attorney Docket Number		3763		
			10-1188-US-CON1		

						U.S.I	PATENTS			Remove	
Examiner Initial*	er Cite No Patent Number Kind Code ¹ Issue Date Name of Patentee or Application of cited Document					Relev	s,Columns,Lines where vant Passages or Relev es Appear				
	1	5	304152		1994-04	I-19	Sams				
	2	5	626566		1997-05	5-06	Petersen et al				
If you wisl	h to ac	ld a	dditional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
				U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite N	٩o	Publication Number	Kind Code ¹	Publica Date	ation	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1		20020052578	A1	2002-05	5-02	Moller				
If you wisl	h to ac	ld a	dditional U.S. Publi	shed Ap	plicatior	n citation	n information	please click the Ade	d butto	n. Add	
					FOREI	GN PAT		IENTS		Remove	
Examiner Initial*	Cite No		reign Document ımber³	Country Code ²		Kind Code⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T 5
	1	093	37471	EP		A2	1999-08-25	Becton, Dickinson a Company	and		
lf you wisl	h to ac	ld a	ا Idditional Foreign Pa	atent Do	cument	l citation	information p	lease click the Add	buttor	Add	<u> </u>
				NON		NT LITE	RATURE DO	CUMENTS		Remove	

ALL REFERENCES CONSIDERED EXCEPT WHERE AND ALL REFERENCES CONSIDERED AND ALL REFERENCES AND ALL REFERENCES CONSIDERED AND ALL REFERENCES AND ALL REFERENCES CONSIDERED AND EFS Web 2.1.17

Receipt date: 01/20/2012

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12944544	12944544 - GAU: 3763			
Filing Date		2010-11-11				
First Named Inventor	Robe	t Frederick Veasey et al.				
Art Unit	-	3763				
Examiner Name		•				
Attorney Docket Numb	er	10-1188-US-C	:ON1			

Examiner Initials*	Cite No	(book, magazine, jo		RS), title of the article (when a talog, etc), date, pages(s), vol			T⁵			
	1									
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									
			EXAMINER	SIGNATURE						
Examiner	Signa	t ure /Manu	el Mendez/	Date Conside	red	08/25/2013				
				on is in conformance with MPE of this form with next communi		-				
Standard ST ⁴ Kind of doo	F.3). ³ F cum <mark>ent</mark>	or Japanese patent docu	ments, the indication of the year of t	201.04. ² Enter office that issued the he reign of the Emperor must precede der WIPO Standard ST.16 if possible.	the ser	rial number of the patent doo	ument.			

12944544 - GAU: 3763 Receipt date: 01/20/2012 Application Number 12944544 Filing Date 2010-11-11 INFORMATION DISCLOSURE First Named Inventor Robert Frederick Veasey et al. STATEMENT BY APPLICANT 3763 Art Unit (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 10-1188-US-CON1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas E. Wettermann/	Date (YYYY-MM-DD)	2012-01-20
Name/Print	Thomas E. Wettermann	Registration Number	41,523

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

EFS Web 2.1.17 ALL REFERENCES CONSIDERED EXCEPT WHERE AND THROUGH. /M.M./

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc description: Information Disclosure Statement (IDS) Filed

12944544 - GALL:037063 Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number Filing Date		12944544		
			2010-11-11		
	First Named Inventor	Robei	ert Frederick Veasey		
	Art Unit		3763		
	Examiner Name MENI		DEZ, MANUEL A		
	Attorney Docket Number		10-1188-US-CON1		

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5674204		1997-10-07	Chanoch	
	2	5688251		1997-11-18	Chanoch	
	3	6083197		2000-07-04	Umbaugh	
	4	6221046		2001-04-24	Burroughs, et al.	
	5	6899698		2005-05-31	Sams	
If you wis	n to add	additional U.S. Paten	t citatio	n information pl	lease click the Add button.	Add
		_	U.S.P		CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040059299		2004-03-25	Moller	
lf you wisl	n to add	additional U.S. Publis	hed Ap	plication citation	n information please click the Add	d button. Add
				FOREIGN PAT		Remove

ALL REFERENCES CONSIDERED EXCEPT WHERE AND ALL REFERENCES CONSIDERED AND ALL REFERENCES AND ALL REFERENCES CONSIDERED AND ALL REFERENCES AND ALL REFERENCES CONSIDERED AND EFS Web 2.1.17

Receipt date: 10/17/2012

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12944544	12944544 - GAU: 3763			
Filing Date		2010-11-11				
First Named Inventor	Robe	rt Frederick Veas	беу			
Art Unit		3763				
Examiner Name	MEN	DEZ, MANUEL A	ι.			
Attorney Docket Numb	er	10-1188-US-CO	DN1			

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code² j	Kind Code⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	0937476	EP		1999-08-25	BECTON DICKINSON CO		
	2	91/14467	wo		1991-10-03	SAMS BERNARD		
	3	99/38554	wo		1999-08-05	NOVO NORDISK AS		
If you wisl	h to ac	dd additional Foreign F	atent Document	citation	information pl	ease click the Add butto	n Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		rnal, serial, symp	osium,	catalog, etc), c	the article (when approp date, pages(s), volume-is		T⁵
	1							
lf you wisl	h to ao	d additional non-pate	nt literature docu	ment cit	ation informati	ion please click the Add I	outton Add	
			EX	AMINE	R SIGNATUR	E		
Examiner	Signa	ture /Manuel Me	ndez/			Date Considered	08/25/2013	
						ormance with MPEP 609 with next communication		
Standard ST ⁴ Kind of doo	F.3). ³ F cum <mark>ent</mark>	or Japanese patent docum	ents, the indication of	the year	of the reign of the	r office that issued the docume Emperor must precede the se dard ST.16 if possible. ⁵ Appli	rial number of the patent docu	ument.

EFS Web 21.17 ALL REFERENCES CONSIDERED EXCEPT WHEN FLANDER HOWGH. /M.M./

12944544 - GAU: 3763 Receipt date: 10/17/2012 Application Number 12944544 Filing Date 2010-11-11 INFORMATION DISCLOSURE First Named Inventor Robert Frederick Veasey STATEMENT BY APPLICANT Art Unit 3763 (Not for submission under 37 CFR 1.99) MENDEZ, MANUEL A Examiner Name Attorney Docket Number 10-1188-US-CON1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas E. Wettermann/	Date (YYYY-MM-DD)	2012-10-15
Name/Print	Thomas E. Wettermann	Registration Number	41523

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12944544		
Filing Date		2010-11-11		
First Named Inventor	Robe	Frederick Veasey		
Art Unit		3763		
Examiner Name	Mend	ez, Manuel A.		
Attorney Docket Number		10-1188-US-CON1		

Examiner (nitial*						
		r Cite No Patent Number		Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
1	1	5304152		1994-04-19	Sams	
2	2	5320609		1994-06-14	Haber et al.	
3	3	5480387		1996-01-02	Gabriel et al.	
2	4	5505704		1996-04-09	Pawelka et al.	
Ę	5	6193698		2001-02-27	Kirchhofer et al.	
6	6	6248095		2001-06-19	Giambattista et al.	
7	7	7241278		2007-07-10	Moller	
f you wish	to add	l additional U.S. Pate	nt citatio	n information p	blease click the Add button.	Add

INFORMATION DISCLOSURE Application Number 12944544 Filing Date 2010-11-11 First Named Inventor Robert Frederick Veasey Art Unit 3763 Examiner Name Mendez, Manuel A. Attorney Docket Number 10-1188-US-CON1

	·											
Examiner Initial*	Cite I	No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		" Rele	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1											
If you wish to add additional U.S. Published Application citation information please click the Add button. Add												
FOREIGN PATENT DOCUMENTS Remove												
Examiner Initial*	Cite No			Country Code² j		Kind Code⁴	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Т5	
	1	993	8554	wo		A1	1999-08-05	Novo Nordisk A/S				
If you wish to add additional Foreign Patent Document citation information please click the Add button Add												
NON-PATENT LITERATURE DOCUMENTS Remove												
Examiner Initials*	Cite No	(bo	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									
	1											
If you wish to add additional non-patent literature document citation information please click the Add button Add												
EXAMINER SIGNATURE												
Examiner Signature Date Considered												
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.												

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		12944544		
	Filing Date		2010-11-11		
	First Named Inventor Rober		bert Frederick Veasey		
	Art Unit		3763		
	Examiner Name	Mend	ez, Manuel A.		
	Attorney Docket Number		10-1188-US-CON1		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

X The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas E. Wettermann/	Date (YYYY-MM-DD)	2013-08-30
Name/Print	Thomas E. Wettermann	Registration Number	41,523

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.



WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61M 5/315, 5/24	A1	(11) International Publication Number: WO 99/38554
 (21) International Application Number: PCT/DK (22) International Filing Date: 28 January 1999 ((30) Priority Data: PA 1998 00130 30 January 1998 (30.01.98) (71) Applicant: NOVO NORDISK A/S [DK/DK]; No DK-2880 Bagsværd (DK). (72) Inventors: STEENFELDT-JENSEN, Søren; Holr 2B, DK-3100 Hornbæk (DK). HANSEN, Ste Frederiksborgvej 64A, DK-3400 Hillerød (DK). (74) Agent: NOVO NORDISK A/S; Corporate Patents, N DK-2880 Bagsværd (DK). 	28.01.9 D ovo All nevæng ffen; C	 BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.

(54) Title: AN INJECTION SYRINGE

(57) Abstract

In an injection syringe comprising a housing (1), a piston rod (6) with a not circular cross section and an outer thread (7), a piston rod drive comprising a piston rod guide (85) mating the cross section of the piston rod (6) and a nut (4) which is not axially displaceable and mates the thread (7) of the piston rod (6) to form a self locking thread connection, and a dose setting mechanism comprising a not self locking thread connection along which an injection button by rotation of a dose setting element (81) is screwed out to project from the housing (1) and which thread connection by axial returning of the injection button (88) transforms this axial movement into a rotation of one of the piston rod guide (85) allows rotation in one direction by which the piston rod (6) is transported in a distal direction. The coupling has an initial reluctance to be overcome before rotation takes place said reluctance being large enough to resist torques exerted during the dose setting.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

	-	•	•	10			11
AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Тодо
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	ТМ	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	ТТ	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	КР	Democratic People's	NZ	New Zealand		
СМ	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

An injection syringe

The invention relates to injection syringes of the kind apportioning set doses of a medicine from a cartridge containing an amount of medicine sufficient for the preparation of a number of therapeutic doses.

1

Such syringes are mainly made for users who have to inject themselves frequently, e. g. diabetics. A number of demands are set to such syringes. The setting of a dose must be

- 10 easy an unambiguous and it must be easy to read the set dose. It must be possible with a minimum of trouble to cancel or change a wrongly set dose and when the dose is injected the dose setting must return to zero. When a disposable syringe is in question, i.e. a syringe which is disposed of when the cartridge is empty, the syringe must further be cheap and made of materials suited for recycling or burning without producing noxious gases. For these
- 15 purposes the number of parts from which the syringe is constructed and the number of different kinds of materials used in the syringe should be kept at a minimum.

Most dose setting devices work with a threaded piston rod co-operating with a nut where the nut and the piston rod may be rotated relative to each other. The dose setting may be ob-

- tained by screwing the nut away from a stop to which it is returned during the injection by pressing the piston rod until the nut member abuts the stop. By other dose setting devices one of the elements, the nut or the piston rod, is kept inrotatable and the other is allowed to rotate a set angle depending on the set dose, whereby the piston rod is screwed a distance through the nut.
- 25

5

In most syringes for apportioning set doses it is preferred that the piston rod is backing up the piston upon which it works during the injection. To obtain this precaution is taken to prevent the piston rod from moving in a proximal direction.

30 The syringe according to EP 327 910 is of the type wherein a nut is screwed away from a stop. During the setting of the dose the screwing may be performed in both direction so that a too large set dose may be lowered just by rotating the nut in an opposite direction. Means are provided preventing that negative doses are set. The mutual rotation of the piston rod and the nut is obtained by rotating a cap relative to the pen housing and a set dose may be

read on a scale and a pointer provided at adjacent edges of the housing and the cap, these edges being so shaped that the cap can only be mounted firmly on the housing when the pointer points zero on the scale. It may be seen as a weak point that doses larger than the one obtained by rotating the parts 360° must be calculated by adding the number pointed at

5 on the scale and a number printed on the side of a tubular extension of the nut which is moved out from the proximal end of the housing proportionally with the dose set and which tubular extension is closed at its proximal end to form an injection button.

In EP 450 905 the above drawback is overcome by writing the numbers along a helical line on a tubular extension of the nut so that these number may successively be seen in a window in a housing element enclosing said tubular extension. Hereby the size of the dose is indicated unambiguously but the user have to remember to set the dose setting device on zero before the next setting of a dose is performed. If this is forgotten a wrong dose may be set and the number may not be seen clearly in the window.

15

In EP 608 343 is described a pen having a dose setting mechanism wherein the dose is set by rotating a button relative to a housing to set a dose. By the rotation the button is screwed up from the end of the housing in a thread having a pitch so large that the thread connection is not self blocking, i. e. when the button is presses back to the end of the housing it will ro-

- 20 tate back in the thread. The button is through a ratchet coupled to a driver, the ratchet forming a unidirectional coupling which during the rotation of the button in one direction to set a dose rides or clicks over the teeth of the ratchet. The cylindrical side of the button carries numbers which shows the size of the set dose in a window when the button is screwed outward. When the button is screwed back the unidirectional coupling will transmit the rotation
- to the driver which has a nut co-operating with a threaded piston rod which is made inrotatable in a housing. This thread connection has a pitch which makes the nut self locking on the piston rod. A set dose may be cancelled by drawing the engaging parts of the ratchet out of engagement against the force of a spring so that the rotation of the button is not transmitted to the driver and then press the button back to the housing. This pen fulfils all the
- 30 objects mentioned only the dose cancelling procedure is a little troublesome as the dose set button cannot as it will come most naturally just be screwed back if a too large dose is set. Concomitantly forcing the coupling parts apart against the force of the spring and pressing or screwing the button back may be a little difficult and the demand for a spring necessitates use of metal parts in the syringe.

It is an object of the invention to provide a syringe which has the mentioned advantageous features without having the drawbacks known from existing syringes.

3

5 This is obtained by an injection syringes for apportioning set doses of a medicine from a cartridge containing an amount of medicine sufficient for the preparation of a number of therapeutic doses, comprising

a housing

10

a piston rod having a not circular cross-section and an outer thread

a piston rod drive comprising two elements

15 a) a piston rod guide in relation to which the piston rod is axially displaceable but not rotatable, and

a nut member which is rotatable but not axially displaceable in the housing and which has an inner thread mating the thread of the piston rod to form a self locking thread
 connection,

a dose setting mechanism comprising a not self locking thread connection along which an injection button by rotation of a dose setting element relative to said housing is screwed out from the proximal end of the housing to project from this proximal end a distance determined by the angle of said rotation and which thread connection by axial returning of the injection button transforms this axial movement to a rotation of one of the piston drive elements relative to the other,

which syringe according to the invention is characterised in that

30

25

a unidirectional coupling is provided between the nut member and the piston rod guide allowing rotation of these parts relative to each other in one direction but not in the opposite direction, the allowed rotation being one by which the piston rod is transported in a distal di-

rection in the syringe, the coupling being so designed that a set initial reluctance has to be overcome before the rotation takes place.

4

During the setting of a dose a torque is exerted on the unidirectional coupling in the direction in which this coupling allows rotation after a set initial reluctance has been overcome. As this

torque is a weak one resulting when the male and the female part of a not self locking thread 5 connection is rotated relative to each other the initial reluctance can be made large enough to allow this rotation without causing any relative rotation of the parts in the coupling.

When the injection button is pressed the movement of this button is transformed into a rotation of the piston rod (or the nut member) relative to the nut member (or the piston rod). 10 When the button is pressed hard enough the initial reluctans is overcome so that the two elements, the piston rod and the nut member, are rotated relative to each other.

- According to the invention a click coupling providing an moderate resistance against rotation is established between the housing and the element rotated relative to the housing to set a 15 dose. Hereby it is ensured that the position corresponding to a set dose is maintained and is not inadvertently altered. The clicks may be taken as an audible signal indicating the size of
- The unidirectional coupling may be a coupling comprising a pawl sliding over a pawl wheel 20 with teeth having a steep front edge and a ramp shaped trailing edge, and the initial reluctance may be obtained by the fact that the trailing edges of the pawl wheel teeth has a depression engaged by a mating protrusion on the pawl.
- A dose scale drum which has in its surface a helical track engaged by a helical rib on the 25 inner side of the housing to form a not self locking thread connection between the housing and the drum may be coupled to the injection button to be moved axially with this button. This way the dose scale drum will be rotated relative to the housing when it is axially displaced with the injection button in said housing.

30

The thread connection by which the injection button is screwed out from the housing by setting a dose may be the thread connection between the dose scale drum and the housing. In this case the dose scale drum must be coupled to a driver rotating the piston rod (or the nut member) relative to the nut member (or the piston rod) when the injection button is pressed.

A dose is set by rotating an element relative to the housing, and this element may be an element carrying the nut member and the unidirectional coupling so that the rotation is transmitted through said unidirectional coupling to the dose setting drum. The rotation

- transmitted is in the direction in which the coupling can run free when an initial reluctance is 5 overcome. However, the force needed to screw the dose scale drum up along its thread is not large enough to overcome said reluctance and consequently the rotation is transmitted through the coupling.
- In one embodiment of the syringe according to the invention the element rotated relative to 10 the housing may be a part carrying the nut member and the unidirectional coupling through which the rotation is transmitted to the dose setting drum.

In another embodiment of the syringe according to the invention the element rotated relative to the housing may be the injection button and the not self locking thread connection which 15 determines the lifting of the injection button may be an inner thread in a bore in the injection butt on engaging an outer thread on an enlargement of the piston rod. When the injection button is screwed up along the piston rod to project from the housing a torque is exerted on

the piston rod trying to rotate this piston rod in a direction which will move it in a distal direction in the syringe. Such a rotation is just the rotation which is allowed by the uniderectional 20 coupling which blocks rotation in the opposite direction. Due to the initial reluctance against rotation of the coupling parts relative to each other the piston rod will not be rotated when the injection button is screwed up along it in a proximal direction in the syringe. If the injection button is screwed in the opposite direction the unidirectional coupling will definitively block a

relative rotation of the piston rod and the nut member in the direction which would draw the 25 piston rod in a proximal direction.

In the last mentioned embodiment of the injection syringe the dose scale drum may be

30

mounted rotateable but not axially displaceable on the injection button. When the dose scale drum is moved with the injection button in the axial direction of the syringe the drum will be rotated due to the not self locking thread connection between said drum and the housing so that a number on the drum corresponding to the set dose is visible in a window provided in the wall of the housing. In this embodiment the pitch of the dose drum thread need not be identical with the pitch of the thread along which the injection button is screwed to set a

> Mylan Exhibit - 1006 Mylan v. Sanofi

dose, only both thread connections must have a pitch large enough to make the thread connection the not self locking type, i.e. of the type by which an axial movement can be transformed into a rotation.

In an appropriate embodiment of the syringe according to the invention the dose scale drum 5 is mounted rotatable but not axially displaceable on the injection button.

During the injection the injection button must be kept inrotatable but axially displaceable relative to the housing in the angular position to which the injection button is rotated during the setting of a dose. This may be obtained by letting the click coupling between the housing 10 and the injection button comprise protrusions on one part engaging axial grooves in the other. When the injection button is pressed home into the housing the internal thread in the bore of this button will act on the engaging outer thread on the enlargement at the end of the piston rod and convert the axial movement of the injection button to a rotational movement of the piston rod in a direction by which the piston rod is screwed through the nut member in a

- distal direction in the syringe. The piston rod guide which is connected to one part of the unidirectional coupling is allowed to rotate when the initial reluctance against rotation in the direction else allowed by the coupling is overcome. Also a rotational movement of the dose scale drum is induced by the axial movement of the injection button so that the scale is re-
- turned to its zero position when the button is pressed home. When rotation of the dose 20 scale drum and the piston rod is induced by the axial movement of the injection button this button is reacted upon by a torque which must be taken up by the click connection between the injection button and the housing which connection must consequently be strong enough to absorb this force without rotating.

25

15

In the following the invention is described in further details with references to the drawing, wherein

Figure 1 shows a front view of an embodiment of an injection syringe according to 30 the invention,

Figure 2 shows a sectional view along the line II-II in figure 1,

Figure 3 shows in a reduced scale an exploded view of the syringe in figure 1,

Mylan Exhibit - 1006 Mylan v. Sanofi

Figure 4	shows a sectional view along the line IV-IV in figure 1.
----------	--

Figure 5 shows a sectional view along the line V-V in figure 1,

Figure 6 shows a front view of another embodiment of an syringe according to the invention,

Figure 7 shows a sectional view along the line VII-VII in figure 6,

10

5

Figure 8 shows in a reduced scale an exploded view of the syringe in figure 6,

Figure 9 shows a sectional view along the line IX-IX in figure 6,

15 Figure 10 shows a sectional view along the line X-X in figure 6.

Figure 11 shows a sectional side view of another embodiment of a syringe according to the invention,

20 Figure 12 shows a sectional side view perpendicular to the view in figure 11,

Figure 13 shows in a reduced scale an exploded view of the syringe in figure 11 and 12,

25 Figure 14 shows a sectional side view of the dose setting part of another embodiment of a syringe according to the invention,

Figure 15 shows a sectional side view of still another embodiment of a syringe according to the invention,

30

Figure 16 shows a sectional side view perpendicular to the view in figure 15,

Figure 17 shows in a reduced scale an exploded view of the syringe in figure 15 and 16,

Initially it may be convenient to define that in this application directions of rotation are always seen from the proximal end of the pen and designed as clockwise or anticlockwise seen in this direction.

8

5

Figure 1 shows an injection syringe of the kind by which a liquid from an ampoule can be apportioned in a number of individually set does. Figure 3 shows an exploded view of this syringe and the figures 2, 4 and 5 sectional views taken along different lines in figure 1.

The syringe comprise a tubular housing 1 which is by a partition 15 divided into a first and a second division into the first one of which an ampoule holder 2 is snapped by a snap lock comprising a ring shaped bead 3 on the ampoule holder 2 which bead is snapped into a corresponding circumferantial grove in the inner wall of the housing 1 near an open end thereof. By this snap connection the ampoule holder 2 is secured in the housing 1 so that it can be

15 rotated but not axially displaced relative to this housing.

In the syringe ready for use an ampoule is mounted in the ampoule holder which is then at its distal end closed by an end wall provided with a needle hub receiving part onto which a needle hub can be mounted having a needle with one end communicating with the content of

20 the ampoule and the other end free to be inserted into a patient. In the shown syringe, however, neither ampoule, end wall nor needle hub are shown.

The end of the ampoule holder 2 inserted in the housing 1 is closed by a wall 4 having a central bore with an internal thread 5. A piston rod 6 having an external thread 7 mating the

25 thread 5 of said bore extends through said bore. The threads are so designed that a clockwise rotation of the piston rod will drive this rod into an ampoule accommodating compartment 8 in the first division of the housing 1. At its end projecting into the compartment 8 the piston rod 6 is provided with a pressure foot 9 designed to abut a piston closing the rear end of an ampoule accommodated in the ampoule holder 2.

30

In the proximal side of the end wall 4 the bore is enlarged and the internal side of the enlargement is provided with pawl wheel teeth 10 having a steep front edge 11 facing the clockwise direction and a ramp shaped rear edge 12 facing the anticlockwise direction. At

> Mylan Exhibit - 1006 Mylan v. Sanofi

WO 99/38554

9

least one pawl 13 mounted on a piston rod guide 14 co-operates with the pawl teeth 10 so that said piston rod guide can only be rotated clockwise in the ampoule holder 2.

On the inner wall of the second division of the housing 1 a helical protruding rib 16 is provided defining an inner thread with a high pitch. A dose scale drum 17 is in its outer wall pro-5 vided with a helical grove defining a corresponding external thread mating the inner thread just mentioned. The pitch angle of the threads exceeds the angle of friction for the materials forming the parts of the thread connection and consequently the thread connection is of the not self locking type which induce a relative rotation of the parts of the connection when these part are moved axially relative to each other. 10

Numbers indicating set doses are printed on the outer wall of the dose drum 17 and the number corresponding to a set dose is shown in a window 18 provided in the side wall of the housing 1.

15

The dose scale drum 17 is provide with a tubular extension 21 having an end near the proximal end of the syringe. Said end of the extension is closed by an end wall 19 having a central outer protrusion 20. In a part of the wall adjacent to the end wall 19 the extension 21 is provided with slots 22. The said end of the extension is covered by a cup shaped cap 23 forming an injection button. Internal hooks 24 at the open end of this cap snaps over an external circumferential bead 25 on the extension 21 and the protrusion 20 on the end wall 19 abuts the inner side of the bottom of the cap 23 to form a journal about which the injection

button can rotate relative to the extension 21 whereas it cannot be axially displaced relative

25

20

A driver tube 26 integral with the piston rod guide 14 extends from this piston rod guide to the end wall 19 of the dose scale drum extension 21 and is at its proximal end divided into tongues 27 terminated by external hooks 28 engaging the slots 22 in the extension 21. This way the dose scale drum 17 is bound to rotate with the driver tube 26 but is axially displaceable relative to this tube.

30

to this extension.

To set a dose the ampoule holder 2 is rotated anticlockwise in the first division of the housing 1. This rotation is performed against a resistance presented due to the fact that a protrusion 30 on the outer wall of the ampoule holder rests in one of a number of depressions 31

> Mylan Exhibit - 1006 Mylan v. Sanofi

10

circumferentially provided in the inner wall of said first division of the housing as shown in the cross-sectional view in figure 3. The angular spacing of the depressions are appropriately made so that a dose of one unit is set when the protrusion is moved from one depression to the neighbouring depression so that the number of clicks heard and felt during the dose set-

5 ting rotation corresponds to the size of the set dose.

The rotation of the ampoule holder is due to the friction in the engaging threads 5 and 7 transmitted to the piston rod 6 and further through the unidirectional coupling to the piston rod guide 14 although the torque is transmitted in a such a direction that the pawl will intend

- to click over the pawl wheel teeth 10. However, before this click function is performed a reluctance have to be overcome. This reluctance is obtained by providing the pawl 13 with a protrusion 29 at its end engaging the pawl wheel teeth 10 and by providing depressions 32 in the ramp shaped edges 12 of the pawl wheel teeth into which depressions the protrusion 29 on the pawl 13 will rest. Before the clicking release of the coupling is obtained a torque
- 15 sufficient to lift up the protrusion 29 of the pawl 13 from the depression 32 in the ramp shaped edge 12 must be provided. Altogether a moderate torque can be transmitted from the rotated ampoule holder 2 to the driver tube 26. As the hooks 28 at the proximal end of the driver tube 26 engage the slots 22 in the dose scale drum extension 21 the dose scale drum will be rotated and be screwed upwards in the second division of the housing 1 and the
- injection button 23 will be lifted to protrude from the proximal end of the housing 1. As only a small torque is needed to screw up the dose scale drum this is obtained without releasing the unidirectional coupling to its clicking release function mode. The size of the set dose can currently be seen on the part of the dose scale drum which is presented in the window 18. If a too large dose has been set the ampoule holder can be rotated in a clockwise direction until the number corresponding to the size of the wanted doe is presented in the window 18.

To inject the set dose the injection button 23 is pressed home into the housing 1. Thereby the dose scale drum 17 is pressed in the distal direction and due to the thread connection between said drum and the housing 1 a torque is exerted on the drum rotating this drum in a clockwise direction. Said torque is via the slots 22 in the drum extension 21 and the hooks 28 at the end of the driver tube 26 and this tube itself transmitted to the piston rod guide 14. The pawls 13 on the piston rod guide are allowed to rotate in the clockwise direction when the torque is strong enough to overcome the reluctance provided by the protrusions 29 on the pawls engaging the depressions 32 in the ramp shaped edges of the pawl wheel teeth.

Mylan Exhibit - 1006 Mylan v. Sanofi

Such a strong torque is provided if only the inject button 23 is pressed hard enough. The piston rod guide 14 will now rotate clockwise with the unidirectional coupling working in its clicking released mode and the piston rod will be rotated clockwise too and will thereby be screwed through the wall 4 further into the ampoule accommodating compartment 8. The unidirectional coupling will never allow an antiplackwise sateties at the state of the state of the state.

5 unidirectional coupling will never allow an anticlockwise rotation of the piston rod guide and the piston and this way it is ensured that the pressure foot 9 will never be drawn out of abutment with the piston in a not shown ampoule in the compartment 8.

In the shown embodiment the end wall 4 with its threaded bore forms a nut member relative to which the piston rod is rotated by the piston rod guide 14 and the driver tube 26. Embodiments may be imagined wherein the piston rod guide is provided in the wall 4 and a nut element is rotated by the driver tube and such embodiment will not be beyond the scope of the invention.

- 15 Another embodiment is described with reference to the figures 6-10. Elements corresponding to elements in the embodiment described with references to the figures 1-5 are provided with the same reference numbers. Different from the embodiment in figure 1-5 is the fact that the injection button 23 and not the dose scale drum 17 is provided with an extension 33, and that the driver tube 26 is omitted. Further the injection button 23 is provided with a flange 32
- 20 which abuts the end of the housing when the injection button is pressed home. The extension 33 serves as a journal for the dose scale drum 17 which is free to rotate on this journal but bound to follow axial movements of the injection button 23 due to hooks 34 at the end of the extension 33. A longitudinal bore 35 in the injection button and its extension 33 is provided with an internal helical rib 36 engaging a corresponding helical groove in an enlarge-
- 25 ment 37 at the proximal end of the piston rod to form a thread connection between said button 23 and said piston rod 6. The pitch of this thread connection is so that a not self locking thread connection is formed.

To set a dose the injection button 23 is manually rotated in a clockwise direction Thereby this button is screwed outwards from the housing 1 as the piston rod 6 will through the piston rod guide 14 and the unidrectional coupling be kept inrotatable although said unidirectional coupling in influenced by a torque in its release direction, however, due to the provided initial reluctance the piston rod guide 14 will not immediately be rotatable. In its movement outwards the injection button 23 will draw the dose scale drum 17 with it. When this drum is

WO 99/38554

12

moved axially in the housing it will be rotated due to the not self locking thread connection between said drum 17 and the housing 1.

By this construction the thread along which the injection button is screwed outwards and the tread along which the dose scale drum is rotated in the housing may be different.

A click connection corresponding to the one established between the cartridge holder 2 and the housing 1 in the embodiment according to figure 1 is in the embodiment according to figure 6 appropriately provided between the injection button 23 and the housing 1 where one or more protrusions 38 provided on the inner wall of the housing engages grooves 39in a cylindrical outer wall of the button 23. Thereby axial movement of the injection button is allowed in all its possible angular positions.

When the injection button is pressed to inject a set dose said button will be maintained inrotatable during its axial movement as the locking between the above mentioned protrusions on the inner wall of the housing and grooves on the outer wall of the button is strong enough to absorb the torque exerted on the injection button when it drives the piston rod to rotation in a clockwise direction after having overcome the reluctance against rotation in the release direction of the unidirectional coupling.

20

25

5

10

The embodiment shown in figure 11, 12 and 13 has the housing 1 with the window 18. The end wall 4 with the internal thread 5 is provided in a separate member 40 which is mounted in an end of the housing, the member 40 having protrusions 41 engaging slots 42 in the housing to lock the member 40 to the housing 1. Further the member 40 has at its periphery longitudinal recesses 43 which are engaged by not shown internal ribs in the housing to lock the member 40 against rotation relative to the housing 1. Further protrusions 44 on the ampoule holder 2 engage the slots 42 to lock the ampoule holder 2 to the housing 1.

The piston rod 6 engages by its external thread 7 the internal thread of the end wall 4 and is at its end in the ampoule holder terminated by a pressure foot 9 relative to which the piston rod 6 is rotatable. A driver tube 45 is at one end provided with the pawl 13 which engages pawl wheel teeth in the member 40 and is held between a ring shaped wall 46 in the housing and the end wall 4 in the member 40 to keep the driver tube 45 from axial movement but allowing it to rotate. On its inner wall the driver tube 45 has a key engaging a longitudinal re-

cess in the piston rod 6. Thereby rotation of the driver tube is transmitted to the piston rod 6 whereas the piston rod can move freely in the axial direction of the driver tube 45. On its outer wall the driver tube 45 has an outer thread 47 which engages an inner thread 50 in a nut member 48 which has at its distal end a flange 49 and is at its proximal end provided

with a part 51 with reduced diameter to which part one end of a tubular part 52 which at its 5 other end carries a button 23 is secured.

In the proximal end of the housing 1 a bushing 53 is secured to be non rotatable an non displaceable relative to said housing 1 the rotational locking being obtained by lugs 54 at the proximal end of the housing engaging recesses 55 at the periphery of the bushing 53. A 10 guide member 56 is longitudinally displaceable in the bushing 53 but inrotatable relative to said bushing and consequently relative to the housing 1. The guide member has at its distal end an annular end wall 57. The part 51 of the nut member 48 is passed through the opening of said end wall 57 and has a bead 58 gripping into a circuferential inner recess in the wall of annular opening through said end wall to keep the bushing 53 secured to said part 51 so that this part can be rotated but not axially displaced in relation to the bushing 53. The scale drum 17 is journalled on the nut member 48 and is held on this nut member by having a flange 90 held between the end wall 57 of the guide member 56 and the shoulder formed where the part 51 connects to the nut member 48.

20

25

15

The button 23 is held rotatably on the guide member 56 which has a ring bead 59 engaging a circumferential recess 60 in the inner wall of the button 23 which recess 60 is somewhat broader than than the bead 59 so that the button in excess of being rotatable on said bushing 53 can be axially displaced a distance defined by the width of the recess 60 relative to the width of the bead 59. The button 23 is coupled to the nut member 48 by internal ribs 61 in the tubular part 52 engaging slots 62 in the proximal part of the part 51 of the nut member 48. This coupling forces the button 23 and the nut member 48 to follow each other in rotational movements but allow a minor relative axial displacement.

The proximal end surface of the guide member 56 has one or more axially directed protru-30 sions 63 which can co-operate with radial recesses 64 in the bottom of the button 23, but mainly a biasing keeps these recesses and protrusions out of engagement. Further the guide member has at its proximal end at least one radial protrusion 65 which is biased to engage axial recesses 66 in an inner wall of the button to produced a click sound each time the

button is rotated relative to the bushing so that the protrusion jump from one recess to the neighbour recess.

To set a dose the button 23 is rotated in a clockwise direction. This rotation is due to the coupling between the ribs 61 and the slots 62 transmitted to the nut member 48 which is then screwed in distal direction along the driver tube 45 which is held inrotatably in the housing due to the reluctans of the pawl 13 to move along the pawl teeth in the member 40. The movement of the nut member 48 in proximal direction makes the scale drum 17, the guide member 56, and the tubular part 52 with the button move in proximal direction so that

10 the button is elevated over the end proximal end of the housing 1. A to high set dose can be reduced by rotating the button in an anti clockwise direction.

During the rotation of the button the radial protrusion 65 of the guide member 56 clicks from one axial recess 66 to the other. The distance between can appropriately be chosen so that a click corresponds to a changing of the set dose by one international unit up or down. Due to engagement between the helical grove on the cylinder wall of the scale drum and a helical rib on the inner wall of the housing the movement of the dose scale drum 17 will rotate and displace said drum so that the set dose is shown in the window 18.

20 When the dose scale drum is displaced outwardly in the housing a steep front side of a saw tooth 91 at the proximal end of the dose scale drum 18 will abut a steep front side of a similar tooth 92 on the bushing whereby the rotation of the dose scale drum is stopped to indicate that a maximum dose has been set.

To inject the set dose the button 23 is pressed. Thereby the bias keeping the protrusions 63 and the recesses 64 out of engagement is overcome and the said engagement is established. The button 23 is now locked relative to the guide element 56 which is again locked against rotation relative to the bushing 53 and consequently relative to the housing 1. The coupling between the tubular part 52 and the nut member 48 makes this nut member inro-

tatable relative to the housing so an axial movement of said nut member in a distal direction will due to the not self locking thread coupling between this nut element and the driver tube 45 make this driver tube 45 rotate in a clockwise direction and due to the key/groove coupling between the driver tube 45 and the piston rod 6 said piston rod will be screwed through the end wall 4 further into the ampoule holder compartment. The locking of the button 23

against rotation during the injection ensures that the set dose is not inadvertently changed during the injection.

In the embodiment shown in figure 14 separate buttons are provided for the dose setting and
the injection. Corresponding to previously described embodiments this one has a housing 1 and a driver tube 67 which is rotatable in only one direction due to a pawl which engage pawl wheel teeth in a part secured in the distal end of the housing. Trapping of the pawl between the member 40 and a ring shaped wall 46 in the housing fixes the driver tube against axial movement. On the outer wall of the driver tube 67 an axial rib 68 is provided which rib engages an axial recess 69 in a tubular injection element 70 to transmit rotation of said injec-

tion element to the driver tube 67.

At the proximal end of the housing 1 a dose setting button 71 is mounted so that this button can be rotated but not axially displaced relative to the housing 1. This is obtained by the fact that the dose setting button 71 on a part fitting into the housing has a ring shaped bead 72 15 which engages a mating circuferential recess 73 in the inner wall of the housing. Outside the housing the dose setting button has a part having a diameter corresponding to or being larger than the diameter of said housing which part can be provided with axial ribs 74 to ensure a good grip by the setting of a dose. The dose setting button 71 has a central bore the inner wall of which has a helical recess 75 engaging a helical rib 76 provided on the outer 20 wall of the proximal part of the injection element 70 which element passes through the bore of the dose setting button 71. The outer wall of the distal part of the injection element 70 forms a journal for the scale drum 17 which through an outer helical recess engaged by an internal helical rib 16 in the housing is rotated to show the set dose in the window 18 when the scale drum is displaced axially in the housing. The proximal end of the injection member 25 is terminated by an end wall 77 which carries an injection button 78 which is by a pivot pin 79 journaled in a central bore in said end wall 77.

30

To set a dose the dose setting button 71 is rotated in a clockwise direction. As the injection member is kept non rotatable by its coupling to the driver tube 67 the collaboration between the helical recess 75 in the inner wall of the dose setting button 71 and the helical rib 76 on the outer wall of the injection element 70 will screw the injection element out through the dose setting button so that the injection button 78 is lifted up from the proximal end of the housing. Although the driver tube 67 with its pawl can be rotated in the clockwise direction

> Mylan Exhibit - 1006 Mylan v. Sanofi

an initial torque is needed which is larger than the torque transmitted from the dose setting button to the injection element.

To inject a set dose the injection button 78 is pressed and the injection element is moved back into the housing. The co-operation of the helical recess 75 in the inner wall of the dose setting button 71 and the helical rib 76 on the outer wall of the injection element 70 will now make the injection element rotate in a clockwise direction and if only the injection button is pressed hard enough a torque is produced large enough to overcome the initial reluctance of the pawl mechanism against rotation in said clockwise direction.

10

The separation of the dose setting button 71 and the injection button 78 makes it less likely that the dose setting button is inadvertently operated during the injection.

Figure 15, 16 and 17 illustrates still another embodiment. To maintain a clockwise rotation of
a dose setting button for increasing the set dose the pawl mechanism working between the
driver tube and the housing is turned so that it bars clockwise rotation and reluctantly allows
anticlockwise rotation of the driver tube. Further the thread of the piston rod and the thread
in the end wall of the housing is so designed that an anticlockwise rotation of the piston will
screw the piston rod through said end wall and into the cartridge holder compartment. The
piston rod has a not round cross-section and fits through the driver tube bore which has a
corresponding not round cross-section. This way rotation is transmitted whereas the piston

rod is allowed to move longitudinally through the driver tube.

A scale drum 80 is in its outer wall provided with a helical track which is engaged by a helical rib16 along the inner wall of the housing 1. At its proximal end the scale drum 80 has a diameter exceeding the inner diameter of the housing to form a dose setting button 81 which on its cylindrical outer wall is knurled to ensure a good finger grip.

A bushing 82 having a flange 83 at its proximal end and having a pair of opposite longitudinal slots 84 through its side walls fits into the scale drum 80 and over the driver tube 85 which tube has on its outer wall hooks 86 engaging the slots 84 of the bushing 82 whereby the bushing 82 and the driver tube 85 is coupled to each other so that rotation but not longitudinal displacement is transmitted between said two elements.

> Mylan Exhibit - 1006 Mylan v. Sanofi

17

In the dose setting button a compartment is provided having a cylindrical side wall circumferentially provided with longitudinal recesses and a bottom with a rosette of teeth having a triangular cross-section. The flange 83 of the bushing 82 is adopted in said compartment and has at its periphery a radial protrusion 87 which is biased toward the side wall of the

5 compartment. At its distal side the flange 83 has a rosette 93 of teeth which can be brought into engagement with the rosette at the bottom of the compartment.

The bushing 82 is mounted in the scale drum 80 with protrusion on the outer wall of the bushing 82 engaging recesses in the inner wall of the scale drum 80 so that a limited movement of the bushing in the scale drum is allowed so that the bushing can be moved axially relative to the scale drum to make or not make the teeth of said rosettes engage each other. An injection button 88 is rotatably mounted with a pivot pin 94 journaled in an end wall of the bushing 82.

- 15 When a dose is set by rotating the dose setting button 81 in a clockwise direction, the scale drum is screwed out of the housing and the dose setting button is lifted away from the proximal end of the housing. The bushing is kept non rotated due to its coupling to the driver tube which is locked against clockwise rotation and if a set dose is reduced by rotating the dose setting button 81 in an anticlockwise direction the pawl mechanism working between
- 20 the driver tube and the housing is sufficient reluctant to rotate in its not blocking direction to prevent the bushing 82 from following this anticlockwise rotation. Therefore by the rotation of the dose setting button 81 in any direction the radial protrusion 87 on the flange 83 of the bushing 82 will click from one of the axial recess in the inner wall of the dose setting button 81 to the next one, the recesses being so spaced that one click corresponds to a chosen change of the set dose, e. g. one unit or a half unit. During the setting the rosette in the
- dose setting button forces the rosette 93 on the flange 83 of the bushing 82 out of engagement.

When the injection button 88 is pressed to inject the set dose the said rosettes are pressed into engagement so that the bushing 82 will follow the anticlockwise rotation of the dose setting button 81 which is induced by the thread engagement between the helical track of the scale drum 80 and the rib 16 in the housing when the scale drum 80 is pressed back into said housing. The bushing will rotate the driver tube 85 in an anticlockwise direction which

> Mylan Exhibit - 1006 Mylan v. Sanofi

_

the pawl mechanism reluctantly allows an the piston rod is thereby screwed further into an ampoule 89 in the ampoule holder 2.

By this device the risk for inadvertent operation of the dose setting button 81 during the in-

5 jection is eliminated. Further the device consist of a minimum of parts whereby the manufacturing is made easy.

10

15

25

20

30

Mylan Exhibit - 1006 Mylan v. Sanofi

<u>CLAIMS</u>

An injection syringes for apportioning set doses of a medicine from a cartridge containing an amount of medicine sufficient for the preparation of a number of therapeutic doses, comprising

a housing

a piston rod having a not circular cross-section and an outer thread

10

5

a piston rod drive comprising two elements

- a) a piston rod guide mating the not circular cross-section of the piston rod to allow axially displacement but not rotatation of the piston rod in relation to said piston rod guide, and
- a nut member which is not axially displaceable in the housing and which has an inner thread mating the thread of the piston rod to form a self locking thread connection,

20

15

a dose setting mechanism comprising a not self locking thread connection along which an injection button by rotation of a dose setting element relative to said housing is screwed out from the proximal end of the housing to project from this proximal end a distance determined by the angle of said rotation and which thread connection by axial returning of the injection button transforms this axial measurement to emtative of the setting element and the setting element element and the setting element element

25 jection button transforms this axial movement to a rotation of one of the piston drive elements relative to the other,

characterised in that

30 a unidirectional coupling is provided between the nut member and the piston rod guide allowing rotation of these parts relative to each other in one direction but not in the opposite direction, the allowed rotation being one by which the piston rod is transported in a distal direction in the syringe, the coupling being so designed that an initial reluctance set large

enough to resist a torque exerted on the coupling by the dose setting has to be overcome before rotation takes place.

2. An injection syringe according to claim 1, characterised in that a click coupling providing

5 an moderate resistance against rotation in either directions is established between the housing and the element rotated relative to this housing to set a dose.

3. An injection syringe according to claim 1 or 2, characterised in that the unidirectional coupling comprises a pawl sliding over a pawl wheel with teeth having a steep front edge and a ramp shaped trailing edge.


4. An injection syringe according to claim 3, characterised in that the trailing edges of the pawl wheel teeth has a depression engaged by a mating protrusion on the pawl.

- 15 5. An injection syringe according to anyone of the preceding claims, characterised in that a dose scale drum has in its surface a helical track engaged by a helical rib on the inner side of the housing to form a not self locking thread connection between the housing, and that the dose scale drum is coupled to the injection button to be moved axially with this button.
- 6. An injection syringe according to claim 5, characterised in that the thread connection by which the injection button is lifted by setting a dose is the thread connection between the dose scale drum and the housing.

7. An injection syringe according to claim 1, 2, 3, or 4 characterised in that the element rotated relative to the housing is the injection button and that the not self locking thread connection which determines the lifting of the injection button is an inner thread in a bore in the injection button engaging an outer thread on a part with enlarged diameter of the piston rod.

8. An injection syringe according to claim 1, 2, 3 or 4, characterised in that the piston rod
guide is mounted in a driver tube in which tube the piston rod is axially displaceable but is rotated with said tube, and that the not self locking thread connection which determines the lifting of the injection button is provided between the driver tube and a part which is axially displaceable with the injection button.

Mylan Exhibit - 1006 Mylan v. Sanofi



Mylan Exhibit - 1006 Mylan v. Sanofi

<u>2</u>3

32

-33

-17

-1

-37

-6

B-13


3


-2

39

34-

18-









Mylan Exhibit - 1006 Mylan v. Sanofi


ون Fig.8 3/5





Mylan v. Sanofi



Mylan Exhibit - 1006 Mylan v. Sanofi







Mylan v. Sanofi

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00042

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61M 5/315, A61M 5/24 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where app	propriate, of the relevant passages	Relevant to claim No.			
A US 5674204 A (LAWRENCE H.CHANOCH (07.10.97), column 4, line 2 figure 3, abstract	1), 7 October 1997 26 - column 6, line 29,	1-8			
A WO 9307922 A1 (NOVO NORDISK A/S) (29.04.93), figures 2-7, abs	WO 9307922 A1 (NOVO NORDISK A/S), 29 April 1993 1-8 (29.04.93), figures 2-7, abstract				
EP 0327910 A2 (D.C.P.AF 1988 A/S), 16 June 1989 1-8 (16.06.89), figures 2,3, abstract					
A EP 0450905 A1 (ELI LILLY AND CO. (09.10.91), column 1, line 1), 9 October 1991 9 - column 2, line 36	1-8			
Further documents are listed in the continuation of Box	C. X See patent family annex	ζ.			
 Special categories of cited documents: 'A" document defining the general state of the art which is not considered to be of particular relevance 	"T" later document published after the inte date and not in conflict with the appli the principle or theory underlying the	cation but cited to understand			
E'' erlier document but published on or after the international filing date L''' document which may throw doubts on priority claim(s) or which is	"X" document of particular relevance: the considered novel or cannot be conside step when the document is taken along	red to involve an inventive			
 cited to establish the publication date of another citation or other special reason (as specified) O" document referring to an oral disclosure, use, exhibition or other means 	"Y" document of particular relevance: the considered to involve an inventive step combined with one or more other such being obvious to a person skilled in th	claimed invention cannot be when the document is a documents, such combination			
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent				
Date of the actual completion of the international search	Date of mailing of the international s	earch report			
7 July 1999	0 8 -07- 1999				
Name and mailing address of the ISA/	Authorized officer				
Swedish Patent Office Box 5055, S-102 42 STOCKHOLM	lani Savalan				
Facsimile No. $+46.8.666.02.86$	Joni Sayeler Telephone No. + 46 8 782 25 00				
orm PCT/ISA/210 (second sheet) (July 1992)	Myla	n Exhibit - 1006			
0	210				
	N	/Iylan v. Sanofi			

		r		01/06/99		399/00042 _
Patent document cited in search repor	t.	Publication date		Patent family member(s)		Publication date
JS 5674204	A	07/10/97	EP WO	0861101 9710865		02/09/98 27/03/97
0 9307922	A1	29/04/93	AT AU CA DE EP SE ES GR JP RU	160946 662021 2795192 2119913 69223521 0608343 0608343 2112915 3026174 7500039 2091087	B A D,T A,B T3 T T T	15/12/97 17/08/95 21/05/93 29/04/93 18/06/98 03/08/94 16/04/98 29/05/98 05/01/95 27/09/97
P 0327910	A2	16/06/89	US SE AU CA CN CN CS CZ DD KK FI FI FI FI FI FI SK SK VO YU	5626566 0327910 74777 3066689 1305003 1025719 1035055 8900905 278561 283332 69288 166948 94930 903893 3004398 930507 61515 89189 2726536 3503129 9615612 170604 89669 2053798 8910315 278253 4973318 8907463 31589	T3 T A A B A A B A A B A B A B A B A B A B	06/05/97 15/05/92 06/09/89 14/07/92 24/08/94 30/08/89 16/12/92 16/03/94 10/10/90 11/08/89 09/08/93 15/08/95 00/00/00 31/03/93 30/04/95 16/11/94 27/02/94 11/03/98 18/07/91 18/11/96 01/09/93 04/10/89 10/02/96 30/04/97 05/06/96 27/11/90 24/08/89 30/06/91

Patent document cited in search report Publication date Patent family member(s) Publication date EP 0450905 A1 09/10/91 SE 0450905 T3 AT 129162 T 15/11/95 AU AU 639542 B 29/07/93 AU 7402691 A 10/10/91 CA 2039471 A, C 05/10/91 DE DE 69113847 D, T 04/04/96 DK 450905 T 27/11/95 ES 2079565 T 16/01/96 FI 911583 A 05/10/91 GR 3017999 T 29/02/96 HU 210293 B 28/03/95 1E 69664 B 02/10/96 IL 97683 A 19/01/96 JP 1888779 C 07/12/94 JP JP 1888779 C 07/12/94 JP JP 1888779 C 07/12/94 JP JP 4224764 A 14/08/92 JP JP 606159 B 26/01/94 KR 9600846 B 13/01/96 MX MX 173301 B 14/02/94 NO 300306 B 12/05/97 NZ 237622 A 25/02/94 Z5/02/94 PT 97248 A, B 31/01/92 RU 2033193 C 20/04/95 20/04/95		ONAL SEARCH REPO on patent family members			Internatio	onal application No.
cited in search report date member(s) date EP 0450905 A1 09/10/91 SE 0450905 T3 AT 129162 T 15/11/95 AU 639542 B 29/07/93 AU 639542 B 29/07/93 AU 7402691 A 10/10/91 CA 2039471 A,C 05/10/91 DE 69113847 D,T 04/04/96 DK 450905 T 27/11/95 ES 2079565 T 16/01/96 FI 911583 A 05/10/91 GR 3017999 T 29/02/96 HU 210293 B 28/03/95 IE 69664 B 02/10/96 JP 1888779 C 07/12/94 JP 4224764 14/08/92 JP 6006159 B 26/01/94 KR 9600846 B 13/01/96 MX 173301 B 14/02/94 NO 300306 B	momator	on patent raining memoers		01/06/99	PCT/DK	99/00042
AT 129162 T 15/11/95 AU 639542 B 29/07/93 AU 7402691 A 10/10/91 CA 2039471 A,C 05/10/91 DE 69113847 D,T 04/04/96 DK 450905 T 27/11/95 ES 2079565 T 16/01/96 FI 911583 A 05/10/91 GR 3017999 T 29/02/96 HU 210293 B 28/03/95 IE 69664 B 02/10/96 JL 97683 A 19/01/96 JP 1888779 C 07/12/94 JP 4224764 A 14/08/92 JP 6006159 B 26/01/94 KR 9600846 B 13/01/96 MX 173301 B 14/02/94 NO 300306 B 12/05/97 NZ 237622 A 25/02/94 PT 97248 A,B 31/01/92 RU						
RU 2033193 C 20/04/95	EP 0450905 A1	09/10/91	AT AU CA DK ES FI GR UE JP JP KRX NO NZ	129162 639542 7402691 2039471 69113847 450905 2079565 911583 3017999 210293 69664 97683 1888779 4224764 6006159 9600846 173301 300306 237622	T B A,C D,T T A T B B A C A B B B B B B B B B B B B B B B	29/07/93 10/10/91 05/10/91 04/04/96 27/11/95 16/01/96 05/10/91 29/02/96 28/03/95 02/10/96 19/01/96 07/12/94 14/08/92 26/01/94 13/01/96 14/02/94 12/05/97 25/02/94
US 5226896 A 13707793					C	
US 5295976 A 22/03/94						

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

In re Application of: Robert Frederick Veasey et al. Serial No.: 12/944,544 Filed: November 11, 2010 For: Pen-Type Injector

Examiner: Mendez, Manuel A. Group Art Unit: 3763 Confirmation No.: 5949

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

GENERAL AUTHORIZATION UNDER 37 C.F.R. § 1.136(a)(3)

Sir:

The Commissioner is hereby generally authorized under 37 C.F.R. § 1.136(a)(3) to treat the present and any future related filings in this or any related application filed pursuant to 37 C.F.R. § 1.53 requiring an extension of time as incorporating a request therefore, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 13-2490 for any fee that may be due in connection with such a request for an extension of time.

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: August 30, 2013

By:

<u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

0213

Mylan Exhibit - 1006 Mylan v. Sanofi

Electronic Patent Application Fee Transmittal					
Application Number: 12944544					
Filing Date:	11.	Nov-2010			
Title of Invention:	Per	n-Type Injector			
First Named Inventor/Applicant Name:	Poplicant Name: Robert Frederick Veasey				
Filer:	Thomas E. Wettermann				
Attorney Docket Number:	orney Docket Number: 10-1188-US-CON1				
Filed as Large Entity					
Utility under 35 USC 111(a) Filing Fees					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Pages:					
Claims:					
Miscellaneous-Filing:					
Petition:					
Patent-Appeals-and-Interference:					
Post-Allowance-and-Post-Issuance:					
Extension-of-Time:					

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)	
Miscellaneous:					
Submission- Information Disclosure Stmt	1806	1	180	180	
	Tot	al in USD	(\$)	180	

Electronic Ac	Electronic Acknowledgement Receipt			
EFS ID:	16731839			
Application Number:	12944544			
International Application Number:				
Confirmation Number:	5949			
Title of Invention:	Pen-Type Injector			
First Named Inventor/Applicant Name:	Robert Frederick Veasey			
Customer Number:	20306			
Filer:	Thomas E. Wettermann			
Filer Authorized By:				
Attorney Docket Number:	10-1188-US-CON1			
Receipt Date:	31-AUG-2013			
Filing Date:	11-NOV-2010			
Time Stamp:	16:18:52			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment	yes				
Payment Type	Deposit Account				
Payment was successfully received in RAM	\$180				
RAM confirmation Number	8194				
Deposit Account	132490				
Authorized User					
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:					
Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees) 0216 Mylan Exhibit - 10					
	0216 J				

	any Additional Fees required under 37 C.F.	A. Section 1.21 (Miscellaneous ree			
File Listing Document Number	g: Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.
	T	10_1188_US_CON1_Suppleme	140338		
1	Transmittal Letter	ntal_IDS_Transmittal_2013_08 _30.pdf	fd17d695bca5ba46b60e6b76f5df3018661 3eb8a	no	1
Warnings:	I		<u> </u>		
Information:					
2	Information Disclosure Statement (IDS)	10_1188_US_CON1_Suppleme	612508	no	4
2	Form (SB08)	ntal_IDS_2013_08_30.pdf	202357856db73c94bec032d277f7539bb55 f2b53	110	4
Warnings:					
Information:					
3	Foreign Reference	10_1188_US_CON1_Foreign_R	1419669	no	30
د	Foreign Reference	ef_1.pdf	75943f9b2c2d6321d26b15381a71b41e81e 4b022		
Warnings:					
Information:					
4	Authorization for Extension of Time all	10_1188_US_CON1_General_A	58797	no	1
т	replies	uthorization_2013_08_30.pdf	8c2a86a625c4c224563be074b5c3a55ca3e 340b3	110	I
Warnings :					
Information:					
5	Fee Worksheet (SB06)	fee-info.pdf	30226		2
ر			cafc80d9d8d128735e56ff4e623acb84e2b5 5241	no	2
Warnings:	· · · · · · · · · · · · · · · · · · ·		·		
Information:					
		Total Files Size (in bytes)	220	51538	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/21 (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	perwork ra		no person	Application Number		12/944,			displays a valid OMB control number.
TRANSMITTAL				Filing Date	_	November 11, 2010			
FORM				First Named Inventor			Frederick Veasey		
				Art Unit	_	3763	1100.01		
the be used for		ondence after initial fi	iling)	Examiner Name		Mendez	z, Man	uel A.	
		This Submission	iiirig)	Attorney Docket Numbe	_	10-118			
	r agoo in								
			ENC	LOSURES (Check	all th	at apply)		
Fee Tran	nsmittal Fo	orm		Drawing(s)				After A	Allowance Communication to TC
- F	Fee Attacl	ned		Licensing-related Papers					al Communication to Board beals and Interferences
	ent/Reply			Petition Petition to Convert to a					al Communication to TC (Appeal , Brief, Reply Brief)
	After Final			Provisional Application	otica				etary Information
	Affidavits/declaration(s)			Power of Attorney, Revoca Change of Correspondence		dress		Status	s Letter
Extensio	n of Time	Request		erminal Disclaimer		\boxtimes		Enclosure(s) (please Identify	
Express	Abandoni	ment Request		Request for Refund		^{below):} Copy of Cited Reference a General Authorization			of Cited Reference and
		Information		CD, Number of CD(s)	_				eral Authorization
Disclosu	re Statem	ent		Landscape Table or	n CD				
Certified Documer	Copy of F nt(s)	Priority	Rem	arks					
	Missing F								
	ete Applica Doplu to N								
		/lissing Parts CFR 1.52 or 1.53							
		SIGNA	L TURE (OF APPLICANT, ATT	FOR	NEY. C	R AG	ENT	
Firm Name	McDor			& Berghoff LLP		, -			
Signature		as E. Wetterm		-					
Printed name	Thoma	as E. Wetterma	ann						
Date	Augus	t 30, 2013			Re	eg. No.	41,52	3	
		C	ERTIFI	CATE OF TRANSMIS	SSIC)N/MAI	LING		
	stage as	first class mail in							e United States Postal Service < 1450, Alexandria, VA 22313-
Signature		/Thomas E. W	Vetterm	ann/					
Typed or printed	name	Thomas E. W	/etterma	ann				Date	August 30, 2013
This collection of int	formation is	 required by 37 CFF 	₹15 The	information is required to obta	uin or r	etain a he	nefit hv tl	ne public	which is to file (and by the USPTO to

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Mylan v. Sanofi

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No.: 10-1188-US-CON1)

In the Applic	ation of:)	
Robe	rt Frederick Veasey et al.)	Examiner: Manuel A. Mendez
Serial No.	12/944,544)	Group Art Unit: 3763
Filed:	November 11, 2010)	Confirmation No.: 5949
For: Pen-7	Type Injector)	
Commission P.O. Box 145			

RESPONSE TO THE OFFICE ACTION MAILED AUGUST 30, 2013

Dear Sir:

Alexandria, Virginia 22313-1450

This paper is submitted in response to the Office Action mailed August 30, 2013. Please enter the following remarks and amendments into the record for this application.

Also enclosed is a Petition for Extension of Time under 37 C.F.R. § 1.136(a) (1 Month), along with requisite fees.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of

this paper.

Remarks/Arguments begin on page 4 of this paper.

1

AMENDMENTS

IN THE CLAIMS

1-14. (canceled)

15. (currently amended) A housing part for a medication dispensing apparatus, said housing part comprising:

a main housing, said main housing extending from a distal end to a proximal end;

a dose dial sleeve positioned within said housing, said dose dial sleeve comprising a helical groove configured to engage a threading provided by said main housing, said helical groove provided along an outer surface of said dose dial sleeve;

a dose <u>dial gripknob</u> disposed near a proximal end of said dose dial sleeve;

a piston rod provided within said housing, said piston rod is non-rotatable during a dose setting step relative to said main housing;

a driver <u>sleeve</u> extending along a portion of said piston rod, said driver <u>sleeve</u> comprising an internal threading near a distal portion of said driver <u>sleeve</u>, said internal threading adapted to engage an external thread of said piston rod; and,

a tubular clutch located adjacent a distal end of said dose <u>dial gripknob</u>, said tubular clutch operatively coupled to said dose <u>dial gripknob</u>,

wherein said dose dial sleeve extends circumferentially around at least a portion of said tubular clutch.

16. (canceled)

2

17. (currently amended) The housing part of claim 15, further comprising

a container housing <u>cartridge retaining part</u> operatively coupled to said main housing, said container housing <u>cartridge retaining part</u> comprising a fluid container,

wherein said fluid container defines a medicament filled reservoir with a movable plunger at a proximal end and an outlet at a distal end,

said plunger <u>cartridge piston</u> movable by said piston rod to be advanced toward an outlet of said fluid container when said piston rod is moved distally, wherein during a dose setting step, said dose <u>dial gripknob</u> is rotated and moves away from said proximal end of said main housing so that a dose of <u>said a</u> medicament contained within said medicament filled reservoir can be selected.

18. (canceled)

19. (currently amended) The housing part of claim 17, wherein said dose <u>dial</u> <u>gripknob</u> is operatively configured to said tubular clutch so that, during said dose setting step, said tubular clutch, said dose dial sleeve, and said dose <u>dial gripknob rotate out of said proximal</u> end of rotate and move in a proximal direction in relation to said main housing.

20-75. (canceled)

3

REMARKS

The Examiner has objected to claims 15, 17, and 19 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA), first paragraph, as allegedly failing to comply with the written description requirement. Specifically, with respect to claims 15, 17, and 19, the Examiner states that the specification does not describe a "dose knob" as there is purportedly "no mention in the specification of a 'dose knob' disposed near a proximal end of the dose dial sleeve." August 30, 2013 Office Action, Page 2. Applicants have replaced the term "dose knob" with the term "dose dial grip." Support for this claim term may be found throughout the Application as filed, including Page 9 Lines 10-17. No new matter has been added.

In addition, the Examiner states that the specification as filed fails to disclose the term "driver." August 30, 2013 Office Action, Page 2. Applicants replaced the term "driver" with the term "drive sleeve." Support for this claim term may be found throughout the Application as filed, including Page 6 Line 27 – Page 7 Line 3. No new matter has been added.

Applicants have also replaced the term "container housing" in claim 17 with the term "cartridge retaining part." Support for such may be found throughout the Application as filed, including Page 5 Lines 19-30. As such, no new matter has been added. A similar claim clarification was made in Applicants' corresponding application S/N: 13/909,649, herein entirely incorporated by reference.

Applicants have replaced the term "plunger" in with the term "cartridge piston" in claim 17. Support for such a replacement may be found throughout the Application as filed, including Page 5 Lines 28-30. As such, no new matter has been added Again, a similar claim clarification was made in Applicants' corresponding application S/N: 13/909,649, herein entirely incorporated by reference.

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 SOUTH WACKER DRIVE, 32ND FLOOR CHICAGO, IL 60606 (312)913-0001 4

In addition, claims 15, 17 and 19 stand rejected on the ground of nonstatutory double patenting over claims of 1-14 of US Patent No. 7,918,833. Applicants note that M.P.E.P. § 2142 states that the Examiner bears the initial burden of factually supporting any *prima facie* conclusion of obviousness. The present Office Action summarily concludes that: "[a]lthough the claims at issue are not identical, they are not patently distinct from each other because both sets of claims identified . . . disclose similar structural elements with minor variations that a person of ordinary skill in the art would have considered as obvious design choices." August 30, 2013 Office Action, Page 5. It is Applicants' present position that the pending Office Action fails to explicitly articulate a *prima facie* case of obviousness which addresses all of the limitations of Applicants' presently pending claims, primarily independent claim 15 and therefore traverses these rejections.

For example, as Applicants' discuss in greater detail in the Application as filed, the presently pending claims are generally directed to a housing part for a medication dispensing apparatus comprising a main housing, a dose dial sleeve, a dose dial grip, a piston rod, a drive sleeve, and a tubular clutch.

As just one example, Applicants' presently pending independent claim 15 expressly recites the following:

- a dose dial grip disposed near a proximal end of the dose dial sleeve;

- a piston rod provided within said housing, the piston rod is non-rotatable during a dose setting step relative to the main housing;

- a drive sleeve extending along a portion of the piston rod;

- a drive sleeve comprising an internal threading adapted to engage an external thread of said piston rod;

- a tubular clutch;

- the tubular clutch located adjacent a distal end of the dose dial grip;

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 SOUTH WACKER DRIVE, 32ND FLOOR CHICAGO, IL 60606 (312)913-0001 5

- the tubular clutch located adjacent a distal end of the dose dial grip, the tubular clutch operatively coupled to the dose dial grip; and

- a dose dial sleeve that extends circumferentially around at least a portion of the tubular clutch.

As such, pending claim 15 is neither anticipated nor rendered obvious by any of the claim of the 7,918,833 Patent and that this double patenting rejection should be withdrawn.

With respect to the prior art rejections, the Examiner has rejected all pending claims as being allegedly unpatentable over Walters et al (EP 0937471A2) ("Walters 471").

Applicants note that the present application is generally directed to pen-type injectors, that is to injectors of the kind that provide for administration by injection of medicinal products from a multidose cartridge. In particular, the present invention relates to such injectors where a user may set the dose. Applicants' Specification, Page 1 Lines 14-17.

With respect to the present rejections in view of Walters 471, Applicants initially note that this reference does not teach or suggest a "dose dial sleeve . . . comprising a helical groove configured to engage a threading provided by said main housing." The main housing or body 40 in Walters 471 does not provide any type of threading. *See, e.g.*, Walters 471 [0012] Lines 39-43 and Figures 1-3. Naturally, therefore, Walters 471 further fails to teach or suggest "dose dial sleeve . . . comprising a helical groove configured to engage a threading provided by said main housing."

Second, to further distinguish Walters 471, Applicants have amended claim 1 slightly as follows: "dose dial sleeve . . . comprising a helical groove configured to engage a threading provided by said main housing, <u>said helical groove provided along an outer surface of said dose dial sleeve</u>." Support for this limitation may be found throughout Applicants' specification as filed, including Page 8, Lines23-25.

The dose knob 50 of Walters 471 does not comprise a helical groove along an outer surface of the dose knob but rather appears to teach an internal thread 53 that purports to engage rod barrel outer diameter threads 76 on rod barrel 74. Walters 471 [0012] Lines 48-52. Moreover, in Walters 471, the dose knob 50 comprises dosage numeral 51 and key slots 52. A dose knob cap is described as being permanently attached to a proximal end 55 of the dose knob 50. *See, e.g.*, Walters 471 [0012-0013] and Figure 1. The dose knob 50 does not comprise any type of "helical groove along an outer surface." As such, the dose knob 50 of Walters 471 fails to teach or suggest a "helical groove to engage a threading provided by said main housing."

Third, Walters 471 does not teach or suggest Applicants' presently claimed "clutch." Rather, the principal components described in the delivery pen 10 illustrated in Figure 1 of Walters 471 comprises a cap 11; a body 40; a vial retainer 35; a dose knob 50; a lens and ring assembly 60; a rod barrel tube 70; a clicker 90; and a plunger screw 100. As such, Walters 471 also fails to teach or suggest Applicants' presently claimed "tubular clutch" and also does not teach or suggest such a tubular clutch "located adjacent a distal end of said dial grip."

Fourth, as can also be seen from Figures 2 and 3 of Walters 471, the dose knob 50 appears to extend "circumferentially" only about portions of the rod barrel tube 70 and the threaded shaft 101. As such, Walters 471 further fails to teach or suggest a dose dial sleeve that "extends circumferentially around at least a portion of said tubular clutch."

Applicants respectfully submit that, in view of the remarks above, the present application, including claims 15, 17 and 19, is in condition for allowance and solicit action to that end.

If there are any matters that may be resolved or clarified through a telephone interview, the Examiner is respectfully requested to contact Applicants' undersigned representative at (312) 913-0001.

7

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: December 27, 2013

By: <u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

PTO/AIA/22 (03-13) Approved for use through 7/31/2016. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, I	to persons are rec	quired to respond to a collecti		it displays a valid OMB control number. et Number (Optional)			
PETITION FOR EXTENSION	OF TIME (JNDER 37 CFR	1.136(a) 10-1	188-US-CON1`			
Application Number 12/944,544		Filed Nove	Filed November 11, 2010				
For Pen-Type Injector							
Art Unit 3763		Examiner Me	endez, Man	uel A.			
This is a request under the provisions of 37 C	FR 1.136(a) to e	extend the period for filing	a reply in the above-	identified application.			
The requested extension and fee are as follow	vs (check time p	eriod desired and enter th	ne appropriate fee be	low):			
	<u>Fee</u>	Small Entity Fee	Micro Entity Fee				
✓ One month (37 CFR 1.17(a)(1))	\$200	\$100	\$50	\$_200.00			
Two months (37 CFR 1.17(a)(2))	\$600	\$300	\$150	\$			
Three months (37 CFR 1.17(a)(3))	\$1,400	\$700	\$350	\$			
Four months (37 CFR 1.17(a)(4))	\$2,200	\$1,100	\$550	\$			
Five months (37 CFR 1.17(a)(5))	\$3,000	\$1,500	\$750	\$			
 Applicant asserts small entity status. Applicant certifies micro entity status Form PTO/SB/15A or B or equivalent muss A check in the amount of the fee is e Payment by credit card. Form PTO-2 The Director has already been autho The Director is hereby authorized to Deposit Account Number 13-2490 	. See 37 CFR 1 it either be enclose nclosed. 2038 is attached rized to charge	.29. ed or have been submitted p fees in this application to	a Deposit Account.	ment, to			
Payment made via EFS-Web. WARNING: Information on this form may be credit card information and authorization of I am the applicant. attorney or agent of record	on PTO-2038.		n should not be inclu	uded on this form. Provide			
attorney or agent acting ur	ider 37 CFR 1.3	4. Registration number _		·			
/Thomas E. Wettermann/ December 27, 2013							
Signature Date							
Thomas E. Wettermann Typed or printed name		41,523	Telephone	Number			
NOTE: This form must be signed in accordan multiple forms if more than one signature is re							
v * Total of 1 forms	are submitted.						
This collection of information is required by 37 CFR		rmation is required to obtain (or retain a benefit by the	public, which is to file (and by the			

In scollection of information is required by 37 CFR 1.136(a). The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

In re Application of: Robert Frederick Veasey et al. Serial No.: 12/944,544 Filed: November 11, 2010 For: Pen-Type Injector

Examiner: Mendez, Manuel A. Group Art Unit: 3763 Confirmation No.: 5949

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

GENERAL AUTHORIZATION UNDER 37 C.F.R. § 1.136(a)(3)

Sir:

The Commissioner is hereby generally authorized under 37 C.F.R. § 1.136(a)(3) to treat the present and any future related filings in this or any related application filed pursuant to 37 C.F.R. § 1.53 requiring an extension of time as incorporating a request therefore, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 13-2490 for any fee that may be due in connection with such a request for an extension of time.

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: December 27, 2013

By:

<u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

Electronic Patent Application Fee Transmittal								
Application Number:	129	944544						
Filing Date:	11.	-Nov-2010						
Title of Invention:	Pen-Type Injector							
First Named Inventor/Applicant Name:	Robert Frederick Veasey							
Filer:	Thomas E. Wettermann							
Attorney Docket Number:	10-1188-US-CON1							
Filed as Large Entity								
Utility under 35 USC 111(a) Filing Fees								
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)			
Basic Filing:								
Pages:								
Claims:								
Miscellaneous-Filing:								
Petition:								
Patent-Appeals-and-Interference:								
Post-Allowance-and-Post-Issuance:								
Extension-of-Time:								
Extension - 1 month with \$0 paid		1251 231	1	Aylan ²⁰⁰ Exhibi	t - 1006 ²⁰⁰			
	C			Mylan v.	Sanofi			

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	Total in USD (\$)			200

Electronic Ac	Electronic Acknowledgement Receipt							
EFS ID:	17766072							
Application Number:	12944544							
International Application Number:								
Confirmation Number:	5949							
Title of Invention:	Pen-Type Injector							
First Named Inventor/Applicant Name:	Robert Frederick Veasey							
Customer Number:	20306							
Filer:	Thomas E. Wettermann							
Filer Authorized By:								
Attorney Docket Number:	10-1188-US-CON1							
Receipt Date:	27-DEC-2013							
Filing Date:	11-NOV-2010							
Time Stamp:	12:57:16							
Application Type:	Utility under 35 USC 111(a)							

Payment information:

Submitted with Payment	yes				
Payment Type	Deposit Account				
Payment was successfully received in RAM	\$200				
RAM confirmation Number	7047				
Deposit Account	132490				
Authorized User					
The Director of the USPTO is hereby authorized to charg	e indicated fees and credit any overpayment as follows:				
Charge any Additional Fees required under 37 C.F.R. Se	ection 1.19 (Document supply fees)				
Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees) Mylan Exhibit - 1006					
	0233 Wiyian Exindit - 1000				

Charge	any Additional Fees required under 37 C.F.I	R. Section 1.21 (Miscellaneous fee	s and charges)		
File Listing	g:				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.
1	Transmittal Letter	10_1188_US_CON1_OA_Trans	140268	no	1
		mittal_2013_12_27.pdf	bb2e3fec12b13e4e055c625a5dbeadfe7a0 54832		·
Warnings:					
Information:					
2	Amendment Copy Claims/Response to	10_1188_US_CON1_OA_Respo	134417	no	8
	Suggested Claims	nse_2013_12_27.pdf	246bcb5fe6b5c7a7de28f77a1fde2d029857 97c6		_
Warnings:					
Information:					
3	Extension of Time	10_1188_US_CON1_1Mo_Ext_	163423	no	2
		Time_2013_12_27.pdf	9637fb3aeb9bd119c7ec31e802a03dc1b0e 4479e		
Warnings:					
Information:					
4	Authorization for Extension of Time all	10_1188_US_CON1_General_A	58794	no	1
	replies	uthorization_2013_12_27.pdf	3bd109e7b06c23e6db88f646b29526b960 e8095f		
Warnings:					
Information:					
5	Fee Worksheet (SB06)	fee-info.pdf	30121	no	2
		bc58aac0c384b9cd51fc54aea2 011b			-
Warnings:					
Information:					
		Total Files Size (in bytes)	52	7023	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/21 (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pa	aperwork Re	eduction Act of 1995,	no person	is are required to respond to a co	lection of inf	formation u	inless it i	displays a valid OMB control number.
(Application Number	12/944	,544		
TRANSMITTAL			Filing Date	Novem	nber 11,	2010		
FORM			First Named Inventor	Robert	Robert Frederick Veasey			
				Art Unit	3763			
(to be used for	r all corresp	ondence after initial fi	ling)	Examiner Name	Mende	z, Manı	uel A.	
Total Number o	of Pages in ⁻	This Submission		Attorney Docket Number	10-118	8-US-C	ON1	
			ENC	LOSURES (Check all	that apply	1)		
Fee Tra	nsmittal Fo	orm		Drawing(s)			After A	Allowance Communication to TC
	Fee Attacl	hed		Licensing-related Papers				l Communication to Board eals and Interferences
Amendn	nent/Reply	/		Petition Petition to Convert to a			Appea	I Communication to TC (Appeal
	After Final	I		Provisional Application				, Brief, Reply Brief) etary Information
	Affidavits/	declaration(s)		Power of Attorney, Revocation Change of Correspondence			Status	-
Extensio	Extension of Time Request			Terminal Disclaimer				Enclosure(s) (please Identify
Express	Abandon	ment Request		Request for Refund				eral Authorization
Informat	tion Disclo	sure Statement		CD, Number of CD(s)				
			l	Landscape Table on C	D			
Certified Docume	I Copy of F ent(s)	Priority	Rem	arks				
	Missing F ete Applica							
		lissing Parts						
	under 37 (CFR 1.52 or 1.53						
		SIGNA		OF APPLICANT, ATTO				
Firm Name	McDo			& Berghoff LLP			_1111	
	-							
Signature		as E. Wetterm						
Printed name	Thoma	as E. Wetterma	Inn					
Date	Decen	nber 27, 2013			Reg. No.	41,523	3	
		C	ERTIFI	CATE OF TRANSMISS	ION/MA	ILING		
	ostage as	first class mail in						e United States Postal Service 1450, Alexandria, VA 22313-
Signature		/Thomas E. W	/etterm	ann/				
Typed or printed	name	Thomas E. W	etterma	ann			Date	December 27, 2013
						-		/

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Mylan v. Sanofi

									alid OMB control number.
P	ATENT APPL		FEE DETE			or Docket Number 944,544	Filing Date 11/11/2010	To be Mailed	
							εντιτή: 🛛 L	ARGE 🗌 SMA	
					ATION AS FIL		r 1		
			(Column 1		(Column 2)				
_	FOR		а.						
	BASIC FEE		NUMBER FIL	ED			RATE (\$)		EE (\$)
	(37 CFR 1.16(a), (b),	or (c))	N/A		N/A		N/A	_	
	SEARCH FEE (37 CFR 1.16(k), (i), (or (m))	N/A		N/A		N/A		
	EXAMINATION FE (37 CFR 1.16(o), (p),		N/A		N/A		N/A		
	TAL CLAIMS CFR 1.16(i))		min	us 20 = *			X \$ =		
	EPENDENT CLAIM CFR 1.16(h))	S	mi	nus 3 = *			X \$ =		
<u> </u>					s exceed 100 s				
	APPLICATION SIZE (37 CFR 1.16(s))	· FEE fo	or small entity) for each additi	ee due is \$310 (onal 50 sheets c	r			
	(0, 0, 1, 1, 1, 0, 0,))		raction therec CFR 1.16(s).	it. See 35 U.S.C	. 41(a)(1)(G) and	37			
	MULTIPLE DEPEN	DENT CLAIN	I PRESENT (37	7 CFR 1.16(j))					
* If	the difference in colu	umn 1 is less t	than zero, ente	r "0" in column 2.			TOTAL		
				APPLICATI	ION AS AMEN	DED – PA	RT II		
		(Column ⁻	1)	(Column 2)	(Column 3	i i			
AMENDMENT	12/27/2013	CLAIMS REMAINING AFTER AMENDME		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EX	TRA	RATE (\$)	Additio	DNAL FEE (\$)
ШМ	Total (37 CFR 1.16(i))	* 3	Minus	** 20	= 0		× \$80 =		0
IND	Independent (37 CFR 1.16(h))	* 1	Minus	***3	= 0		x \$420 =		0
AME	Application Si	ize Fee (37 Cl	FR 1.16(s))						
		NTATION OF MU	ULTIPLE DEPENI	DENT CLAIM (37 CFF	R 1.16(j))				
							TOTAL ADD'L FE	E	0
		(Column *	1)	(Column 2)	(Column 3	I			
		CLAIMS REMAININ AFTER AMENDME	NG	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EX	TRA	RATE (\$)	ADDITIC	ONAL FEE (\$)
ENT	Total (37 CFR 1.16(i))	*	Minus	**	=		X \$ =		
ME	1.16(I)) Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =	1	
ENDM	Application Si	ize Fee (37 Cl	FR 1.16(s))						
AM		NTATION OF MU	ULTIPLE DEPENI	DENT CLAIM (37 CFF	R 1.16(j))				
							TOTAL ADD'L FE	E	
* lf	the entry in column	1 is less than	the entry in col	umn 2, write "0" in	column 3.		LIE	L	
	f the "Highest Numbe If the "Highest Numb						/DEBRA SAV	OY/	
	0					ound in the ap	propriate box in colur	mn 1	
proce prepa requi Depa	ess) an application. (aring, and submitting re to complete this fo	Confidentiality I the complete orm and/or sug e, P.O. Box 14	is governed by ed application fo ggestions for re 450, Alexandria	35 U.S.C. 122 and orm to the USPTO. educing this burden , VA 22313-1450.	d 37 CFR 1.14. Thi Time will vary dep n, should be sent to DO NOT SEND FE	s collection is ending upon t the Chief Info ES OR COMF	benefit by the public estimated to take 12 he individual case. Ar prmation Officer, U.S. PLETED FORMS TO	minutes to complete ny comments on the Patent and Tradem	, including gathering, amount of time you

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

20306 7590 01/16/2014 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606 EXAMINER

MENDEZ, MANUEL A

ART UNIT PAPER NUMBER
3763

DATE MAILED: 01/16/2014

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.					
12/944,544	11/11/2010	Robert Frederick Veasey	10-1188-US-CON1	5949					

TITLE OF INVENTION: PEN-TYPE INJECTOR

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	04/16/2014

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED</u>. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Page 1 of 3 0238

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: <u>Mail</u> Mail Stop ISSUE FEE **Commissioner for Patents** P.O. Box 1450 Alexandria, Virginia 22313-1450

(571)-273-2885 or <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

20306 7590 01/16/2014 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)	
(Signature)	
(Date)	

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/944,544 TITLE OF INVENTION	11/11/2010 PEN-TYPE INJECTO	R	Robert Frederick Veasey	•	10-1188-US-CON1	5949
APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE	FEE TOTAL FEE(S) DUI	E DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	04/16/2014
EXAM	INER	ART UNIT	CLASS-SUBCLASS			
MENDEZ, N	IANUEL A	3763	604-209000	-		
	ence address or indicatio ondence address (or Cha 8/122) attached. ication (or "Fee Address 2 or more recent) attach	nge of Correspondence	 For printing on the p The names of up to or agents OR, alternativ The name of a singli registered attorney or a 2 registered patent atto listed, no name will be 	3 registered patent vely,	attorneys 1	
PLEASE NOTE: Unl recordation as set forth (A) NAME OF ASSIC	ess an assignee is ident 1 in 37 CFR 3.11. Comp JNEE	ified below, no assignee oletion of this form is NC	(B) RESIDENCE: (CITY	atent. If an assigned assignment. ′ and STATE OR CO	DUNTRY)	document has been filed for roup entity D Government
	are submitted: o small entity discount p of Copies	permitted)	 b. Payment of Fee(s): (Pleat A check is enclosed. Payment by credit car The Director is hereby overpayment, to Depo 	d. Form PTO-2038 i	is attached.	
Applicant asserting	tus (from status indicate g micro entity status. Se g small entity status. See g to regular undiscounte	ee 37 CFR 1.29 37 CFR 1.27	<u>NOTE:</u> Absent a valid ce fee payment in the micro <u>NOTE:</u> If the application to be a notification of loss	rtification of Micro entity amount will n was previously undo s of entitlement to m x will be taken to be	Entity Status (see forms PT ot be accepted at the risk of	O/SB/15A and 15B), issue f application abandonment. king this box will be taken
NOTE: This form must b	e signed in accordance v	with 37 CFR 1.31 and 1.3	33. See 37 CFR 1.4 for signa	ature requirements a	nd certifications.	
Authorized Signature				Date		
Typed or printed name	2			Registration No)	
PTOL-85 Part B (10-13)	Approved for use throug	sh 10/31/2013	Page 2 of 3 0239 OMB 0651-0033	IS Patent and Trade	Mylan Exhibi	t - 1006 Ementiof commerce

PTOL-85 Part B (10-13) Approved for use through 10/31/2013.

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMER United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Mexandria, Virginia 22313-1450 www.uspto.gov							
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.			
12/944,544	11/11/2010	Robert Frederick Veasey	10-1188-US-CON1	5949			
20306 75	90 01/16/2014		EXAM	IINER			
		RT & BERGHOFF LLP	MENDEZ, I	MANUEL A			
300 S. WACKER I 32ND FLOOR	DRIVE		ART UNIT	PAPER NUMBER			
CHICAGO, IL 606	06		3763				
			DATE MAILED: 01/16/201	4			

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 272 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 272 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation. Mylan Exhibit - 1006

Mylan v. Sanofi

	Application No.	Applicant(s				
Notice of Allowability	12/944,544 Examiner MANUEL MENDEZ	VEASEY ET Art Unit 3763	AL. AIA (First Inventor to File) Status No			
The MAILING DATE of this communication ap All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOL- NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.3	IS (OR REMAINS) CLOSED in t 85) or other appropriate commun RIGHTS. This application is su	his application. If no ication will be mailed	t included in due course. THIS			
1. X This communication is responsive to <u>amendment filed or</u>	n 12/27/2013.					
A declaration(s)/affidavit(s) under 37 CFR 1.130(b) v	vas/were filed on <u>.</u>					
2. An election was made by the applicant in response to a r requirement and election have been incorporated into this		uring the interview or	n; the restriction			
 3.	tual property office for the corres	ponding application.	For more information,			
4. 🛛 Acknowledgment is made of a claim for foreign priority up	nder 35 U.S.C. § 119(a)-(d) or (f)					
Certified copies:						
a) ⊠ All b) □ Some *c) □ None of the: 1. □ Certified copies of the priority documents ha	ave been received					
2. Certified copies of the priority documents h		No. 10/790.225				
3. Copies of the certified copies of the priority			application from the			
International Bureau (PCT Rule 17.2(a)).		0				
* Certified copies not received:						
Applicant has THREE MONTHS FROM THE "MAILING DAT noted below. Failure to timely comply will result in ABANDO THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		reply complying with	the requirements			
5. CORRECTED DRAWINGS (as "replacement sheets") m	nust be submitted.					
including changes required by the attached Examin Paper No./Mail Date	er's Amendment / Comment or i	n the Office action of				
Identifying indicia such as the application number (see 37 CF each sheet. Replacement sheet(s) should be labeled as such			(not the back) of			
 6. DEPOSIT OF and/or INFORMATION about the deposit of attached Examiner's comment regarding REQUIREMENT 	of BIOLOGICAL MATERIAL mus	t be submitted. Note	the			
Attachment(s) 1.	5 🗖 Evominaria /	Amendment/Commer	+			
2. ☑ Information Disclosure Statements (PTO/SB/08),		Statement of Reasons				
Paper No./Mail Date <u>8/31/2013</u>			s for Allowance			
3. Examiner's Comment Regarding Requirement for Depos of Biological Material	3. Examiner's Comment Regarding Requirement for Deposit 7. Other					
4. Interview Summary (PTO-413), Paper No./Mail Date						
/MANUEL MENDEZ/						
Primary Examiner, Art Unit 3763						
U.S. Patent and Trademark Office						

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

The examiner of record acknowledges receipt of the amendment filed on 12/27/2013. The examiner concurs with the arguments presented on pages 1-7 of the Remarks, and therefore, claims 15, 17, and 19 are considered to be allowable over the prior art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MANUEL MENDEZ whose telephone number is (571)272-4962. The examiner can normally be reached on 0730-1800 hrs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Nicholas D. Lucchesi can be reached on 571-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Mylan v. Sanofi

Page 2

Application/Control Number: 12/944,544 Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Respectfully submitted, /MANUEL MENDEZ/ Primary Examiner, Art Unit 3763

Doc description: Information Disclosure Statement (IDS) Filed

12944544 - GALL:037063 Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12944544
Filing Date		2010-11-11
First Named Inventor	Robei	t Frederick Veasey
Art Unit		3763
Examiner Name Mend		ez, Manuel A.
Attorney Docket Numb	er	10-1188-US-CON1

				U.S	.PATENTS	Remove	
Examiner Initial*	er Cite No Patent Number		Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5304152		1994-04-19	Sams		
	2	5320609		1994-06-14	Haber et al.		
	3	5480387		1996-01-02	Gabriel et al.		
	4	5505704		1996-04-09	Pawelka et al.		
	5	6193698		2001-02-27	Kirchhofer et al.		
	6	6248095		2001-06-19	Giambattista et al.		
	7	7241278		2007-07-10	Moller		
lf you wisl	n to ad	d additional U.S. Pat	ent citatio	n information	please click the Add button.	Add	
	_		U.S.P	ATENT APPL	ICATION PUBLICATIONS	Remove	

ALL REFERENCES CONSIDERED EXCEPT WHERE AND ALL REFERENCES CONSIDERED AND ALL REFERENCES AND ALL RE EFS Web 2.1.17

Receipt date: 08/31/2013

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12944544	12944544 - GAU: 3763		
Filing Date		2010-11-11			
First Named Inventor	Robei	t Frederick Veas	sey		
Art Unit		3763			
Examiner Name	Mend	ez, Manuel A.			
Attorney Docket Numb	er	10-1188-US-CC	DN1		

Examiner Initial*	Cite I	۷o	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines whe Relevant Passages or Rel Figures Appear		
	1										
If you wis	h to ac	ld a	dditional U.S. Publi	shed Ap	plication	n citation	n information p	lease click the Add	d butto	n. Add	
					FOREIC	GN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No		reign Document mber ³	Country Code ²		Kind Code⁴	Publication Date	Name of Patentee Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Т5
	1	993	8554	WO		A1	1999-08-05	Novo Nordisk A/S			
If you wis	h to ac	ld a	dditional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	buttor	Add	<u> </u>
				NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	(bc	lude name of the au ok, magazine, journ olisher, city and/or c	nal, seria	al, symp	osium,	catalog, etc), c			iate), title of the item sue number(s),	T⁵
	1										
If you wis	h to ac	ld a	dditional non-paten	t literatu	re docu	ment cit	ation informati	ion please click the	Add k	outton Add	
					EX	AMINE	R SIGNATUR	E			
Examiner	Signa	ture	/Manuel M	endez/				Date Conside	ered	01/09/2014	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											
Standard ST ⁴ Kind of doo	¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.										

EFS Web 2.1.17 ALL REFERENCES CONSIDERED EXCEPT WHEN SIAN ER DET HROUGH. /M.M./

Mylan v. Sanofi

12944544 - GAU: 3763 Receipt date: 08/31/2013 Application Number 12944544 Filing Date 2010-11-11 INFORMATION DISCLOSURE First Named Inventor Robert Frederick Veasey STATEMENT BY APPLICANT Art Unit 3763 (Not for submission under 37 CFR 1.99) Examiner Name Mendez, Manuel A. Attorney Docket Number 10-1188-US-CON1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

X The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas E. Wettermann/	Date (YYYY-MM-DD)	2013-08-30
Name/Print	Thomas E. Wettermann	Registration Number	41,523

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Mylan v. Sanofi

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE **Commissioner** for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

20306 7590 01/16/2014 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Thomas E. Wettermann	(Depositor's name)
/Thomas E. Wettermann/	(Signature)
January 28, 2014	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/944,544	11/11/2010	Robert Frederick Veasey	10-1188-US-CON1	5949

TITLE OF INVENTION: PEN-TYPE INJECTOR

	APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
	nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	04/16/2014
	EXAM	fINER	ART UNIT	CLASS-SUBCLASS			
	MENDEZ, N	MANUEL A	3763	604-209000	-		
 Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 			 2. For printing on the patent front page, list (1) The names of up to 3 registered patent attorney or agents OR, alternatively, (2) The name of a single firm (having as a member registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name i listed, no name will be printed. 		era 2 Hulbert &	Hulbert & Berghoff LLP	

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

DCA Design International, LTD.

Warwick, UNITED KINGDOM

Please check the appropriate assignee category or categories (will not be printed on the patent) : 🔲 Individual 🖾 Corporation or other private group entity 🖵 Government					
 4a. The following fee(s) are submitted: X Issue Fee Publication Fee (No small entity discount permitted) Advance Order - # of Copies	 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) A check is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number 13-2490 (enclose an extra copy of this form). 				
5. Change in Entity Status (from status indicated above)					
Applicant certifying micro entity status. See 37 CFR 1.29	<u>NOTE:</u> Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.				
Applicant asserting small entity status. See 37 CFR 1.27	<u>NOTE</u> : If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.				
Applicant changing to regular undiscounted fee status.	<u>NOTE:</u> Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.				
NOTE: This form must be signed in accordance with 37 CFR 1.31 and	1.33. See 37 CFR 1.4 for signature requirements and certifications.				
Authorized Signature //Thomas E. Wettermann/ Typed or printed name Thomas E. Wettermann	Date January 28, 2014 Registration No. 41,523				

Page 2 of 3

0249 OMB 0651-0033

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

))

)

In re Application of: Robert Frederick Veasey et al. Serial No.: 12-944,544 Filed: November 11, 2010 For: Pen-Type Injector

Group Art Unit: 3763 Examiner: Mendez, Manuel A. Confirmation No.: 5949

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

Sir:

Responsive to the Notice of Allowance mailed January 16, 2014, the Applicants express appreciation for the allowance of the present application. The Applicants note the Examiner's reasons for allowance, but further comment that the art of record, alone and in combination, fails to show, teach or suggest the entirety of each combination of steps and/or structure recited by each of the allowed claims of the present invention.

The Applicants respectfully submit that the reasons for allowance are only warranted in instances in which the record of the prosecution as a whole does not make clear his or her reasons for allowing a claim or claims. The Applicants do not necessarily agree with each statement in the reasons for allowance. The Applicants believe that the Statements of Reasons for Allowance in this case are improper as it merely copies limitations of the claims

1

0250

into the reasons for allowance. While the Applicants believe that the claims are allowable, the Applicants do not acquiesce that patentability resides in the features, as explicitly set forth in the claims, nor that each feature is required for patentability.

> Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: January 28, 2014

By:

<u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

0251

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 10-1188-US-CON1)

In re Application of: Robert Frederick Veasey et al. Serial No.: 12-944,544 Filed: November 11, 2010 For: Pen-Type Injector

Examiner: Mendez, Manuel A. Group Art Unit: 3763 Confirmation No.: 5949

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

GENERAL AUTHORIZATION UNDER 37 C.F.R. § 1.136(a)(3)

Sir:

The Commissioner is hereby generally authorized under 37 C.F.R. § 1.136(a)(3) to treat the present and any future related filings in this or any related application filed pursuant to 37 C.F.R. § 1.53 requiring an extension of time as incorporating a request therefore, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 13-2490 for any fee that may be due in connection with such a request for an extension of time.

Respectfully submitted, McDonnell Boehnen Hulbert & Berghoff LLP

Date: January 28, 2014

By:

<u>/Thomas E. Wettermann/</u> Thomas E. Wettermann Reg. No. 41,523

Electronic Patent A	4pp	lication Fee	e Transmi	ittal	
Application Number:	129	944544			
Filing Date:	11-	Nov-2010			
Title of Invention:	PEI	N-TYPE INJECTOR			
First Named Inventor/Applicant Name:	Rol	oert Frederick Veas	ey		
Filer:	The	omas E. Wetterman	n		
Attorney Docket Number:	10-	1188-US-CON1			
Filed as Large Entity					
Utility under 35 USC 111(a) Filing Fees					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Pages:					
Claims:					
Miscellaneous-Filing:					
Petition:					
Patent-Appeals-and-Interference:					
Post-Allowance-and-Post-Issuance:					
Utility Appl Issue Fee		1501	1	960	960
Extension-of-Time:	6	253	Ν	⁄Iylan Exhibi	t - 1006

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	Tot	al in USD) (\$)	960

Electronic Ac	knowledgement Receipt
EFS ID:	18044834
Application Number:	12944544
International Application Number:	
Confirmation Number:	5949
Title of Invention:	PEN-TYPE INJECTOR
First Named Inventor/Applicant Name:	Robert Frederick Veasey
Customer Number:	20306
Filer:	Thomas E. Wettermann
Filer Authorized By:	
Attorney Docket Number:	10-1188-US-CON1
Receipt Date:	28-JAN-2014
Filing Date:	11-NOV-2010
Time Stamp:	13:44:57
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 960
RAM confirmation Number	14808
Deposit Account	132490
Authorized User	
The Director of the USPTO is hereby authorized to charg	e indicated fees and credit any overpayment as follows:
Charge any Additional Fees required under 37 C.F.R. Se	ection 1.19 (Document supply fees)
Charge any Additional Fees required under 37 C.F.R. Se	ection 1.20 (Post Issuance fees) Mylan Fxhibit - 1006
	0255 Wiyian Exindit = 1000

	any Additional Fees required under 37 C.F.		s and charges,		
File Listing	g: Document Description	File Name	File Size(Bytes)/	Multi	Pages
Number			Message Digest	Part /.zip	(if appl.
1	Transmittal Letter	10_1188_US_CON1_lssue_Fee	140472	no	1
		_Transmittal_2014_01_28.pdf	26d82cd0ae02afba740ac188e9cb6fbfb045 da16		
Warnings:					
Information:					
		10_1188_US_CON1_Issue_Fee	1597082		
2	Issue Fee Payment (PTO-85B)	_2014_01_28.pdf	cd42a74b53e10ff44435d5fe98b487ca6756 f8c3	no	1
Warnings:					
Information:					
		10_1188_US_CON1_Comment	53018		_
3	Miscellaneous Incoming Letter	s_Statement_Reasons_Allowan ce_2014_01_28.pdf	751d5464a7ff12e3beb636f654a477c9d6e1 5fac	no	2
Warnings:			· · · · · · · · · · · · · · · · · · ·		
Information:					
4	Authorization for Extension of Time all	10_1188_US_CON1_General_A	59372	20	1
4	replies	uthorization_2014_01_28.pdf	674bac7ebc40f0cb12d7501bfa2669a5724 10813	no	I
Warnings:					
Information:					
5	Fee Worksheet (SB06)	fee-info.pdf	30277	no	2
ر	i ee worksheet (5000)	iee-into.put	5808a8302fab3f513f59cad1286f0e59800d de1a	no	2
Warnings:					
Information:					
		Total Files Size (in bytes)	18	30221	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/21 (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pa	aperwork Re	eauction Act of 1995,	no persoi		-				ays a valid OMB control number.
(Application Number	1(0-1188	3-US-CC	N1	
TR		MITTAL		Filing Date			oer 11, 2		
	FO	RM		First Named Inventor			Frederic	< Vease	әу
				Art Unit	_	763			
(to be used for	all corresp	ondence after initial f	iling)	Examiner Name	Μ	lendez	, Manue	IA.	
Total Number o	of Pages in	This Submission		Attorney Docket Numbe	er 1(0-1188	3-US-CC	N1	
			ENC	CLOSURES (Check	all that	t apply)	I		
Fee Trar	nsmittal Fo	orm		Drawing(s)			<u> </u>	fter Allow	vance Communication to TC
	Fee Attac	hed		Licensing-related Papers					ommunication to Board and Interferences
Amendm	nent/Reply	/		Petition Petition to Convert to a			П А	ppeal Co	ommunication to TC (Appeal ef, Reply Brief)
	After Fina			Provisional Application Power of Attorney, Revoca	ation				y Information
	Affidavits/	declaration(s)		Change of Correspondence		ress	🗌 s	tatus Lett	ter
Extensio	on of Time	Request		Terminal Disclaimer				ther Encl elow):	losure(s) (please Identify
Express	Abandon	ment Request		Request for Refund			ls	ssué Fe	e, Comments on
Informati	ion Disclo	sure Statement		CD, Number of CD(s)	_				ent of Reasons for ce and General
				Landscape Table or	n CD			uthoriz	
Certified Docume	Copy of F nt(s)	Priority	Rem	narks					
	Missing F ete Applic								
	Reply to N	lissing Parts							
l	under 37 (CFR 1.52 or 1.53							
		SIGNA		OF APPLICANT, ATT	FORN	EY, O	R AGEN	Т	
Firm Name	McDo	nnell Boehnen	Hulber	t & Berghoff LLP					
Signature	/Thom	as E. Wetterm	ann/						
Printed name	Thoma	as E. Wetterma	nn						
Date	Janua	ry 28, 2014			Reg	. No.	41,523		
		С	ERTIF	ICATE OF TRANSMIS	SSIO	N/MAI	LING		
l hereby certify th with sufficient po 1450 on the date	ostage as	first class mail in	eing elec an envel	ctronically transmitted to the lope addressed to: Commis	e USPT ssioner	FO or de r for Pat	eposited w tents, P.O	ith the Ur Box 14	nited States Postal Service 50, Alexandria, VA 22313-
Signature		/Thomas E. V	/etterm	nann/					
Typed or printed	name	Thomas E. W	etterma	ann			D	ate Jai	nuary 28, 2014
This collection of in	formation i	- s required by 37 CFF	₹15 The	information is required to obta	in or ret	ain a ber	nefit by the r	- ublic whic	ch is to file (and by the USPTO to

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Mylan v. Sanofi

UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICATION NO.		ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/944,544		03/25/2014	8679069	10-1188-US-CON1	5949
20306	7590	03/05/2014			

MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment is 406 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Robert Frederick Veasey, Warwickshire, UNITED KINGDOM; Robert Perkins, Oxfordshire, UNITED KINGDOM; David Aubrey Plumptre, Worcestershire, UNITED KINGDOM;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit <u>SelectUSA.gov</u>.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (10-1188-US-CON1)

Applicant:Robert Frederick Veasey, et al.Patent No.:8,679,069Issued:March 25, 2014Title:PEN-TYPE INJECTORArt Unit:3763Confirmation No.:5949

Examiner: MENDEZ, MANUEL A.

ATTN: Certificate of Corrections Branch Commissioner for Patents P.O. Box 1450 Alexandria Virginia 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION

Sir:

The patentee hereby requests issuance of a certificate of correction pursuant to 35 U.S.C §3.81 and 37 C.F.R. § 1.323 for the above patent. The certificate is needed to correct an error on the cover page of the patent in the name of the assignee. The patent incorrectly states **DCA DESIGN INTERNATIONAL LTD.** as the assignee. The correct assignee, however, is **SANOFI-AVENTIS DEUTSCHLAND GMBH.** The Assignment from DCA Design International Ltd. To Sanofi-Aventis Deutschland GmbH was recorded pursuant to 37 C.F.R. § 3.11 before issuance of the '069 patent and can be found at Reel/Frame 026978 / 0938. The error is due to a mistake of the Applicant, and correctable under 37 C.F.R. § 1.323 and 35 U.S.C. §3.81.

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 South Wacker Drive Chicago, IL 60606 Telephone: 312-913-0001 Facsimile: 312-913-0002

> Mylan Exhibit - 1006 Mylan v. Sanofi

A PTO/SB/44 form for the certificate of correction is attached. All fees associated with this submission have been paid through the electronic filing process. However, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.

If there are any matters that may be resolved or clarified through a telephone interview, the Examiner is respectfully requested to contact Applicants' undersigned representative at (312) 913-2143.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: <u>April 18, 2014</u>

By: /David M. Frischkorn/ David M. Frischkorn Reg. No. 32,833

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 South Wacker Drive Chicago, IL 60606 Telephone: 312-913-0001 Facsimile: 312-913-0002

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page <u>1</u> of <u>1</u>

PATENT NO. : 8,679,069

APPLICATION NO.: 12/944,544

ISSUE DATE : March 25, 2014

INVENTOR(S) : Robert Frederick Veasey, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page, item 73, Assignee:

delete "DCA DESIGN INTERNATIONAL LTD."

replace with -- SANOFI-AVENTIS DEUTSCHLAND GMBH --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

McDonnell Boehnen Hulbert & Berghoff LLP 300 South Wacker Drive Chicago, IL 60606

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Mylan Exhibit - 1006 Mylan v. Sanofi

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent A	4pp	lication Fee	e Transmi	ttal	
Application Number:	129	944544			
Filing Date:	11-	Nov-2010			
Title of Invention:	PEI	N-TYPE INJECTOR			
First Named Inventor/Applicant Name:	Rol	oert Frederick Vease	ey		
Filer:	Da	vid M. Frischkorn			
Attorney Docket Number:	10-	1188-US-CON1			
Filed as Large Entity					
Utility under 35 USC 111(a) Filing Fees					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Pages:					
Claims:					
Miscellaneous-Filing:					
Petition:					
Patent-Appeals-and-Interference:					
Post-Allowance-and-Post-Issuance:					
Certificate of Correction		1811	1	100	100
Extension-of-Time:	~		Ν	⁄Iylan Exhibi	t - 1006
	-0	264			~ ~

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	Tot	al in USD)(\$)	100

Electronic Ac	knowledgement Receipt
EFS ID:	18801952
Application Number:	12944544
International Application Number:	
Confirmation Number:	5949
Title of Invention:	PEN-TYPE INJECTOR
First Named Inventor/Applicant Name:	Robert Frederick Veasey
Customer Number:	20306
Filer:	David M. Frischkorn
Filer Authorized By:	
Attorney Docket Number:	10-1188-US-CON1
Receipt Date:	18-APR-2014
Filing Date:	11-NOV-2010
Time Stamp:	13:19:46
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$100
RAM confirmation Number	10216
Deposit Account	132490
Authorized User	
The Director of the USPTO is hereby authorized to charge	e indicated fees and credit any overpayment as follows:
Charge any Additional Fees required under 37 C.F.R. Se	ction 1.21 (Miscellaneous fees and charges)

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.
1			118004		2
1	Request for Certificate of Correction	10-1188-US-CON1_Request.pdf	f4b0bd25b7706b0fe3ae33b04afc91565858 fb3d	no	2
Warnings:		1	I	1	
Information:					
2	Request for Certificate of Correction	10-1188-US-	164506	no	2
2	Request for Certificate of Conection	CON1_Cert_of_Corr.pdf	9f2022df128b210d705f6e850e2146ea8e1e 1a5b	110	2
Warnings:		I	I	l	
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	29730	no	2
5	ree worksheet (5000)		214ec0f87fba0a653a9a89ef1908dc386f1d de53	no 6f1d 312240	2
		1		I	
Warnings:					
-					
	edgement Receipt evidences receip	•	SPTO of the indicated	documents	

Document code: WFEE

United States Patent and Trademark Office Sales Receipt for Accounting Date: 06/25/2014

CKHLOK	SALE	#00000	0011	Mailroom Dt:	04/18/2014	12944544
		01	FC : 1	811	100.00 DA	A
		02	FC : 1	830	140.00 DA	λ

Document code: WFEE

United States Patent and Trademark Office Sales Receipt for Accounting Date: 06/25/2014

CKHLOK	ADJ #00000012	2 Mai	Iroom Dt: 04/18/2014		
	Seq No:	10216	Sales Acctg Dt: 04/18/2014	132490	12944544
	01 FC:	1811	100.00 CR		



MCDONNELL BOEHNEN HULBERT & B 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606	ERGHOFF LLI	M <u>AILE</u> JUN 2'6 2014
In re Patent No. 8,679,069 Issue Date: March 25, 2014 Application No. 12/944,544 Filed: November 11, 2010 Attorney Docket No.: 10-1188-US-CON1	: : : :	OFFICE OF PETITIONS

This is a decision in response to the communication filed April 18, 2014, which is being treated as a request under 37 CFR $3.81(b)^1$ to correct the name of the assignee on the front page of the above-identified patent by way of a Certificate of Correction.

The request is **GRANTED**.

The present communication requests that a certificate of correction be issued to reflect the correct assignee on the front page of the Letters Patent. It is noted that an incorrect assignee's name was included on the Fee(s) Transmittal form PTOL-85(b).

37 CFR 3.81(b), effective June 25, 2004, reads:

After payment of the issue fee: Any request for issuance of an application in the name of the assignee submitted after the date of payment of the issue fee, and any request for a patent to be corrected to state the name of the assignee, must state that the assignment was submitted for recordation as set forth in § 3.11 before issuance of the patent, and must include a request for a certificate of correction under § 1.323 of this chapter (accompanied by the fee set forth in § 1.20(a) and the processing fee set forth in § 1.17(i) of this chapter.

A review of the details of the assignment recorded on September 28, 2011 confirms that SANOFI-AVENTIS DEUTSCHLAND GMBH is the assignee of record. Further, a request for a certificate of

¹ See MPEP 1309, subsection II; and <u>Official Gazette</u> of June 22, 2004.

U.S. Patent No. 7,300,547

Page 2

correction under § 1.323 and the fee required by § 1.20(a) has been provided. The \$140 processing fee set forth in § 1.17(i) will be charged to counsel's deposit account as authorized.

In view of the above, the request is found to comply with the provisions of 37 CFR 3.81(b).

The Certificates of Correction Branch will be notified of this decision granting the petition under 37 CFR 3.81(b) and directing issuance of the requested Certificate of Correction.

Telephone inquiries concerning this decision may be directed to the undersigned at (571) 272-3204. Inquiries regarding the issuance of a certificate of correction should be directed to the Certificates of Correction Branch at (703) 756-1814.

/SDB/

Sherry D. Brinkley Paralegal Specialist Office of Petitions

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.: 8,679,069 B2APPLICATION NO.: 12/944544DATED: March 25, 2014INVENTOR(S): Robert Frederick Veasey et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page, item 73, Assignee:

delete "DCA DESIGN INTERNATIONAL LTD."

replace with -- SANOFI-AVENTIS DEUTSCHLAND GMBH --

Signed and Sealed this Twenty-second Day of July, 2014

Michelle K. Lee

Michelle K. Lee Deputy Director of the United States Patent and Trademark Office

Mylan Exhibit - 1006 Mylan v. Sanofi

Case 1:14-cv-00884-RGA-MPT Document 54 Filed 05/11/15 Page 1 of 2 PageID #: 580

AO 120 (Rev. 08/10) **REPORT ON THE** Mail Stop 8 TO: Director of the U.S. Patent and Trademark Office FILING OR DETERMINATION OF AN P.O. Box 1450 **ACTION REGARDING A PATENT OR** Alexandria, VA 22313-1450 TRADEMARK In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court for the District of Delaware on the following Trademarks or ✓ Patents. (□ the patent action involves 35 U.S.C. § 292.): DOCKET, NO. HOUBBY - ROA DATE FILED U.S. DISTRICT COURT 7/7/2014 for the District of Delaware PLAINTIFF DEFENDANT SANOFI-AVENTIS U.S. LLC and SANOFI-AVENTIS ELI LILLY AND COMPANY DEUTSCHLAND GMBH PATENT OR DATE OF PATENT HOLDER OF PATENT OR TRADEMARK TRADEMARK NO. OR TRADEMARK 1 7,476,652 1/13/2009 Sanofi-Aventis Deutschland GmbH 2 7,713,930 5/11/2010 Sanofi-Aventis Deutschland GmbH 3 7,918,833 4/5/2011 Sanofi-Aventis Deutschland GmbH 4 8,512,297 8/20/2013 Sanofi-Aventis Deutschland GmbH 5 8,556,864 10/15/2013 Sanofi-Aventis Deutschland GmbH

In the above---entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY	
		Answer Cross Bill Other Pleading
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above---entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

see attached order

CLERK	(BY) DEPUTY CLERK	DATE
John A. Cerino	n. Schmyer	5/11/15

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

Case 1:14-cv-00884-RGA-MPT Document 54 Filed 05/11/15 Page 2 of 2 PageID #: 581

AO 120 (Rev. 08/10)		·····		
Mail Stop 8TO:Director of the U.S. Patent and Trademark OfficeP.O. Box 1450Alexandria, VA 22313-1450			FILING OR DETE ACTION REGARI	T ON THE RMINATION OF AN DING A PATENT OR DEMARK
In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § filed in the U.S. District Court for the Trademarks or Z Patents. (the patent action involve			District of Delaware	court action has been on the following
DOCKET NO. DA-ROA	DATE FILED 7/7/2014	U.S. DI	STRICT COURT for the District o	f Delaware
PLAINTIFF		4	DEFENDANT	
SANOFI-AVENTIS U.S. DEUTSCHLAND GMBH	LLC and SANOFI-AVENTI	S	ELI LILLY AND COMPANY	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK		HOLDER OF PATENT	OR TRADEMARK
I 8,603,044	12/10/2013	San	ofi-Aventis Deutschland Gmbl	H
2 8,679,069	8,679,069 3/25/2014 San		ofi-Aventis Deutschland Gmbl	H
3				
4		Ī		
5		1		

In the above---entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY				
		dment		Cross Bill	Other Pleading
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK		HOLDE	R OF PATENT OR 1	TRADEMARK
1			· · ·		
2					
3					
4					
5					

In the above---entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

Au attached Order

CLERK John A. Cerno (BY) DEPUTY CLERK N. Schmyn DATE 5/11/2015

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

Case 1:16-cv-00812-UNA Document 4 Filed 09/16/16 Page 1 of 2 PageID #: 174

AO	120	(Rev.	08/10)
----	-----	-------	--------

DECISION/JUDGEMENT

Mail Stop 8 TO: Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450			REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
			§ 1116 you are hereby advised that a court action has been ISTRICT OF DELAWARE on the following
Tradematks o	r 📝 Patents. (🗌 the pat	tent action involve	es 35 U.S.C. § 292.):
DOCKET NO.	DATE FILED	U.S. DI	ISTRICT COURT FOR THE DISTRICT OF DELAWARE
DI AINTING			DEFENDANT
DEUTSCHLAND (INDUSTRIE	S U.S. LLC, SANOFI-AVEI GMBH, and SANOFI WNT	THROP	MERCK SHARP & DOHME CORP.
SANOFI-AVENTIS	GMBH, and SANOFI WIN DATE OF PATE		MERCK SHARP & DOHME CORP. HOLDER OF PATENT OR TRADEMARK
SANOFI-AVENTIS DEUTSCHLAND (INDUSTRIE PATENT OR	GMBH, and SANOFI WIN DATE OF PATE	THROP NT RK	
SANOFI-AVENTIS DEUTSCHLAND INDUSTRIE PATENT OR TRADEMARK N	O. DATE OF PATE	THROP NT RK San	HOLDER OF PATENT OR TRADEMARK
SANOFI-AVENTIS DEUTSCHLAND (INDUSTRIE PATENT OR TRADEMARK N 1 US 7,918,833	GMBH, and SANOFI WINT DATE OF PATE O. OR TRADEMAN 4/5/2011	THROP NT RK San San	HOLDER OF PATENT OR TRADEMARK ofi-Aventis Deutschland GmbH
SANOFI-AVENTIS DEUTSCHLAND (INDUSTRIE PATENT OR TRADEMARK N 1 US 7,918,833 2 US 8,512,297	GMBH, and SANOFI WINT DATE OF PATE OR TRADEMAN 4/5/2011 8/20/2013	THROP NT RK San San San	HOLDER OF PATENT OR TRADEMARK ofi-Aventis Deutschland GmbH ofi-Aventis Deutschland GmbH

In the above---entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY	dment 🗌 Answer	Cross Bill	Other Pleading
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK		ER OF PATENT OR T	
1				
2				
3			~~~~	
4				
5				

In the above---entitled case, the following decision has been rendered or judgement issued:

CLERK (BY) DEPUTY CLERK DATE

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

PATENT OR	DATE OF PATENT	HOLDER OF PATENT OR
TRADEMARK NO.	OR TRADEMARK	TRADEMARK
6. US 8,679,069	3/25/2014	Sanofi-Aventis Deutschland GmbH
7. US 9,011,391	4/21/2015	Sanofi-Aventis Deutschland GmbH
8. US 9,233,211	1/12/2016	Sanofi-Aventis Deutschland GmbH
9. US 7,476,652	1/13/2009	Sanofi-Aventis Deutschland GmbH
10. US 7,713,930	3/11/2010	Sanofi-Aventis Deutschland GmbH

ADDITIONAL PATENTS TO THE COMPLAINT